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ABSTRACT 
Pancreatic cancer is a devastating disease with a five year survival of only 2-3%. 
Only 10-15% of patients have resectable disease at presentation and the only 
potential cure is major surgery with adjuvant chemotherapy. The outcomes of 
surgery are disappointing with a median survival of only15-17 months and 
operative mortality and morbidity figures of 5-10% and 40% respectively. This 
abysmal prognosis is likely due to the highly aggressive nature of the tumour, its 
resistance to adjuvant therapy, its late presentation and the likely presence of 
micro-metastases not detectable at staging or surgery. 
 
A pre-operative systemic inflammatory response (as measured by CRP) is known 
to be associated with a poor prognosis in a number of cancers including pancreatic 
cancer. The reasons behind this poor prognosis are not yet known. The main 
driver of plasma CRP levels is the cytokine IL-6, known to be elevated in the 
plasma of patients with pancreatic cancer. This thesis hypothesises that 
upregulation of two IL-6-dependent pathways, the JAK STAT and MAPK 
pathways is responsible for the poor prognosis associated with an inflammatory 
response in pancreatic cancer. Both of these pathways are known to be involved in 
cellular growth, differentiation and apoptosis and when activated they may confer 
a growth or survival advantage to tumour cells. The aims of this thesis were to 
establish the prognostic role of a systemic inflammatory response in resectable 
pancreatic cancer in both a retrospective and prospective cohort and establish 
whether increased protein expression in either the JAK STAT or MAPK pathways 
is associated with a poor prognosis in the same retrospective cohort. 
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A retrospective database of 148 patients who had undergone Whipple resection 
for either pancreatic cancer (PC) or non-pancreatic peri-ampullary cancer (NPPC) 
was created with pre-operative CRP values and survival data. The author then 
created tissue micro-arrays (TMA’s) with both tumour and normal pancreatic duct 
tissue from each of the 148 patients in the retrospective cohort and carried out 
immunohistochemistry on 12 antibodies known to be crucial in IL-6 signalling (6 
in the JAK STAT and 6 in the MAPK pathways). Following staining the author 
scored each of the antibodies using the weighted histoscore to allow analysis of 
antigen expression. During the period of research the author also created a 
prospective database of 36 patients who underwent surgery for either PC or 
NPPC. Plasma was stored pre-operatively from each of the patients and this was 
later thawed and using an ELISA kit another research fellow (JL) was able to 
establish plasma levels of IL-6 in the prospective cohort. 
 
On univariate analysis a raised pre-operative CRP was associated with poorer 
survival, 374 days versus 618 days (p=0.0001) in the retrospective PC group only. 
On multivariate analysis, only pre-operative CRP retained statistical significance 
amongst those factors shown to be significant on univariate analysis (P=0.009). In 
the prospective group, patients with low levels of IL-6 had a median survival of 
799 days, against a median survival of 537 days in those with high plasma IL-6 
levels (P=0.002) when all 36 patients were analysed together. On analysis of 
protein expression, no significant relationship between increased expression and 
poor survival was seen for any of the 12 proteins analysed. 
 
The results from this thesis confirm that a pre-operative inflammatory response is 
associated with poor survival in patients with resectable pancreatic cancer. Raised 
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plasma levels of IL-6 are also associated with poorer survival in similar patients. 
However, the poor prognosis appears to be via a JAK STAT/ MAPK independent 
mechanism. Other possible explanations for this poor prognosis including the 
connection between inflammation and cachexia and other important inflammatory 
proteins such as NF-κB and SOCS are explored in the discussion of this thesis. 
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1.0 INTRODUCTION 
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1.1 Pancreatic Cancer 
1.1.1 Epidemiology 
In the year 2000 pancreatic cancer was the tenth most common cancer in the UK, 
accounting for 3% of the total cancer burden with nearly 7000 registered cases1. 
Over the last thirty years the incidence of pancreatic cancer in UK men appears to 
be falling, from just over 12 cases per 100,000 in 1971 to 10 in 2001. The rate in 
women appears to be static at around 7.5 cases per 100,000. 
 
In 2002 pancreatic cancer was the sixth most common cause of cancer death, 
behind lung, bowel, breast, prostate and oesophageal cancer. It is a devastating 
disease with figures from 1996-1999 in the UK showing a 5 year survival of only 
2% in men and 3% in women, the worst in both sexes. 
 
The reason for this abysmal prognosis is the late presentation of pancreatic cancer, 
coupled with the highly aggressive nature of the tumour and its resistance to 
extant treatments. The only potential cure is radical surgery combined with 
chemotherapy which can only be performed for localised disease2. Figures from 
2003 in the USA show that only 8% of patients presenting with pancreatic cancer 
had localised disease. This compared with 15%, 36%, 60%, 83% and 25% in lung, 
bowel, breast, prostate and oesophageal cancers respectively3.  
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1.1.2 Pathology 
1.1.2.1 Tumour Types 
The terminology surrounding pancreatic cancer is often confused and it is 
important to establish it correctly early in this thesis. The term pancreatic cancer 
means a tumour arising from the pancreatic ductal tissue and from this point 
whenever the term pancreatic cancer is used it is referring only to tumours arising 
from pancreatic ducts. The term peri-ampullary cancer encompasses a number of 
different tumours that arise at, or near to the Ampulla of Vater. This term includes 
pancreatic cancer (cancer arising from the pancreatic ducts in the head of the 
pancreas only), Ampullary adenocarcinoma (arising from the Ampulla of Vater 
itself), distal Cholangiocarcinoma (adenocarcinoma arising from the distal bile 
duct adjacent to the Ampulla) and duodenal adenocarcinoma (tumour arising in 
the duodenum adjacent to the Ampulla). It is worth noting that the term peri-
ampullary cancer does not include pancreatic cancer arising from the neck, body 
and tail of the gland, which account for approximately 30% of pancreatic cancers 
(the other 70% arising within the head of the gland)4. Another group of tumours 
that can also cause confusion are neuroendocrine tumours arising within the 
pancreas. These tumours are out with the scope of this thesis and are not referred 
to again. 
 
Although the anatomical origins of these tumours are often only separated by 
millimetres it important to differentiate between them as their prevalence and 
prognoses differ significantly. Yeo et al looked at 242 patients who underwent  
pancreatico-duodenectomy for peri-ampullary cancer over a 22 year period5. Of 
the 242 patients identified 62% were pancreatic cancers, 19% were ampullary 
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adenocarcinomas, 12% were cholangiocarcinomas and 7% were duodenal 
tumours. Post-operative 5 year survival varied greatly with tumour type: duodenal 
adenocarcinomas 59%; ampullary adenocarcinomas 39%; cholangiocarcinomas 
27%; pancreatic tumours 15%. The median survival times for the different 
tumours follows a similar pattern: duodenal tumour patients median survival was 
not reached at the time of publication; ampullary tumours 49 months; 
cholangiocarcinomas 22 months; pancreatic cancers 12 months. 
 
The study by Yeo et al demonstrates the difference in outcome for patients with 
pancreatic cancer (PC) and non-pancreatic peri-ampullary cancer (NPPC). The 
factors associated with poor survival post-resection in this study were poorly 
differentiated tumours, tumour within resected lymph nodes and tumour at 
resection margins. All of these factors were shown to be associated more 
commonly with pancreatic cancers and may account for the extremely poor 
survival statistics for that sub-group of patients. 
 
1.1.2.2 Pancreatic Cancer 
Pancreatic adenocarcinoma is generally thought to arise from the pancreatic ductal 
cells, the first evidence for this being published by Cubilla and Fitzgerald in 1976. 
This seminal study showed an increased incidence of abnormal ductal structures 
in patients with pancreatic cancer6. Cubilla and Fitzgerald, examined 227 cases of 
pancreatic cancer and 100 autopsies of patients without pancreatic cancer as 
controls. In the patients with pancreatic cancer they found the incidence of ductal 
papillary hyperplasia to be 50%, 20% of these with marked atypia and 18% with 
carcinoma in-situ, neither features were found in control cases. It was noted that 
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there was a similar spatial distribution of these lesions to malignant tumours 
which is consistent with the theory that they are developing adenocarcinomas. 
These lesions are now named areas of pancreatic intra-epithelial neoplasia 
(PanIN). 
 
Many invasive cancers have histologically well-defined precursor lesions, most 
notably carcinomas of the cervix, breast and colon. Screening programs aimed at 
discovering and treating these pre-clinical lesions in the cervix and breast have 
been in place for a number of years and studies have shown a reduction in 
mortality due to these screening programs7. These tumours are readily accessible 
for biopsy purposes, a significant advantage over the pancreas which is very 
difficult to sample and as a result, nearly all pancreatic specimens come either 
from patients who have undergone a pancreatic resection or autopsy specimens. 
These offer only a snapshot of the histological picture and it is virtually 
impossible to observe the natural history of these pre-cancerous lesions within the 
pancreas. A classification of these pre-cancerous PanIN lesions was published in 
2001with three basic categories PanIN 1, 2 and 3 with PanIN 1 separated further 
into A and B8.  
 
The detection of pancreatic cancer at an early stage is the key to treating a disease 
which has almost always spread by the time the majority of patients present to 
their medical practitioner. Current imaging techniques are unable to detect areas 
of PanIN and the inaccessibility of the pancreas makes it impossible to biopsy as 
is done with the cervix looking for precursor lesions. We currently don’t know 
what the risks of developing invasive cancer from these lesions are or the time 
scale involved, but with further research development of the correct tools, the 
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detection of PanIN lesions may offer a method of detecting very early and 
potentially curable pancreatic cancer.  
 
Currently, only a small proportion of pancreatic cancers are resectable, the only 
potentially curative option being a pancreaticoduodenectomy and a number of 
large studies have looked specifically at the factors leading to a poor outcome 
following this resection. These include: poor tumour differentiation; large tumour 
diameter; positive lymph nodes; positive resection margins; surgery out with a 
specialist centre9-13. In 2005 a study was published that added another indicator of 
poor outcome to this list and forms the basis of this thesis, a raised pre-operative 
inflammatory response14. This will be discussed in detail later in this chapter. 
 
1.1.2.3 Cholangiocarcinoma 
Tumours of the bile duct or cholangiocarcinomas are uncommon lesions arising 
from the epithelial cells of the biliary tract. They can arise at any point along the 
intra or extra-hepatic biliary tree and have a peak incidence in the seventh decade 
of life. The exact cause of cholangiocarcinoma is unknown with most cases 
occurring sporadically, but there are a number of risk factors including primary 
sclerosing cholangitis, congenital biliary cysts, hepatolithiasis, biliary infection, 
dioxin exposure and dietary nitrosamines. A number of genetic defects have also 
been associated with cholangiocarcinoma including over-expression of the genes 
Bcl-2, K-ras, p53 and p16. All of these genetic alterations are also associated with 
pancreatic cancer and will be discussed in more detail later in section 1.1.3. The 
only potential cure comes following a pancreaticduodenectomy for those patients 
with localised disease. 
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1.1.2.4 Ampullary Adenocarcinoma 
Cancers of the ampulla of Vater are the second commonest of the peri-ampullary 
tumours behind pancreatic cancers, accounting for approximately 20% of cases15. 
Ampullary tumours have a better prognosis and higher resectability rate than 
pancreatic cancers. A study by Talamini et al of 120 patients, all of whom had 
biopsy proven adenocarcinoma of the ampulla, showed a resectability rate of 
88%, a median survival of 46 months and a five year survival of 38% in patients 
undergoing resections15. The reasons for this improved prognosis may include the 
advent of endoscopy, allowing visualisation of early changes in the area of the 
ampulla and the earlier onset of jaundice thought to be due to increased intra-
luminal growth resulting in patients seeking more prompt medical attention. If 
they are resectable, ampullary tumours are removed by pancreaticoduodenectomy, 
but there has been a recent move to attempt local resection for very carefully 
selected localised ampullary tumours. With the aid of endoscopic ultrasound 
(EUS), benign lesions smaller than 3cm, small neuroendocrine tumours and T1 
carcinomas have been treated with localised resections with mixed results 16-18. 
 
1.1.2.5 Duodenal Adenocarcinomas 
Of the four peri-ampullary tumours duodenal tumours are the rarest, accounting 
for less than 10%5. Cancers of the duodenum account for approximately 45% of 
all small intestinal cancers, with 20% of them appearing in the peri-ampullary 
region19. Patients with familial adenomatous polyposis have a 100 fold increased 
risk of developing duodenal adenocarcinoma, but the vast majority of cases are 
sporadic20. Duodenal adenocarcinoma is associated with a better prognosis than 
pancreatic cancer and a higher resectability rate. A study describing 40 years of 
experience with duodenal cancers by Ryder found a resectability rate of 63%, a 
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median survival overall of 22 months, and a 5year survival of 33%19. Including 
only those patients who underwent resection, a 5 year survival of 43% was 
achieved. This same study found the factors associated with decreased survival 
were large tumours, moderate and poor tumour differentiation and invasion of 
surrounding fat. These tumours as with the other peri-ampullary tumours when 
operable are again removed by pancreaticoduodenectomy. 
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1.1.3 Genes and the Development of Pancreatic Cancer 
Pancreatic cancer, like many other malignancies appears to result from the 
accumulation of genetic abnormalities in key genes such as oncogenes and tumour 
suppressor genes, this is known as the multi-hit theory21. A number of key genetic 
abnormalities occurring with pancreatic cancer have been identified over recent 
years with the advent of modern genetic techniques. If the PanIN lesions 
described earlier are precursors to invasive adenocarcinoma then they should 
harbour some, but not all of the genetic alterations seen in invasive tumours and 
the number of these genetic abnormalities would be expected to increase with 
increasing severity of dysplasia22.  
 
1.1.3.1 K-Ras 
K-ras is a proto-oncogene that encodes a protein involved in cell growth and 
differentiation23. K-ras is mutated in over 90% of pancreatic ductal tumours 
leading to its constitutive activation and a crucial role in signal transduction24. The 
fact that the vast majority of mutations are limited to one codon means it is 
relatively easy to detect and has led to a number of efforts to create a screening 
test for pancreatic cancer. Analysis of pancreatic juice25, duodenal fluid26 and 
stool samples27 for K-ras mutations have been attempted, but none have yet been 
successful in producing a reliable screening test. 
 
A number of papers over recent years have shown that PanIN lesions harbour 
mutations in the K-ras gene and that these mutations increase in frequency with 
increasing levels of atypia28,29. These mutations have been found in specimens 
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with minimal atypia and therefore K-ras mutations are believed to be an early 
genetic event in the development of pancreatic cancer. 
 
1.1.3.2 HER-2/neu 
HER-2/neu is a member of the epidermal growth factor receptor family and is 
over expressed in approximately 70% of pancreatic ductal carcinomas30 . Day et 
al examined the expression of HER-2/neu in a series of ductal lesions and found 
there to be increasing over expression with increasing atypia in the pancreatic 
ducts31. HER-2/neu over expression is also an early event in the development of 
pancreatic cancer. 
 
1.1.3.3 p16 (INK4A) 
The p16 tumour suppressor gene is located on chromosome 9p and is inactivated 
in up to 95% of pancreatic cancers32,33. Inactivation of this gene leads to 
phosphorylation of a number of growth proteins and leads to loss of cellular 
control and unchecked proliferation24. Wilentz et al showed that 30% of flat 
ductal lesions, 55% of papillary without significant atypia and 71% of papillary 
ductal lesions with significant atypia had loss of expression of the p16 gene 
product34. Yamano et al found there was loss of heterozygosity at 9p in 13% of 
low grade ductal lesions compared with 90% of high grade lesions at the same 
location35. Although not exclusively, the loss of p16 expression occurs in higher 
grade ductal lesions and is felt to arise after HER-2/neu and K-ras abnormalities 
in the development of pancreatic cancer.  
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1.1.3.4 p53 
The p53 gene is a tumour suppressor found on chromosome 17p and is crucial to 
the way a cell responds to stressful insults as it is essential for tumour growth 
suppression. The function of p53 is lost in around 50% of cancers secondary to 
mutation and the remaining cancers appear to have defective p53 signalling36. 
Under normal non-stressful conditions p53 is kept at very low levels, but when 
exposed to DNA damage, hypoxia or other insults, activated p53 induces growth 
arrest and/or apoptosis by the induction or repression of specific genes. The p53 
gene is inactivated in 50-70% of infiltrating pancreatic cancers37,38. Maitra et al 
showed that  the p53 gene was abnormal in 57% of PanIN 3 lesions39. 
Interestingly none of the earlier PanIN lesions exhibited p53 abnormalities 
suggesting that it is an abnormality that occurs late in the development of a 
pancreatic tumour. 
 
1.1.3.5 DPCA4 (SMAD4) 
The Deleted in Pancreatic Carcinoma 4 (DPCA4) gene is a tumour suppressor 
gene located on chromosome 18q and is a member of the transforming growth 
factorβ (TGFβ) family39. DPC4 is inactivated in approximately 55% of 
invasive pancreatic adenocarcinomas by a number of different mechanisms40. A 
study by Wilentz et al looked at DPC4 in 188 PanIN lesions and found expression 
to be normal in PanIN 1 and 2 but 31% of PanIN 3 lesions had loss of 
expression41. Maitra et al also found there to be inactivation of DPC4 in 28% of 
PanIN 3 lesions and completely intact in lesions with less atypia (PanIN 1 and 
2)39. These studies both confirm that inactivation of DPC4 occurs late in the 
development of pancreatic cancer. 
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1.1.3.6 BRCA2 
Those patients with inherited tumour suppression gene BRCA2 mutations are 
known to be at an increased risk of developing breast and ovarian tumours. The 
same patients are also at an increased risk of developing  tumours in other areas 
such as the prostate, the gallbladder, the stomach, malignant melanomas and they 
have a relative risk of 3.51 (95% CI 1.87-6.58) of developing  pancreatic cancer42. 
Goggins et al found Mutations in BRCA2 occurred late in the development of 
pancreatic cancer, although this was a very limited study of only 14 PanIN lesions 
with a single mutation43. It is possible that BRCA2 loss promotes the malignant 
progression of existing lesions in the pancreas. BRCA2 is necessary for 
maintaining genomic stability by regulating the DNA repair process. The fact that 
the mutation occurs late in the tumour development suggests that it requires other 
mutations such as p53 to be present to allow the DNA damage to be tolerated as 
BRCA2 loss in normal cells leads to lethal chromosomal abnormalities44. 
 
1.1.3.7 The Pancreatic Cancer Progression Model 
Over the past 2-3 decades there have been huge advances in genetics, one of the 
key developments being the proof that cancer is a genetic disease45. Cancer is 
mostly caused by somatic mutations as opposed to germline mutations in other 
genetic diseases and generally requires an accumulation of mutations to develop. 
This theory is known as the multi-hit concept and is key to understanding the 
development of cancer21. The incidence of most common human cancers 
increases exponentially with age due to the multi-hit concept, where human 
beings collect genetic abnormalities until enough are present to cause invasive 
cancer45.  
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Vogelstein et al published their progression model for colorectal cancers 
development from colonic adenomas in 198846. A progression model for 
pancreatic cancer has more recently been published by Hruban et al (Figure 1.1) 
as a result of the improved understanding of genetic abnormalities involved in 
pancreatic cancer (discussed above) and the stage at which they appear from 
normal epithelium through the PanIN stages to invasive adenocarcinoma47. 
 
Figure 1.1: The pancreatic cancer progression model (Hruban et al47) 
    
 
The development of the progression model for pancreatic cancer paves the way 
for further research aimed at identifying lesions early before the inevitable spread 
has occurred. This research may involve the development of molecular genetic 
based screening tests looking at pancreatic or duodenal fluid25,26.  
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1.1.4 Risk Factors For Pancreatic Cancer 
As the vast majority of patients presenting with pancreatic cancer have incurable 
disease, a lot of research has been directed at disease prevention and the 
identification of risk factors involved with the development of pancreatic cancer. 
These risk factors can be divided into two categories, those that are modifiable 
and those that are not. 
 
1.1.4.1 Non-modifiable Risk Factors 
Pancreatic cancer is a disease of the elderly, its incidence increasing with age48,49. 
Over 80% of cases are diagnosed in the 60-80 year old age group, the main reason 
being the collection of genetic abnormalities discussed in section 1.1.350,51. 
In the US it has been noted for a number of years that the rate of pancreatic cancer 
was higher for African Americans than Caucasians. A number of studies have 
examined the reasons for this, but the evidence appears to be conflicting, some 
studies claiming that any difference is due confounding environmental factors, 
others claiming differing genetic mutation rates and biomarker expression52,53. 
 
A relatively small proportion of pancreatic cancers (7-10%) appear to be due to an 
inherited disposition49,54.  This “familial pancreatic cancer” appears to be distinct 
from a number of syndromes associated with an increased chance of developing 
pancreatic cancer discussed later. A study following 535 families on the National 
Familial Pancreas Tumour Registry found that in those families where there were 
three or more relatives affected, unaffected first-degree relatives were 57 times 
more likely to develop pancreatic cancer than the general population55. None of 
the families whose members developed pancreatic cancer had a history of 
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syndromes associated with aggregation of pancreatic cancer and this study 
appears to highlight a separate group of patients at a significantly higher risk of 
developing pancreatic cancer, but their genetic backgrounds are not yet 
understood. 
 
Hereditary pancreatitis (HP) is an autosomal dominant disorder that accounts for 
3-6% of all cases of pancreatitis and is caused by mutation in the cationic 
trypsinogen gene56. HP is associated with a recognised increase in the risk of 
developing pancreatic cancer. A longitudinal study followed 246 patients with a 
diagnosis of HP and compared the incidence of pancreatic cancer with that of the 
general population, showing a cumulative risk of developing pancreatic cancer of 
40% by the age of 70, increasing to 75%  with paternal transmission of HP 57. 
 
The autosomal-dominant Peutz-Jeghers syndrome, which is caused by a 
LKB1/STK11 mutation and characterised by hamartomatous gastrointestinal 
polyps and mucocutaneous pigmentation is associated with an increased risk of 
developing pancreatic cancer compared with the general population58. 
 
Hereditary non-polyposis colorectal cancer (HNPCC) is caused by a mutations in 
the DNA mismatch repair genes and accounts for approximately 5% of new cases 
of colorectal cancer a year4. Lynch first noted the connection between HNPCC 
and pancreatic cancer and pancreatic cancer is now considered an integral lesion 
in the Lynch syndrome II, with patients being at a greater risk of developing 
pancreatic cancer when compared with the general population59. 
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Familial adenomatous polyposis (FAP) is a dominantly inherited condition, the 
gene for which is carried on the long arm of chromosome 5. It is responsible for 
approximately 1% of colorectal cancers and is characterised by the formation of 
thousands of adenomas in the colon and rectum that left untreated will inevitably 
progress to colorectal cancer4. A study of 197 FAP pedigrees found a relative risk 
of 4.46 for pancreatic cancer in patients with the syndrome60. 
 
Familial atypical multiple-mole melanoma (FAMMM) is an autosomal 
dominantly inherited disorder characterised by multiple atypical nevi and multiple 
cutaneous malignant melanomas59. Patients with FAMMM who were p16 tumour 
suppressor gene positive were a subgroup at risk of developing pancreatic cancer 
and this subgroup is now termed FAMMM-PC (pancreatic cancer)61,62. 
 
A number of publications, many of them conflicting, have examined the role that 
diabetes mellitus has in pancreatic cancer63-65. A meta-analysis on the subject 
reveals that patients with diabetes do have an increased risk of developing 
pancreatic cancer66. This study identified 20 case-control and cohort studies 
between 1975 and 1994 that included cases with a duration of diabetes of at least 
1 year prior to either pancreatic cancer diagnosis or death. Their results show an 
overall relative risk of 2.1 (95% CI 1.6-2.8) for developing pancreatic cancer in 
patients with diabetes. If all patients who had diabetes for less than 5 years prior 
to their diagnosis of cancer were excluded, the relative risk was still calculated to 
be 2.0 (95% CI 1.2-3.2). As pancreatic cancer is such an aggressive disease, with 
a high proportion of patients dead within a year of diagnosis, it is highly unlikely 
that the relationship between pancreatic cancer and diabetes mellitus is due to the 
former causing the latter. Interestingly, the only two studies in this meta-analysis 
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that made a distinction between insulin-dependent and non-insulin-dependent 
diabetes both found all cases of pancreatic cancer arose from the non-insulin-
dependent group65,67. There are a number of possible explanations for this: the 
vast majority of patients developing pancreatic cancer are over 70 years of age 
and are therefore more likely to have non-insulin-dependent diabetes; the pancreas 
is exposed to low levels of exogenously administered insulin in insulin-dependent 
diabetes, but to high levels of insulin years before and after their diagnosis in non-
insulin-dependent diabetes; the hyperinsulinaemia associated with non-insulin-
dependent diabetes causes localised increases in blood flow and cell division and 
exposure to insulin has been reported to promote growth in one pancreatic cancer 
cell line68,69. 
 
A number of large studies have found an association between gastric surgery and 
pancreatic cancer. Caygill et al found there to be a four-fold risk of developing 
pancreatic cancer among 5010 post-gastric resection patients70. A review article 
found a statistically significant increased risk of developing pancreatic cancer 
after gastric resection for benign peptic disease in 4 out of 7 suitable papers71. 
This increased risk is postulated to be caused by hypoacidity leading to excess 
carcinogens such as N-nitroso compounds in gastric juice23. 
 
A number of other conditions are linked with an increased incidence of pancreatic 
cancer including Ataxia Telangiectasia and Pernicious Anaemia72-74. A persons 
height has also been postulated as a risk of developing pancreatic cancer, taller 
people having an association with the disease75. 
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1.1.4.2 Modifiable Risk Factors 
The most consistently reported modifiable risk factor associated with pancreatic 
cancer is cigarette smoking, which is named as a major risk factor in multiple 
review articles48,76-78. A prospective trial by Fuchs et al in the US looked at 
smoking as a risk factor for pancreatic cancer in healthcare professionals and 
included over 100,000 individuals followed up over a 12 year period79. They 
found the relative risk of developing pancreatic cancer to be 2.5 for current 
smokers and 1.6 for those people who had ever smoked, when compared with 
people who had never smoked. There was a dose dependent increase in risk 
between those who consumed less than 10 pack years and those who had 
consumed 26-50 pack years. The effect of cessation of smoking was also analysed 
and, the relative risk of former smokers decreasing precipitously and approaching 
that of never smokers within 10 years of giving up. Fuchs et al estimated that up 
to 25% of pancreatic cancers were attributable to cigarette smoking. 
 
The role of alcohol in the aetiology of pancreatic cancer dates back to the 1960’s 
in a retrospective review of chronic alcoholics by Burch et al80. A number of more 
recent studies have shown alcohol to be responsible for an increased risk of 
developing pancreatic cancer when consumed to excess81-83.  
 
A retrospective cohort study performed in Sweden recently looked at over 
200,000 alcoholics admitted to hospital over a 30 year period84. All patients 
developing pancreatic cancer within a year of follow up were excluded to avoid 
selection bias. Alcoholics were shown have a modest 40% increased chance of 
developing pancreatic cancer when compared to the normal population (Standard 
Incidence Ratio of 1.4 [95% CI of 1.2-1.5]). The authors acknowledged that 
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information regarding smoking was deficient but using data regarding the rates of 
smoking among the different groups of patients in Sweden over the time period in 
question calculated that the increased risk of pancreatic cancer in those groups 
related to alcohol consumption could be entirely explained by the confounding of 
smoking. 
 
Another large study published by a Canadian group looked again at the 
relationship between pancreatic cancer and alcohol consumption in 583 confirmed 
cases with 4813 controls85. The results showed that there were varying risks 
depending not only on the types and amounts of alcohol consumed, but also 
between the sexes. The fact that there are differing reports into the effects of 
alcohol on pancreatic cancer and so many confounding issues suggests that further 
research is needed including details into the specific types of alcohol consumed. 
 
Although the connection between pancreatic cancer and alcohol consumption 
alone is not yet established, alcohol excess can lead to pancreatitis. Hereditary 
pancreatitis is associated with a significantly increased lifetime risk of developing 
pancreatic cancer, but are other forms of pancreatitis (chronic) associated with a 
similar risk? Two large studies have shown an increased risk of pancreatic cancer 
in patients with chronic pancreatitis varying between a relative risk of 2.04 and 
18.586,87. However, both are retrospective, relying on information gathered from 
patient registers and have differing definitions for the diagnosis of chronic 
pancreatitis. A prospective, single centre trial observing 373 consecutive patients 
with a definite diagnosis of chronic pancreatitis based on: pancreatic calcifications 
on imaging; moderate to marked pancreatic ductal lesions on ERCP (Cambridge 
criteria); typical histology on adequate surgical pancreatic specimens; shows a 
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connection between chronic pancreatitis and pancreatic cancer88. The results show 
a significantly increased risk of developing pancreatic cancer amongst these 
patients with a standardised incidence ration (SIR) of 26.7. However, this study 
contained only four cases of pancreatic cancers and no real conclusions about this 
relationship can be drawn from this or the previously discussed retrospective 
studies. 
 
Early evidence indicated that coffee drinkers were associated with an increased 
relative risk of developing pancreatic cancer, but more recent studies have found 
no evidence for this85,89-91. 
 
The ingestion of fatty foods and foods high in cholesterol is associated with an 
increased risk of pancreatic cancer76,92-95. A high dietary intake of meat, 
particularly smoked meat is also associated with an increased risk of pancreatic 
cancer92,95,96. Other high risk foods for the disease include dairy products and diets 
including high amounts of carbohydrate, salt and sugar92,95,97. Food types which 
seem to have a protective role in other cancers also seem to be associated with 
lower rates of pancreatic cancer, these include fruit and vegetables and other high 
fibre foods76,92,93,95. 
 
A large cohort study involving over 150,000 healthcare professionals found 
obesity to be associated with an increased risk of pancreatic cancer with moderate 
physical activity having a protective role75. A body mass index (BMI) of 30kg/m2  
or greater was associated with a relative risk for developing pancreatic cancer of 
1.72 (95% CI 1.19-2.48) when compared with those patients with a BMI of 
23kg/m2 or less. A relative risk of 0.45 (95% CI 0.29-0.70) was observed for those 
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undertaking moderate activity when compared to those in the lowest activity 
category. 
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1.1.5 The Presentation of Pancreatic Cancer 
Pancreatic cancer is associated with a dismal prognosis, with only 5-15% of 
patients presenting with disease that is amenable to surgery, the only potential 
cure98. The idea that pancreatic cancer classically presents with painless jaundice 
does not always hold true and a number of other symptoms are commonly 
associated with the disease. When the literature is examined the commonest 
presenting symptoms are pain, jaundice, weight loss, anorexia, early satiety, 
nausea, vomiting, diarrhoea, xerostomia and are associated with signs such as 
jaundice, a palpable liver or gallbladder, ascites and thrombophlebitis.  
 
One of the reasons the prognosis for pancreatic cancer is so poor is because the 
symptoms and signs that lead a patient to present to a medical practitioner are 
often only present once the tumour has reached an advanced stage. A review 
article by Brand describes a group of early vague symptoms that include non-
specific abdominal pain, nausea, vomiting, sleeping difficulties, anorexia and 
general malaise99. These symptoms although troublesome may not lead a patient 
to their doctor and even if they do, may not prompt the necessary investigations to 
uncover an early pancreatic malignancy. The onset of jaundice which would 
usually lead to investigations of the biliary tract may be a late sign depending on 
the location of the growing tumour. 
 
A study by Krech et al looked at the common symptoms experienced by patients 
with pancreatic cancer100. The commonest symptom described was abdominal 
pain with 82% of patients experiencing it, most commonly in the right upper 
quadrant. The other symptoms described by more than 50% of the patients were 
anorexia (64%), early satiety (62%), xerostomia (54%), sleep problems (54%), 
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and weight loss (51%). None of these symptoms are specific to pancreatic disease 
which again demonstrates the reasons for late diagnosis. 
 
There are certain signs and symptoms that should prompt investigation, but are 
often associated with more advanced disease. Migratory thrombophlebitis 
(Trousseau’s sign) has been reported in around 7% of patients with pancreatic 
cancer101. Diabetes Mellitus is present in around 15% of patients with pancreatic 
cancer and many more have glucose intolerance. New onset diabetes or a change 
in insulin requirements in a stable diabetic may be signs of a pancreatic 
malignancy. As mentioned earlier controversy exists around the role that 
pancreatitis plays in pancreatic cancer, whether it is just a sign of a developing 
tumour, or is itself a risk factor for the disease. Patients presenting with 
pancreatitis that have none of the normal risk factors (alcohol excess, gallstones) 
for the disease, should have further investigations to rule out a malignancy.  
 
Jaundice, a sign that would lead to investigations of the biliary tract, can appear 
early or at an advanced stage depending on the location of the tumour. Kalser et al 
looked at the prognosis of 399 patients with pancreatic cancer by examining their 
clinical presentation102. The patients were grouped according to their disease 
stage, group 1 potentially curative, group 2 locally unresectable, and group 3 had 
metastatic disease. Group one had the smallest lesions and 90% had a pancreatic 
head tumour. In this group painless jaundice was the most frequent presentation 
(52%). Group 2 had 83% of their tumours located in the head of the pancreas with 
pain present in 80% of cases, jaundice in 62% and 48% having both. In group 3 
lesions of the body and tail were 4 and 3 fold greater than in groups 1 and 2 
respectively. Pain was present in 85% of cases and jaundice in only 31%. This 
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study suggests that those patients with potentially resectable disease do not tend to 
present with pain which is the commonest symptom in most other papers100,103,104. 
 
From the studies discussed above, pain appears to be associated with more 
advanced disease and is probably caused by invasion through the capsule and into 
the coeliac and superior mesenteric plexuses. We can conclude that the 
commonest symptom for patients presenting with pancreatic cancer is pain. These 
patients are likely to have more advanced disease and make up the vast majority 
of the 85-95% of patients who have inoperable disease. Those with tumours of the 
body and tail of the gland are likely to be in this group. Those patients who have 
tumours in close proximity to the bile duct (ie. head tumours) are much more 
likely to present with obstructive jaundice and undergo relevant investigations 
quickly. These are likely to be the patients with potentially resectable disease and 
are unfortunately in the minority.  
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1.1.6 The Diagnosis and Staging of Pancreatic Cancer 
A patient presenting to either their GP or a hospital with any of the symptoms 
discussed above will need to undergo a number of different investigations before a 
diagnosis of pancreatic cancer can be made. Following a detailed history and 
examination it is likely the treating doctor will go on to request blood tests, the 
results of which are likely to lead to a number of radiological investigations. Only 
after the relevant investigations have been completed can the definitive diagnosis 
be made and the process of staging the tumour can begin. 
 
1.1.6.1 Blood Tests 
Unfortunately laboratory blood tests on patients with pancreatic cancer are 
generally non-specific. If jaundice is present the patient will likely have 
obstructive liver function tests (LFT’s) with raised alkaline phosphatase, raised 
γglutamyl transferase along with an increased bilirubin. If the transaminases are 
increased disproportionally, this may be a sign of extensive liver metastases. 
Along with the abnormal LFT’s, the patients clotting may be affected due to the 
malabsorption of fat soluble vitamin K and hence decreased production of vitamin 
K dependent clotting factors. There may be other non-specific abnormalities such 
as a low albumin, anaemia and evidence of impaired glucose tolerance or frank 
diabetes. 
 
There are a number of serological markers often used to help establish a diagnosis 
of pancreatic cancer. The most commonly used is Carbohydrate antigen 19-9 
(CA19-9). The efficacy of this marker in detecting pancreatic cancer has been 
extensively studied, having a sensitivity of around 80% and a specificity of 60-
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70%103,105. There are a number of drawbacks with this marker. First, increased 
concentrations are normally only found in tumours with a diameter of more than 
3cm, excluding the vast majority of resectable tumours. Second, CA19-9 is not 
only raised in other GI tumours including the stomach, bile ducts and the colon, 
but in some benign conditions such as pancreatitis, hepatitis and cirrhosis103. 
However, when combined with radiological imaging such as CT, US or ERCP the 
diagnostic accuracy is improved and approaches 100%106. CA 19-9 has also been 
correlated with prognosis and tumour recurrence. Generally a higher CA 19-9 pre-
operatively indicates a larger tumour and an increased chance of unresectability. 
When used post-operatively to assess adjuvant treatments, increasing levels of CA 
19-9 generally indicate disease progression or recurrence, whereas stable or 
decreasing levels tend to  indicate a stable tumour burden or absence of 
recurrence107. 
 
Other serological assays have been identified as potential markers for pancreatic 
cancer, these include carcinoembryonic antigen (CEA), carbohydrate antigen 50 
(CA-50) and carbohydrate antigen 242 (CA-242). However, none of these have 
been found to be consistently superior to CA 19-9108-110. 
 
Currently none of the serological markers are able to detect an early pancreatic 
cancer and certainly none are suitable as a screening test which would lead to 
potentially improved survival figures due to earlier surgical treatment. The 
developments in molecular and genetic medicine are most likely to lead to the 
early detection of pancreatic cancer in the future, but at the moment serological 
tests are only used as adjuncts to radiological imaging. 
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1.1.6.2 Diagnostic Imaging 
Over the last 20 years there have been huge advances in radiological imaging 
which have greatly enhanced the ability to diagnose and stage pancreatic cancer. 
During the process of diagnosing and then staging patients with pancreatic cancer 
the results of a number of radiological investigations are combined to provide 
adequate information on the tumour and enable accurate staging. There is 
currently no single modality that can accurately stage the disease in its own right. 
 
The two aims of imaging in patients who have or may have either PC or NPPC 
tumours are: 
1/. To confirm the diagnosis. 
2/. To assess resectability. 
The features that are generally accepted to preclude surgical resection are111,112: 
1/. Metastatic spread to the liver or peritoneum. 
2/. Vascular invasion/ encasement. 
3/. Lymph node spread. 
4/. Spread to contiguous structures such as the stomach, colon, spleen, or spine. 
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1.1.6.2.1 Computed Tomography (CT) 
Abdominal CT scanning is currently the method of choice for the diagnosis and 
staging of pancreatic. Modern multi detector CT scanners (MDCT) mean faster 
scanning with thinner slices allowing multi-planar, three dimensional 
reconstruction. The use of water as oral contrast and timed IV contrast injections 
(venous, arterial, pancreatic) enable the visualisation of the course of blood 
vessels and bile ducts in and around the pancreas. CT has been shown to have 
excellent results in the diagnosis of pancreatic cancer with a positive predictive 
value of 92%, a sensitivity of 96%, a specificity of 81% and an accuracy of 
88%113,114. 
 
CT is excellent for predicting unresectability of pancreatic tumours, helical CT 
having accuracies of non-resectability of between 93 and 96%115,116. However, of 
patients with tumours deemed to be resectable on pre-operative scanning, the 
accuracy of helical CT has been shown to be far less 72-91%113,117. The 
commonest reasons for the under staging of pancreatic tumours are small liver 
metastases, lymph node involvement, peritoneal spread and vascular 
invasion113,118,119. 
 
CT is an excellent modality for diagnosing PC’s and NPPC’s and for identifying 
non-resectable tumours but is not good at giving accurate information on 
borderline tumours or identifying small peritoneal or liver metastases. To try and 
identify these non-resectable tumours CT is used in conjunction with other 
radiological modalities described below. 
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Figure 1.2: MDCT reconstruction of pancreatic duct showing small pancreatic 
head cancer (arrow) and a dilated pancreatic duct immediately distal to the 
obstruction120. 
 
 
Figure 1.3: MDCT paracoronal reconstruction of dilated common bile duct 
(arrowhead) and a peri-ampullary tumour projecting into the duodenum (arrow)111 
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1.1.6.2.2 Endoscopic Ultrasonography (EUS) 
Endoscopic ultrasonography (EUS) was developed in the 1980’s to try and 
overcome the limitations of trans-abdominal US by eliminating interference from 
overlying bowel gas, improving resolution of the pancreas and surrounding 
structures and also enables tissue sampling 121. 
 
Midwinter et al compared 48 patients with suspected pancreatic and ampullary 
cancers122. EUS demonstrated 33 of the 34 tumours compared to 26 with CT. EUS 
was particularly useful in demonstrating small tumours missed by CT.  
Tierney et al found EUS to be more sensitive in the identification of vascular 
involvement in 51 patients with non-metastatic, peri-ampullary malignancies 
when compared to helical CT and concluded that EUS is particularly useful when 
CT findings were equivocal123. 
 
The added advantage of EUS is its ability to take tissue samples. The diagnostic 
ability of EUS guided fine needle aspiration (EUS-FNA) in diagnosing pancreatic 
malignancies has been examined in a number of studies124-126. Sensitivities of 91-
94%, specificities of 67-100% and accuracies of 92% were achieved. 
 
EUS cannot replace CT as it is unable to include the whole of the abdominal 
cavity in the staging process. However, EUS is of particular value as an adjunct to 
CT scanning, particularly where the diagnosis is not known, in small tumours and 
where resectability is uncertain after CT. EUS is also able to gain tissue diagnoses 
from pancreatic lesions or from lymph nodes if spread is being questioned. 
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1.1.6.2.3 Magnetic Resonance Imaging (MRI) 
MRI has always had the advantage of not exposing the patient to ionising 
radiation and the ability of modern MRI scanners to perform pancreatography 
(MRCP) and angiography at one sitting has shown comparable accuracy in terms 
of the diagnosis and staging of pancreatic cancer114,118. 
 
With the current technology MRI is unlikely to replace CT as the Gold-standard 
investigation, but may have a role to play in those patients where CT is 
inconclusive or resectability is uncertain. Trials are awaited to see if the 
administration of secretin prior to MRI scanning and the resulting increased 
secretion of pancreatic juice improves results112,127. 
 
1.1.6.2.4 Ultrasound (US) 
Abdominal US is often the initial screening investigation for patients with 
pancreatic cancer, particularly those suffering from jaundice as it is non-invasive, 
cheap and readily available. US can also identify gallstones, liver metastases, the 
level of biliary obstruction and the presence of abdominal ascites as well as the 
size, site and characteristics of the primary tumour103. Overlying bowel gas, 
abdominal ascites large amounts of fat and the operator can all significantly affect 
the accuracy of US, particularly when looking at the pancreas due to its 
retroperitoneal location. US will never be considered as a rival to CT, but with the 
advent of new technologies such as contrast harmonics it may have a role to play 
as an adjunct to CT looking for liver metastases for example, but trials of this new 
technology are awaited. 
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1.1.6.2.5 Endoscopic-retrograde-cholangiopancreatography (ERCP) 
ERCP allows direct visualisation of the pancreatic duct, the ability to gain 
cytological information with brushings and the deployment of biliary stents where 
necessary. ERCP will never be the mainstay of staging and its role tends to be in 
those patients who present with jaundice and are found to have a dilated common 
bile duct (CBD). The finding of an irregular stricture in an otherwise normal 
pancreatic duct is a sign of a possible malignancy and a simultaneous stricture in 
the common bile duct, the ‘double-duct sign’ (Figure 1.4) is often considered a 
specific sign of ductal adenocarcinoma128. However, cancers arising in the 
pancreatic body or tail rarely present with a double duct sign and not all head 
cancers involve the common bile duct meaning this sign will not be present in a 
significant proportion of pancreatic cancers. Despite this, ERCP has been has 
been shown to predict pancreatic adenocarcinoma with a sensitivity of 70-92% 
and a specificity of 90-94%129,130. It should be remembered that ERCP is an 
invasive procedure with associated risks such as pancreatitis (moderate-severe 
1.3%), cholangitis (0.87%), haemorrhage (0.76%) and perforation (0.58%)131. The 
relief of biliary obstruction in those patients with resectable disease by biliary 
stenting is controversial, a meta-analysis showing no statistical advantage and a 
higher post-op complication rate132. 
 
ERCP will continue to be used commonly in the investigation of obstructive 
jaundice, diagnosing the vast majority of pancreatic tumours that present in this 
way, however its main advantages are therapeutic in both operable and non-
operable pancreatic and biliary malignancies.  
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Figure 1.4: Double-duct sign on ERCP 
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1.1.6.2.6 Positron Emission Tomography (PET)   
Positron emission tomography scanning or PET scanning, is a newer imaging 
technique that works on the basis that an IV administered radio-labelled glucose 
analogue metabolism is increased in malignant cells when compared to normal 
tissue allowing them to be identified121. A number of studies have compared PET 
to CT scanning, but due to its current lack of availability PET will not replace CT 
in the near future. As with a number of imaging techniques it may add to the 
staging information of patients with pancreatic cancer, particularly in picking up 
small hepatic or peritoneal deposits. 
 
Rose et al examined 70 patients who were being investigated for either primary 
(65) or recurrent (5) pancreatic cancer performing CT and PET133. PET scanning 
suggested changes in the management in 43% of patients after CT. In nine 
patients who underwent FDG-PET before and after neo-adjuvant chemotherapy, 
four had evidence of tumour regression, three showed stable tumours and two 
showed disease progression, none of these changes were identifiable on CT. This 
paper shows that FDG-PET not only has a role in the diagnosis and staging of 
pancreatic cancer, but may also be useful in evaluating treatment response and 
tumour progression.  
 
The latest advances have combined CT (anatomical imaging) and PET 
(physiological imaging), with promising results. Heinrich et al looked at 59 
patients with presumed resectable pancreatic cancer, comparing standard staging 
(chest x-ray, CT) and combined CT/PET134. The CT/PET demonstrated hepatic 
metastases in five patients and 2 patients with synchronous rectal tumours that 
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weren’t seen on standard staging. Management was changed in 16% of cases 
(p<0.03) as a result of CT/PET. 
 
This new technology needs to be evaluated in large, prospective trials to see if 
these promising results hold true, but until PET scanners are more available it will 
not form part of standard staging for pancreatic cancer. 
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1.1.6.3 Surgical Staging 
A proportion of patients who have been found to have potentially resectable 
tumours following a combination of the previously discussed imaging modalities, 
will in fact have metastatic disease discovered at the time of surgery. A large 
study in 768 patients undergoing laparotomy for peri-ampullary cancer found 33% 
had evidence of metastatic disease at laparotomy not seen on pre-operative 
staging135. Of this 33%, 68% were found to have metastatic deposits in the liver or 
peritoneum suggesting that a staging laparoscopy would have enabled surgeons to 
discover these small metastatic deposits thus avoiding a laparotomy and the 
morbidity and mortality it entailed (3.1% and 22% respectively in this study). 
 
Conlon et al performed extended laparoscopy (with the use of several ports) on 
108 patients felt to have resectable disease following radiological investigations 
and discovered 41 (36%) had metastatic deposits136.  
 
The addition of laparoscopic US (LUS) was examined in 90 patients with 
pancreatic cancer by Merchant and Conlon137. Of the initial 90, 17 were found to 
have non-resectable disease radiologically, laparoscopy went on to identify a 
further 41 (45%) patients with metastatic disease. Thirteen patients were deemed 
to have equivocal findings and underwent additional LUS, which deemed 8 non-
resectable cases. Overall, only one patient deemed resectable actually had non-
resectable disease, giving the combined technique a positive predictive index of 
100% and a negative predictive index of 98%.  
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The largest study looked at 239 patients with peri-ampullary/pancreatic 
malignancy who underwent both CT and LUS for staging purposes138. Of the 239 
patients, 190 were found by CT to have resectable disease, the addition of LUS 
identified 23 further patients who had metastatic spread. However, of the 167 
patients identified by both CT and LUS as having resectable disease, 31 (16%) 
were found to have metastatic disease at laparotomy. 
 
The role of laparoscopy with or without US in the staging of pancreatic cancer 
remains controversial. There appears to be substantial evidence in the literature 
supporting its use, however the largest study to date showed that LUS still missed 
16% of the cases of metastatic spread. It can be argued that performing a 
laparotomy in the first instance allows the surgeon to perform a prophylactic 
bypass if a non-resectable tumour is found, but laparoscopic-gastro-jejunostomy is 
now a widely used and safe alternative and many patients will have a biliary stent 
in place139. The use of LUS in the staging of pancreatic cancer is not universal and 
performed at the discretion of individual investigators. 
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1.1.7 Treating Pancreatic Cancer 
1.1.7.1 Background 
Pancreatic cancer has one of the poorest outlooks of all malignancies, with 
surgical resection improving the outlook in the 10% of patients who are eligible 
for the procedure after staging2,140. Following surgery survival is poor and 
dependent on a number of factors, firstly the type of tumour, with pancreatic 
cancer having a median survival of 15-17 months, significantly worse than the 
other non-pancreatic peri-ampullary cancers (NPPC)5,9.  
 
When the reasons for treatment failure are examined, local spread is the major 
culprit with 72-86% of patients succumbing to recurrence in the pancreatic bed 
and 62-92% to hepatic recurrence13,141. These figures suggest microscopic spread 
present prior to surgery which is not visible either in pre-operative staging, or 
during the procedure itself and is an obvious target for adjuvant therapy. 
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1.1.7.2 Factors Associated with Poor Outcome 
A number of factors have been shown to have a negative affect on survival on 
patients with pancreatic cancer on multivariate analysis. These factors are: the size 
of the tumour (larger tumours doing poorly); positive resection margin; lymph 
node invasion; poor differentiation; surgery performed out-with a specialist unit9-
13
. Table 1.1 below displays the factors associated with poor survival and the 
relevant publications. 
 
 
Table 1.1: Factors associated with poor survival following Whipple operation for 
pancreatic cancer. 
Author Ref. 
Number 
Patients Tumour 
Size 
(>2cm) 
+’ve 
RM 
LN 
Invasion 
Poor 
Diff 
Surgery 
Out with 
Specialist 
Centre 
Sohn TA 9 616 X* X - X - 
Yeo CJ 10 650 X* X X X - 
Lim JE 11 396 X - X X X 
Birkmeyer 
JD 
12 7229 - - - - X 
Sperti C 13 78 X X X X - 
* Size >3cm. 
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1.1.7.3 Surgical Treatment 
Surgery for pancreatic cancer involves a major abdominal procedure with retro-
peritoneal dissection and multiple anastamoses, resulting in significant morbidity 
and mortality. The technique of pancreaticoduodenectomy (PD) was first 
described by Kausch in 1912 but later popularized by Whipple whose name is 
now synonymous with the procedure142. Post-operative morbidity and mortality 
rates were exceptionally high, 60% and 25% respectively in early series in the 
1960’s. Now, the majority of Whipple operations are carried out in specialist 
centres, where mortality rates are reported as less than 5%, although morbidity 
still remains high at around 40%10,143-146. The most common causes of morbidity 
are often not life threatening, but amount to increased hospital stay and delayed 
onset of adjuvant therapy. These include delayed gastric emptying, pancreatic 
fistula and wound infection.  
 
Despite the advances in surgical techniques, equipment and peri/post-operative 
care, survival rates in the 10% of pancreatic cancer patients who have disease 
amenable to surgery remain poor. Five-year survival for patients undergoing a 
potentially curative resection, vary greatly depending on the site of origin of the 
tumour, the best being duodenal (59%), followed by ampullary (39%), 
cholangiocarcinoma (27%) and finally ductal (15%) in a study of 242 patients5.  
 
The most common technique of a Whipple procedure consists of the en bloc 
removal of the distal segment (antrum) of the stomach, the first and second 
portions of the duodenum, the head of the pancreas, the common bile duct, and 
the gallbladder. Following removal of the specimen, continuity of the bowel is re-
established along with a pancreaticojejunostomy and a hepaticojejunostomy. 
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More recently, the pylorus- preserving pancreatico-duodenectomy (Whipple) has 
been described. A large randomised trial of 214 patients comparing the two 
techniques was published by Seiler et al in 2005147. On analysis, the only 
significant differences between the two groups were operating time, blood loss 
and blood transfused, all being less in the pylorus-preserving group. There was no 
significant difference in mortality and morbidity (both medical and surgical which 
included delayed gastric emptying) and long-term follow up found no significant 
difference between the two groups in terms of overall survival, tumour recurrence 
or quality of life. 
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1.1.7.4 Adjuvant Treatment 
A number of retrospective studies have suggested that adjuvant therapy may 
improve long-term survival, but until recently adjuvant therapy was not routinely 
used following surgery for pancreatic cancers and NPPC’s  9,11,148. 
 
A large, multi-centre randomised trial looking at surgery, combined chemo-
radiation and chemotherapy alone was needed and The European Study Group for 
Pancreatic Cancer (ESPAC) was set up to do this2. The study used a two-by-two 
design where, following resection each patient was randomly assigned to receive 
chemoradiotherapy or chemotherapy, neither treatment, or both treatments, with 
70 patients enrolled in to each group, yielding combined data for 140 patients in 
each group for the two main treatment comparisons (chemo-radiotherapy vs no 
chemo-radiotherapy and chemotherapy vs no chemotherapy). Patients who 
underwent a complete macroscopic resection of a histologically proven pancreatic 
ductal adenocarcinoma underwent randomisation.  
 
Chemo-radiotherapy consisted of a 20-Gy dose to the tumour given in 10 daily 
fractions over a two week period plus IV bolus of fluorouracil on each of the first 
three days of radiotherapy and again after a break of two weeks. Chemotherapy 
consisted of an IV bolus of leucovorin, followed by an IV bolus of fluorouracil on 
each of five consecutive days every 28 days for six cycles. Combination therapy 
was the above regimes starting with chemo-radiotherapy followed by 
chemotherapy.  
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A total of 289 patients were enrolled from 53 hospitals all over Europe between 
February 1994 and June 2000. When the results were analysed for the two main 
areas of comparison, those patients who underwent chemo-radiation had a median 
survival of 15.9 months and estimated five year survival of 10% compared with 
17.9 months and 20% for those who did not get chemo-radiation (p=0.05). Those 
that had chemotherapy had a median survival of 20.1 months and estimated five 
year survival of 21% compared to 15.5 months and 8% in those that didn’t receive 
chemotherapy (p=0.009). When the four individual groups were examined their 
median survivals were 16.9 months in those that had observation alone, 13.9 
months in those that had chemo-radiation, 21.6 months for those that got 
chemotherapy alone and 19.9 months in those that received both chemo-radiation 
and chemotherapy. The estimated five year survival for each of these groups was 
11%, 7%, 29% and 13% respectively. The explanation given for the apparent 
detrimental effect of chemo-radiation on those that received chemotherapy was 
that the chemo-radiation delayed the onset of chemotherapy post-operatively. This 
study shows that the standard treatment for those patients with resectable 
pancreatic cancer should be curative surgery followed by adjuvant systemic 
chemotherapy. 
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1.1.8 Summary 
In summary, pancreatic cancer is a devastating condition with only a very small 
proportion of patients with potentially curable disease. Current methods of staging 
still miss a significant number of patients who actually have non-resectable 
disease, although there have been improvements in radiological staging over the 
last couple of decades. The treatment hasn’t changed significantly for half a 
century in those patients lucky enough to have resectable disease, but even after 
major surgery and more recently adjuvant chemotherapy, median survival is a 
mere 21 months2. There are a number of well established pathological factors that 
have a negative affect on survival including, larger tumours, positive resection 
margins, lymph node spread, and poorly differentiated tumours but these rely on 
the post-operative specimen9-13. Identifying the patients that do poorly after 
surgery and learning more about the genetic and molecular make-up of these 
patients may lead to new therapeutic options and improved survival. 
 
In 2005 Jamieson et al published a paper looking at 65 patients who underwent 
resection for ductal adenocarcinoma of the head of the pancreas. On univariate 
analysis, sex (p<0.05), tumour size (p<0.05), vascular invasion (p<0.001), pre-
operative CRP (p<0.001) and post-operative CRP (p<0.001) were significantly 
associated with survival. On multivariate analysis of the significant variables, 
tumour size, vascular invasion, pre and post-operative CRP retained independent 
significance. In fact the group of patients who did not have a raised pre-op CRP 
(<10mg/l) had a median survival of 18.2 months compared with only 8.3 months 
in those with a raised CRP (p<0.001). There was no significant difference in the 
stage, presence of positive resection margins, lymph node metastases or perineural 
invasion between the inflammatory and non-inflammatory groups. 
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This paper suggests that a pre-operative inflammatory response is significantly 
associated with a poor post-operative survival in patients with resectable 
pancreatic cancer. This paper forms the basis of this thesis and in the next section 
the relationship between inflammation and cancer is explored. 
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1.2 Inflammation and Cancer 
1.2.1 Introduction 
The link between inflammation and cancer has been recognised for many years, 
Virchow noting the presence of leukocytes in neoplastic tissue in 1863, suggesting 
that this reflected the origin of cancer at sites of chronic inflammation149. A 
number of cancers are known to have a relationship with chronic inflammation, 
including: squamous cell carcinoma development at the site of burned skin 
(Marjolins ulcer)150; Barretts metaplasia pre-disposing to oesophageal cancer151; 
the increased chance of colorectal cancer development in patients with 
inflammatory bowel disease (IBD)152; the development of mesothelioma 
following asbestos exposure153. As mentioned above hereditary pancreatitis57 and 
more controversially chronic pancreatitis88 are associated with an increased risk of 
developing pancreatic cancer. There are also a number of cancers associated with 
chronic infections leading to chronic inflammation which are thought to account 
for up to 15% of the worlds cancer burden154, including: schistosomiasis and 
bladder cancer; liver fluke infection and cholangiocarcinoma; papillomavirus and 
cervical cancer; helicobacter pylori and gastric cancer; Hepatitis B and C and 
hepatocellular tumours. These examples demonstrate the link between 
inflammation and the development of malignancy, but what are the mechanisms 
behind this transformation? 
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1.2.2 Inflammation and the Pathogenesis of Cancer  
Chronic inflammation may progress from acute inflammation if the initial cause is 
not removed, but can be chronic from the outset. Chronic inflammation is 
characterized by infiltration of damaged tissue by cells such as macrophages, 
lymphocytes and plasma cells that attempt repair of the damaged tissues155. 
Macrophages are the most important cells in the chronic inflammatory reaction 
due to their production of multiple inflammatory mediators and products. These 
include plasminogen activator, enzymes, plasma proteins, complement 
components, coagulation factors, reactive metabolites of oxygen, cytokines, 
chemokines, growth factors and nitric oxide. A number of these mediators and 
products are thought to be crucial in the transformation from inflamed tissue to 
cancer. 
 
The pro-inflammatory cytokine tumour necrosis factor (TNF) is a key 
downstream promoter of inflammation and is known to regulate a cascade of 
cytokines, chemokines and inflammatory mediators149. The major source of TNF 
appears to be macrophages which have infiltrated the area of inflamed tissue. 
TNF’s actions include both tissue destruction as well as recovery and whilst it can 
destroy a diseased cell at sites of inflammation it can also stimulate fibroblast 
growth. TNF can also be both pro and anti-angiogenic depending on the 
surrounding conditions and the amount present at a specific site. Chronically 
produced TNF, for example in areas of chronic inflammation, can act as a tumour 
promoter aiding the development of the necessary stroma tumours require for 
growth and spread. It may be that TNF is one of the ways in which inflammation 
acts as a tumour promoter. Evidence for this has been demonstrated using 
genetically engineered mice that lack the TNF gene. These mice were shown to be 
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resistant to skin carcinogenesis despite exposure to known carcinogens156. TNF 
has also been the target for a number of clinical trials involving inflammatory 
disorders such as rheumatoid arthritis and Crohns disease using licensed TNF 
antagonists such as inflixamab, with initial results showing symptomatic relief157. 
Anti-TNF drugs are licensed for cytokine/chemokine inhibition, reduced 
angiogenesis and prevention of leucocyte infiltration, all of which may be useful 
in a biological therapy for cancer. In fact there are a number of ongoing and 
planned studies involving anti-TNF therapies as single agents and in combination 
with other therapies in the treatment of cancer. 
 
There are many similarities between tumour stroma and areas of inflammation 
and thus similarities between wound healing and tumour stroma formation. In a 
review article Dvorak described tumours as ‘wounds that do not heal’ and it may 
be that a persistent stimulus over a long period of time (chronic inflammation) 
disrupts the normal balance between key molecules in the inflammatory response 
leading to tumour promotion, with TNF being one of these molecules158.  
 
Another key molecule in the inflammatory pathway is the ubiquitously expressed 
transcription factor nuclear factor kappa B (NF-κB). NF-κB regulates the 
expression of various inflammatory, apoptotic and oncogenic genes159. Activation 
of NF-κB occurs by a number of stimuli including IL-1, protein kinase C, reactive 
oxygen species, viruses, but is primarily induced by TNF160,161. Once activated at 
sites of inflammation NF-κB causes increased transcription of 27 different genes 
encoding for cytokines, chemokines  and receptors crucial for neutrophil adhesion 
and migration including IL-2, IL-2R, IL-6, IL-8, IL-12 and TNF162. These 
cytokines can in turn activate the NF-κB pathway establishing a positive 
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autoregulatory loop that sustains and amplifies the inflammatory response. NF-κB 
also induces nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX 2), two 
enzymes vital to the inflammatory response and may be responsible for the 
initiation of oncogenic changes in inflamed tissue. 
 
NF-κB has been shown to exert important effects on cellular apoptosis and 
proliferation via the activation of anti-apoptotic genes including cellular inhibitors 
of apoptosis (c-IAP1, c-IAP2, and IXAP) the TNF receptor-associated factors 
(TRAF1 and TRAF2), the Bcl-2 homologue A1/Bfl-1, and IEX-IL162. In 
pancreatic cancer, TNF related apoptosis was shown to be inhibited by the co-
activation of NF-κB which in turn activated the anti-apoptotic genes mentioned 
above blocking the activation of caspase-8, an initiator protease, involved at an 
early step in stimulating the apoptotic pathway163. 
 
Although more research is needed, NF-κB may well be the key molecule that 
connects inflammation and cancer. It is activated in inflammatory conditions 
going on to regulate many genes coding for key inflammatory proteins. This 
creates an autoregulatory loop that propagates and prolongs inflammation in the 
exposed tissues, as well as causing inhibition of apoptosis. 
 
The generation of nitric oxide (NO) by the inflammatory cytokine induction of 
nitric oxide synthase (iNOS) is present in inflamed tissue and is thought to exert 
oncogenic effects via a number of mechanisms. These include direct DNA and 
protein damage, inhibition of apoptosis, mutation of DNA and cellular repair 
functions (e.g. p53) and promotion of angiogenesis164
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by macrophages, the iNOS gene is under transcriptional control of inflammatory 
cytokines which are in rich supply in inflamed tissue. 
 
Another inducible enzyme that is active within inflamed and malignant tissues is 
cyclo-oxygenase-2 (COX-2)155. COX or prostaglandin H2 synthase is the key 
enzyme in the biosynthesis of prostaglandins mediating inflammation and other 
important physiological processes165. It has been shown to exist as two isoforms, 
COX-1 and COX-2. COX-1 is a housekeeping enzyme and expressed in nearly all 
tissues mediating physiological responses such as protection of the stomach, 
platelet aggregation and regulation of renal blood flow. COX-2 is expressed in 
cells that mediate inflammation such as macrophages and monocytes and is 
primarily responsible for the synthesis of prostaglandins involved in acute and 
chronic inflammatory states and hence may be involved in malignant change in 
inflamed tissues. Many malignancies produce more prostaglandins than normal 
tissue and this increased production comes from enhanced expression of COX-2. 
This increased expression is thought to be due to mutations activating signalling 
pathways such as the mitogen activated protein kinase (MAPK) pathway. 
 
There are different mechanisms by which COX-2 is thought to enhance 
carcinogenesis each of which has evidence to support it. Accumulation of 
arachidonic acid favours apoptosis and its depletion favours cell survival therefore 
increased levels of COX-2 will decrease available arachidonic acid giving cells a 
survival advantage166. The second mechanism which is more widely accepted is 
that prostaglandins formed via COX-2 govern key processes involved in cell 
growth and differentiation such as the suppression of apoptosis and the 
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enhancement of angiogenesis, providing an optimal environment for tumour 
growth and spread. 
 
Further evidence for the role of COX-2 in neoplastic progression comes from 
studies examining cancer risks amongst long-term users of non-steroidal anti-
inflammatory drugs (NSAID’s) which work by inhibiting COX. There is evidence 
that 15-20 years of NSAID ingestion can reduce the risk of sporadic colorectal 
cancer as well as reduce the adenoma load in patients with familial polyposis coli. 
Epidemiological evidence also suggests a protective role in stomach and 
oesophageal cancers with long term NSAID use167. 
 
The mechanisms by which areas of chronic inflammation undergo malignant 
change are far more complex but the above information connects both 
intrinsically. It is likely the change from inflammation to neoplasia is a very 
gradual process, with affected tissues being exposed to a range of mutagens over a 
long period of time causing a collection of mutations, in other words the multi-hit 
concept mentioned earlier when discussing the pancreatic cancer progression 
model. The role that inflammation and the inflammatory response has on 
established malignancies is explored in the next section. 
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1.2.3 Inflammation and the Progression of Cancer 
A significant body of evidence exists showing that a systemic inflammatory 
response (as measured by C-reactive protein) is a predictor of poor outcome in a 
number of cancers including bladder168, lymphoma169, colorectal170, renal171, non-
small cell lung cancer172, and pancreatic cancer14. The mechanisms behind this 
poor prognosis are not fully understood. Does this systemic inflammatory 
represent the body attempting to mount a response to tumour load? Or, does this 
inflammatory response represent a pro-inflammatory tumour micro-environment 
with cytokines, chemokines and leucocytes149,173. 
 
The micro-environment in and around tumours is created by a number of 
interlinked mechanisms. It is characterised by the presence of host leucocytes 
including macrophages, T-cells and  natural killer (NK) cells, with mast cells in 
smaller numbers174. Tumour associated macrophages (TAM) are a major 
component of almost all tumours and derive from circulating monocyte precursors 
attracted to tumours by chemokines175. TAM can, in the correct conditions 
produce growth and angiogenic factors (TNF, TGF, platelet derived growth factor 
and interleukin-6) creating an environment in favour of tumour growth and 
spread. Also activated in these conditions is NF-κB mentioned above, that itself 
induces the up-regulation of many pro-inflammatory protein genes, creating an 
auto-regulatory loop within and around the tumour. 
 
Chemokines, mentioned above, play a central role in the recruitment of leucocytes 
to sites of inflammation and tumours and are induced by inflammatory cytokines. 
Their name is derived from their function, they are chemotactic cytokines and aid 
the migration of responsive cells. Most tumours produce the two major groups of 
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chemokines CXC and CC, with CXC chemokines active on neutrophils and 
lymphocytes and CC chemokines acting on monocytes, eosinophils, dendritic 
cells and lymphocytes149. Other than their function, CC and CXC chemokines 
differ by having an extra amino-acid separating the first two cysteine residues. 
Interleukin-8 (IL-8) is a chemokine of the CXC family and is known to be 
increased in pancreatic cancer. IL-8 is strongly inducible by hypoxia, another 
factor initiating an inflammatory response in tumours. 
 
One of the major physiological differences between normal tissue and tumours is 
the presence of hypoxia in the latter. A hypoxic environment as found in tumours 
is known to induce a number of cytokines including TNF, IL-1, IL-6 and various 
chemokines such as IL-8149. Pancreatic tumours have been shown to have areas of 
significant hypoxia with normal tissue oxygen levels in surrounding unaffected 
pancreatic tissue, possibly explaining the reason for a localised inflammatory 
reaction at the site of a tumour176.  The other reason for this rich pro-inflammatory 
environment at the sites of tumours is the fact that tumour cells themselves have 
been shown to produce a host of cytokines including IL-1, IL-6, TNF, IL-8, 
PDGF, TGF amongst others177. 
 
The pro-inflammatory environment within and surrounding tumours influences its 
survival, growth and spread via a number of different mechanisms. The action of 
reactive oxygen species such as NO has been mentioned above for their role in the 
pathogenesis of tumours. Evidence suggests that these compounds are induced at 
tumour sites by inflammatory cytokines such as IL-1 and TNF. Further more, in a 
study of cholangiocarcinomas the induction of reactive oxygen species was shown 
to be present in all tumours examined and was responsible for a 70% decrease in 
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DNA repair activity178. Further evidence linking the inflammatory response to 
DNA damage came when an inflammatory cytokine known as macrophage 
migration inhibitory factor (MIF) was identified as a negative regulator of p53 
activity179. In some tumours there is evidence of p53 inhibition but without gene 
mutation meaning p53 regulation has been altered. MIF a known pro-
inflammatory cytokine was shown to overcome p53 activity meaning the 
inflammatory response is responsible in potentially creating genomic instability 
and explains why for example, mutations created by reactive oxygen species may 
not be dealt with in the normal way at tumour sites. 
 
To survive, proliferate and spread, tumours and their supporting stroma must 
grow and cytokines are crucial for tumour growth. To support the growing tumour 
the necessary vascular structures must develop and if there is an absence of new 
blood vessel formation then the tumour will reach equilibrium with the rate of 
apoptosis and not have the ability to grow and spread. One of the key molecules in 
angiogenesis is vascular endothelial growth factor (VEGF) which was first 
characterised in the 1980’s as a vascular permeability factor180. It has 
subsequently been shown to be absolutely critical in tumour angiogenesis which is 
essential for tumour development and progression. More recently VEGF has been 
shown to have other characteristics crucial to tumour progression such as anti-
apoptosis activity, lymphangiogenesis, and immunosuppression.  VEGF is present 
in higher concentrations within tumours when compared with normal tissue and 
its levels are correlated with poor survival in breast cancer, ovarian cancer, non-
small cell lung carcinoma, colorectal cancer and pancreatic cancer. VEGF 
expression is also correlated with tumour grade, depth of invasion, nodal mets, 
and TNM staging180. VEGF is a crucial part of tumour growth and its production 
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is known to be stimulated by the inflammatory infiltrate with TNF and IL-6 key 
players. 
 
The micro-environment in and around tumours is clearly pro-inflammatory with a 
high concentration of cytokines, chemokines and leukocytes forming an 
environment where growth and angiogenesis can flourish. Key factors in this 
process include TNF, IL-6, IL-8, VEGF and NF-κB. There is also evidence of 
altered DNA repair that along with the abundance of growth and angiogenic 
factors appear to promote tumour growth and spread.  
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1.2.4 Markers of Inflammation 
The most commonly used measurements of inflammation or the inflammatory 
response involve measuring acute phase proteins. The most widely used indicators 
are the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) 
mentioned above. The ESR measures the rate that erythrocytes fall through 
plasma and is largely influenced by the plasma concentration of fibrinogen (an 
acute phase protein). The ESR is therefore an indirect measurement of the acute 
phase response and is greatly influenced by the size, shape and quantity of 
erythrocytes as well as other plasma constituents leading to inaccuracies181. 
Although the ESR has been measured for over 70 years with supporting evidence, 
it has now been superseded by CRP. This is due to the ability to measure acute 
phase proteins (e.g. CRP and fibrinogen) directly, the inaccuracies mentioned 
above, the fact that the ESR rises with age and the inability of the ESR to change 
rapidly with a patient’s condition. 
 
CRP is a protein belonging to the pentraxin family, with five identical subunits 
forming a ring which conveys very high stability to the protein182. CRP was 
discovered in the 1930’s and is so named because of its ability to react with the 
pneumococcal C-polysaccharide in the plasma of patients during the acute phase 
of pneumococcal pneumonia. CRP is synthesised predominantly in hepatocytes 
under the influence of cytokines. Although a number of cytokines are capable of 
inducing CRP, overwhelmingly the major inducer of CRP via hepatocytes is 
Interleukin-6 (IL-6)183-186. Other sites of CRP production include smooth muscle 
cells, macrophages, kidney tubular cells, neurons, and lymphocytes, however, 
these sites contribute only a small proportion of the CRP value and plasma CRP 
measurements reflect hepatocyte production.  
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CRP is able to bind to bacteria, fungi and parasites as well as damaged 
membranes in apoptotic or necrotic cells. Once bound to these molecules CRP 
facilitates their removal by phagocytes. This opsonization effect is in addition to 
CRP’s ability to activate the classic complement pathway therefore aiding innate 
immunity. 
 
CRP has been used to help differentiate inflammatory from non-inflammatory 
conditions for a number of years. Serial measurements are useful in managing 
inflammatory conditions (e.g. rheumatoid arthritis) as well as sepsis and reflect 
the patients response to treatment interventions as plasma levels change rapidly. 
More recently CRP measurements have been recommended for cardiovascular 
risk prediction. Studies in apparently healthy populations reported a relative risk 
of 2.3 for major adverse cardiovascular events at the highest quintile of CRP 
levels, but only 1.5 for the highest LDL cholesterol quintile, indicating that these 
events are more strongly associated with CRP than LDL cholesterol187. In a 
significant number of patients with normal LDL cholesterol levels, elevated CRP 
was shown to be associated with major adverse cardiovascular events. 
 
As discussed earlier, an elevated CRP has also been shown to have prognostic 
value in a variety of tumours including bladder, colorectal, renal, non-small cell 
lung cancer, lymphoma and pancreatic cancer.  
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1.2.5 Inflammation and Pancreatic Cancer 
The inflammatory response and its influence on survival in patients with 
unresectable pancreatic cancer has been explored by a number of authors. 
Engelken et al looked at a combined prospective and retrospective cohort of 
patients who were found to have non-resectable pancreatic cancer over a seven 
year period188. The authors looked at a variety of prognostic factors in 325 
patients whose overall median survival was 5.7 months. In 51 patients they had 
CRP measurements available, although no information was given as to the timing 
of these CRP results. They found a normal CRP (<5mg/l) was associated with a 
three-fold increase in survival compared to those with a raised CRP (7.29 months 
versus 2.23 months, p<0.001). When they performed multivariate analysis on this 
subset of 51 patients, CRP was found to be the only statistically significant factor. 
It should be noted however that only 10 patients in this study had elevated CRP 
levels. 
 
Ueno et al looked at 103 patients who had been treated with palliative systemic 
chemotherapy for metastatic pancreatic cancer189. The median survival overall 
was just 3.2 months and again CRP was found to significantly influence outcome. 
On multivariate analysis a raised CRP (>5mg/l) (along with performance status 
and CA19-9 levels) was an independent predictor of poor outcome (p<0.0023). In 
this study 17 patients had an elevated CRP which was taken prior to the start of 
chemotherapy in all patients. The authors also state that the patients with an 
elevated CRP had no other causes such as sepsis and they believed the 
inflammatory response was caused entirely by the malignancy. 
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Falconer et al looked at 102 patients with non-resectable pancreatic cancer190. A 
number of factors were found to negatively influence survival. On multivariate 
analysis increasing age, disease stage, elevated albumin and a raised CRP 
(>10mg/l) all retained statistical significance. Those patients with a normal CRP 
had a greater than three-fold survival advantage over those with a raised CRP (66 
days versus 222 days respectively, p=0.001). 
 
The only paper to look at patients with operative pancreatic cancer was mentioned 
in section 1.1.8 and published in 2005 by Jamieson et al14. This paper looked at 65 
patients who underwent resection for ductal adenocarcinoma of the head of the 
pancreas and had pre and post (1 month) -operative CRP measurements taken. Of 
the 65 patients, 51% had a raised CRP (>10mg/l) pre-operatively. On univariate 
analysis, sex (p<0.05), tumour size (p<0.05), vascular invasion (p<0.001), pre-
operative CRP (p<0.001) and post-operative CRP (p<0.001) were significantly 
associated with survival. On multivariate analysis of the significant variables, 
tumour size, vascular invasion, pre and post-operative CRP retained independent 
significance. In fact the group of patients who did not have a raised pre-op CRP 
had a median survival of 18.2 months compared with only 8.3 months in those 
with a raised CRP (p<0.001). There was no significant difference in the stage, 
presence of positive resection margins, lymph node metastases or perineural 
invasion between the inflammatory and non-inflammatory groups. 
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There is compelling evidence in pancreatic cancer patients that having a raised 
systemic inflammatory response as measured by CRP has a significant negative 
effect on patients survival in both resectable and non-resectable disease. The 
mechanisms behind this poor prognosis are not known. It is likely that a raised 
CRP is a by-product of another process which influences survival and as the main 
driver of plasma CRP, Interleukin-6 (IL-6) is likely to be involved. 
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1.2.6 Interleukin-6 
Interleukin-6 (IL-6) belongs to a family of cytokines known as IL-6-type 
cytokines other members being IL-11, LIF (leukaemia inhibitory factor, OSM 
(oncostatin M), CNTF (ciliary neutrophic factor), CT-1 (cardiotrophin-1) and 
CLC (cardiotrophin-like cytokine). The IL-6-type cytokines are part of a larger 
group of cytokines characterised by their four-α-helix bundle structure, but are 
generally grouped together due to their similar and overlapping physiological 
actions as a consequence of their use of the common receptor subunit glycoprotein 
130 (gp130), a signal transducer 191. 
 
This family of cytokines are major players in a number of physiological processes 
including haematopoiesis, the developmental differentiation of lymphocytes, 
endocrine functions, bone formation, inflammation, acute phase and immune 
responses and target genes involved in differentiation, survival, apoptosis and 
proliferation192,193. Many cell types respond to IL-6, including, neural, lung, 
ovarian, endometrial, heart, renal, macrophages, monocytes, osteoblasts, mast 
cells, fibroblasts, leydig cell precursors, endothelial, hepatocytes and prostatic 
cells193. There are also many inducers of IL-6 including IL-1, TNF-α, NF-κB, 
prostaglandins, VEGF along with enterotoxins, growth factors, hypoxia, ionising 
radiation and oxidative stress193. With these multiple inducers and the many cell 
types sensitive to IL-6, the presence of IL-6 in tissues is not an abnormal 
occurrence. 
 
The role of IL-6 in the immune and inflammatory responses to pathogens and 
tissue damage is essential in the survival of the host cells, but the protective effect 
cytokines have on these cells, by inhibiting apoptosis and promoting growth, may 
 78 
also make them susceptible to neoplastic change. IL-6 has been implicated as an 
autocrine growth factor in a number of cancers including multiple myeloma, 
prostatic, bladder, renal cell, and cervical194-197. Elevated serum levels of IL-6 
have also been found in a number of cancers including ovarian, renal cell, 
cholangiocarcinoma, lymphoma, lung and melanoma198-203. IL-6 has been shown 
in certain types of cancer to inhibit apoptosis. This was shown by Lauta in 
multiple myeloma and by Leu in oesophageal carcinoma204,205. 
 
When looking specifically at pancreatic cancer, IL-6 has been identified as an 
autocrine growth factor, serum levels of IL-6 have also been found to be elevated 
and it is thought to lead to activation of anti-apoptotic genes. Miyamoto et al 
examined the expression of IL-6 on pancreatic cell lines and the effect it had on 
ionising radiation206. They showed that in certain cell lines IL-6 inhibited 
apoptosis by causing up-regulation of Bcl-2 family proteins (known anti-apoptotic 
proteins) and concluded that IL-6 is likely produced in an autocrine and/or 
paracrine fashion by certain pancreatic cell lines. Barber et al found that serum 
levels of IL-6 were significantly raised in patients with advanced pancreatic 
cancer when compared to healthy subjects207. Okada et al also found serum IL-6 
to be increased in patients with advanced pancreatic cancer, not only when 
compared to healthy controls but also patients with chronic pancreatitis208. They 
also found that higher levels of IL-6 corresponded with greater weight loss in the 
pancreatic cancer group. Ebrahimi et al examined the serum of 51 patients with 
pancreatic cancer and measured cytokine levels (using ELISA), comparing results 
with healthy controls209. Not only were IL-6 levels raised significantly when 
compared to controls, these higher levels were associated with poor performance 
 79 
status, increased weight loss and decreased survival. On multivariate analysis 
raised serum IL-6 was shown to be an independent predictor of poor survival. 
 
The actions of IL-6 are carried out via two intra-cellular pathways that transmit 
signals from the plasma membrane to the nucleus. These two pathways are the 
Janus Kinase (JAK)  and signal transducers and activators of transcription (STAT) 
pathway and the mitogen-activated protein kinase (MAPK) pathway192. 
 
Both of these signalling pathways are known to be crucial in the development and 
progression of numerous types of cancer. There is also evidence that the two 
pathways far from being separate are connected with cross-talk between the two 
of them potentially being crucial in the progression of cancer. Both pathways are 
discussed below. 
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1.3 The JAK STAT Pathway 
1.3.1 Introduction 
The Janus kinase-signal transducer and activator of transcription (JAK STAT) 
pathway transmits information received from extra-cellular polypeptides (e.g. IL-
6) via transmembrane receptors to target genes within the nucleus. These genes 
are responsible for a variety of biological functions including, the immune 
response, the acute phase reaction, inflammation, haematopoiesis and achieve this 
by regulating cell growth, differentiation, and survival210. The first stage in this 
complex process is the binding of IL-6 to its receptor. 
 
1.3.1.1 IL-6 Receptor (IL-6R) 
IL-6R is a member of the cytokine class I family of receptors which are defined 
by the presence of at least one cytokine binding module (CBM). The IL-6R can be 
divided into two sub-units, a non-signalling subunit (IL-6Rα) and a signalling 
subunit (gp130). 
 
The first stage in the pathway involves the binding of IL-6 to the receptor subunit 
IL-6Rα. Although this is not involved in the intracellular signal transduction 
cascade, it is a crucial process as it is only after this step that the cytokine and α-
receptor complex can efficiently recruit the signal-transducing subunit (gp-130). 
Although gp130 is ubiquitously expressed, the expression of the α-subunit is 
much more tightly regulated meaning the number of cells responding to IL-6 is 
restricted by expression of the non-signalling subunit192. 
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The next stage in the pathway involves the recruitment of gp130 signalling 
molecules to the IL-6-receptor complex. The gp130 subunits have a similar 
structure to the IL-6Rα, but have a considerably larger cytoplasmic part due to 
their signal transducing properties. IL-6 (along with IL-11) differs from the other 
IL-6-type-cytokines as it induces gp130 homodimerisation (other members of the 
family cause heterodimerisation) when it binds to its receptor211. Once IL-6 
binding has taken place gp130 homodimerisation occurs, followed by 
phosphorylation on serine, threonine and tyrosine residues211. The binding of IL-6 
to its receptor leads to internalisation of the ligand. Internalisation has been shown 
to be entirely dependent on the signal transducing subunit (gp130) of the receptor 
and is modulated by the phosphorylation of the serine residue212.  
 
1.3.1.2 Janus Kinases (JAK’s) 
It wasn’t until 1994 that it was discovered that IL-6-type cytokines utilised 
tyrosine kinases of the JAK family (and transcriptors of the STAT family) as 
mediators of signal transduction213,214. JAK's are intracellular tyrosine kinases, 
with mammalian cells expressing four types, Jaks1-3 and Tyk2. Jak1, 2 and Tyk2 
are widely expressed but Jak3 expression is confined mainly to haemopoietic 
cells. JAK’s all have a similar structure with a typical kinase domain and 
substitutions of single tyrosine residues within this domain have been shown to 
eliminate all tyrosine kinase activity. 
 
Receptor dimerisation as described above brings the associated JAK’s into close 
proximity with the receptors. JAK’s bind to the membrane-proximal region of 
cytokine receptors and they transphosophorylate each other becoming 
activated215. Once activated, their kinase activity stimulated, JAK’s go on to 
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phosphorylate tyrosine residues on the cytoplasmic portion of the receptors and 
thus create binding sites for STAT proteins216. 
 
IL-6 binding to its receptor has been shown to activate Jak1, Jak2 and Tyk2 but 
Jak1 has been shown to be dominant in IL-6 signal transduction. In fact Jak1 is 
essential for IL-6 signalling via the JAK-STAT pathway as Jak1 negative cells 
have absent signalling in response to IL-6217,218.  
 
1.3.1.3 Signal Transducers and Activators of Transcription (STAT’s) 
In human beings there are seven STAT genes, STAT 1-6 (including STAT5a and 
STAT5b). STAT genes are located in clusters on chromosomes and their 
expression is ubiquitous. STAT proteins are known to be activated by a wide 
variety of ligands, probably all known cytokines and large numbers of growth 
factors that exhibit tyrosine kinase activity, such as EGF and PDGF. In a given 
cell type more than one STAT protein can be activated by a given ligand, but the 
identity of the STAT activated depends on the state of cell differentiation and 
maturation. This builds a degree of variability into STAT activation and hence 
increases the panel of genes whose expression will be modulated in different 
cellular contexts219.  
 
As described above, ligand binding to the receptor leads to JAK binding and their 
close proximity to each other on the dimerised receptor subunit (gp130) leads to 
JAK transphosphorylation. Once phosphorylated, their kinase activity enabled, 
JAK’s phosphorylate tyrosine residues on the cytoplasmic region of the receptor 
subunit, thus creating binding sites for STAT proteins. Once binding has taken 
 83 
place the receptor-bound JAK’s activate the STAT proteins by phosphorylating 
them at a single tyrosine residue191. 
  
Following phosphorylation at the receptor, the activated STAT proteins form 
stable homo and hetero-dimers in the cytoplasm. The choice of whether to bind 
with an active receptor or another STAT protein appears to be related to the state 
of phosphorylation of the STAT in question. Unphosphorylated STAT exhibits a 
high affinity for receptor docking sites, but activated or phosphorylated STAT 
have a much higher affinity to other STAT proteins, encouraging dimerisation 
following tyrosine phosphorylation220. This dimerisation of STAT proteins is 
essential for subsequent DNA binding221. Whether STATs form homo or hetero-
dimers appears to be influenced by the original activating ligand, the receptor sub-
unit and the individual STAT protein involved, adding further variability to the 
signalling process191. 
 
STAT activation and dimerisation takes place in the cytoplasm, but to exert their 
effect they need to enter the nucleus and bind to DNA. The mechanism by which 
the STAT dimers are transported to the nucleus remains unknown, but active 
transport is required as their size is greater than the limit of the nuclear pore192. 
Once in the nucleus the active dimers go on to bind with specific DNA sequences.  
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1.3.2 IL-6 Signalling and STAT3 
There are seven known STAT proteins, as mentioned above, but not all are 
activated in response to IL-6. IL-6 potently activates STAT3 and to a lesser extent 
STAT1, but STAT3 is widely recognised as the key player in IL-6 signalling and 
the major activator of acute-phase gene transcription191,193,222-225. As described 
above, STAT3 undergoes tyrosine phosphorylation under the influence of Jak1 
following its binding to the gp130 receptor subunit. This tyrosine phosphorylation 
is crucial for subsequent dimerisation and adequate to activate the protein, in 
STAT3 it takes place at tyrosine705 (tyr705)191,219,226.  
 
There is clear evidence that STAT3 can undergo phosphorylation at another site in 
addition to tyr705 and that it involves serine phosphorylation at serine727 
(ser727)191,205,215. What induces this serine phosphorylation, its significance in cell 
signalling and the biological effects it has been the subject of some interest over 
recent years. It is thought that to completely activate STAT3 that serine 
phosphorylation also has to take place and that the MAPK pathway may well be 
involved in the process227,228. Further work is required to establish the precise role 
of serine phosphorylation in STAT3 proteins. 
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1.3.3 STAT3 and Cancer 
Tumourogenesis is a multi-step process, with cells losing their normal ability to 
detect and repair DNA damage and adequately regulate cell cycle progression and 
apoptosis. There is mounting evidence that STAT proteins, and in particular 
STAT3 are heavily involved in cellular apoptosis, angiogenesis and differentiation 
via growth factor signalling and are therefore likely to play key roles in cancer 
development, growth and spread. STAT proteins, including STAT3 are 
persistently activated in non-malignant processes such as inflammation and their 
activation alone is not enough to lead to cellular transformation. However, with 
cells collecting crucial genetic mutations in the development of cancer, in the 
appropriate context, STAT3 is likely to be a crucial contributor to the cancerous 
phenotype. 
 
Abnormal tyrosine kinase activity and increased levels of tyrosine 
phosphorylation are common in cancer cells and are usually caused by 
overexpression of growth factor receptors and their relevant ligands, IL-6 for 
example229. STAT3 has strong associations with many cancers including multiple 
myeloma, melanoma, lung, breast, renal, prostate, colonic, gastric, cervical, 
ovarian, hepatocellular, head and neck and pancreatic cancer193. The reason for 
the association between STAT3 and cancer appears to be the genes it targets once 
activated. 
 
A gene profiling study by Croonquist et al using DNA microarrays determined the 
subset of genes activated by IL-6 signalling in multiple myeloma230. Out of 138 
identified, 54% were found to be involved in cell cycle regulation. The genes 
involved in the cell cycle are activated by IL-6 and its subsequent activation of 
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STAT3, highlighting the importance of the JAK-STAT pathway in 
tumourogenesis. 
 
A review article published in 2007 looked at the role of STAT3 and neoplastic 
cellular transformation and discussed a 12 gene STAT3 signature231. Using mouse 
fibroblasts, specific STAT3 target genes were identified, a number of which were 
known to be co-expressed by primary human tumours. Using this approach, the 12 
gene STAT3 signature was identified. Closer analysis of these genes shows they 
have the ability to regulate almost all of the essential properties of a tumour cell. 
Part of this12 gene set are Egr-1, JunB and Cyclin D1, all genes involved in 
promotion of cell cycle progression. Three genes known to be prominent in the 
inhibition of apoptosis, Mcl-1, Bcl-2 and Bcl-x1 are also part of this 12 gene 
signature. The group also contains the genes Klf-4 and Bcl-6, both known to be 
involved in the inhibition of differentiation and the self-renewal of cells. STAT3 
directly regulates matrix metallo-proteinases, enzymes which are known to be 
involved in tumour cell invasion and may suggest a role for STAT3 in the 
metastatic spread of a tumour. Also crucial to the growth and invasion of a tumour 
is its blood supply and one of the 12 signature genes is vascular endothelial 
growth factor (VEGF).  
 
Levels of VEGF, a potent angiogenic growth factor in both benign and malignant 
tissue, have been shown in a number of trials to be related to IL-6 levels232,233. 
Cohen et al showed that IL-6 induces expression of VEGF, in fact the strength of 
this induction is comparable to that exhibited by hypoxia in tissues234. IL-6 exerts 
this effect via the JAK STAT pathway as activated STAT3 protein levels have 
been shown to correlate with the level of VEGF expression180. Abdelrahim et al 
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looked at the effect of NSAID’s on certain transcription factors associated with 
vascular endothelial growth factor (VEGF) expression in mice235. Tolfenamic acid 
(an NSAID) was shown to cause degradation of Sp1, Sp3 and Sp4 (transcription 
factors involved in VEGF expression) and the resultant statistically significant 
decreases in VEGF mRNA, VEGF levels, tumour growth, tumour weight and 
hepatic metastasis. 
 
More relevant to this thesis is the fact that VEGF, under the influence of IL-6 and 
hence STAT3 appears to have a key role in pancreatic cancer. In pancreatic cell 
lines it has been demonstrated that IL-6 is responsible for VEGF expression and 
the extent of VEGF expression appears to be related to the extent of IL-6 Receptor 
expression on cells236,237. Wei et al examined the relationship between STAT3 and 
VEGF in pancreatic cancer cell lines238. Immunohistochemical analysis 
demonstrated that STAT3 was constitutively activated in more than 80% of 
human pancreatic cell lines and this STAT3 activation correlated with expression 
levels of VEGF. Blocking STAT3 activation led to a significant suppression of 
VEGF expression and subsequent decrease in angiogenesis, tumour growth and 
metastasis in vivo. This study indicates that STAT3 regulates VEGF expression 
and is therefore involved in angiogenesis, tumour growth and metastasis in human 
pancreatic cancer. 
 
In addition to the role of STAT3 in VEGF regulation there are other publications 
describing the relationship between the JAK STAT pathway, or more specifically 
STAT3 and pancreatic cancer. Greten et al examined the role of STAT3 in the 
regulation of anti-apoptotic genes in mice crossbred to develop ductal pancreatic 
cancer similar to the human form of the disease239. They demonstrated increased 
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transcription of Bcl-x, the anti-apoptotic gene described previously with STAT3 
and subsequent down-regulation when it was blocked. This study also noted that 
the transcription factor NF-KappaB, first discussed in section 1.2.2, had a similar 
effect on Bcl-x and that down-regulation of the gene took place when either 
STAT3 or NF-KappaB was blocked, indicating that both may be required. If both 
transcription factors were blocked together programmed cell death was induced 
and the authors highlight this as a possible future avenue for therapeutic 
intervention. NF-KappaB is a key transcription factor in inflammation and 
carcinogenesis and will be discussed in greater detail later in this discussion. 
 
Scholz et al examined the expression and activation of STAT3 in pancreatic 
cancer cell lines240. They were able to show that activated STAT3 is over-
expressed in ductal cells but not in chronic pancreatitis cells. Subsequent 
inactivation of STAT3 led to decreased proliferation in vitro and tumour growth 
in vivo. The authors concluded that STAT3 promoted cellular proliferation by 
accelerating the G(1)/S-phase progression contributing to the malignant 
phenotype of pancreatic cancer. 
 
Toyonaga et al examined the significance of JAK and STAT3 on the malignant 
potential of human pancreatic cancer cell lines241. Their studies revealed that 
STAT3 was constitutively activated in certain pancreatic cancer cell lines and 
went on to use a JAK inhibitor tyrphostinAG490. The JAK inhibitor led to a 
marked inhibition of STAT3 activation and also diminished expression of the 
genes cyclin D1, Bcl-x and VEGF, causing arrested growth in pancreatic cancer 
cells. The authors in this study again highlighted the JAK-STAT3 signalling 
pathway as a potential target for future treatment of pancreatic cancer. 
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A study using RNA-interference (RNAi) technology which works by silencing 
specific target genes was employed to look at the role that STAT3 plays in the 
invasion and metastasis of pancreatic cancer242. The authors used a metastatic 
pancreatic cancer cell line known to highly express STAT3 and using this RNAi 
technique, observed the effects of reduced STAT3 expression in both in-vitro and 
in-vivo conditions. They were able to demonstrate a significant suppression in the 
expression of matrix metallo-proteinases-2 (MMP2) and VEGF and a resulting 
inhibition of invasion and metastasis in-vitro and in-vivo. The authors make the 
conclusion that silencing the STAT3 gene may offer one way of controlling 
pancreatic cancer invasion and spread. 
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1.4 The Mitogen Activated Protein Kinase (MAPK) 
Pathway 
1.4.1 Introduction 
Mitogen-activated protein kinases (MAPK) belong to a larger family of serine-
threonine kinases and form major cell-proliferation signalling pathways from the 
cell surface to the nucleus. There are three major subfamilies of MAPK: the extra-
cellular-signal-regulated kinases (ERK-MAPK, Ras/Raf1/MEK/ERK); the c-jun 
N-terminal or stress activated protein kinases (JNK or SAPK); and MAPK14243. 
The ERK-MAPK pathway is one of the most important cascades in cell 
proliferation and will be the subject of further discussion in this report. Signals 
transmitted through Ras trigger ERK pathway signalling, which then activate 
Raf1, leading to a cascade involving MEK and ERK. The ERK-MAPK cascade is 
involved in the control of growth signals and cell survival. 
 
1.4.1.1 Ras 
There are more than 50 low molecular weight proteins in the Ras-related 
superfamily serving multiple functions in virtually all eukaryotic cells244. Ras-
related proteins control various cellular signalling pathways including cell cycle 
entry and mitogenesis. The term Ras actually encompasses a group of proteins 
including H-Ras, K-Ras, N-Ras and R-Ras. Ras is a small GTP-binding protein 
which is modified with a hydrophobic lipid moiety allowing it to be anchored to 
the membrane. This feature allows the protein to be functional in the transduction 
of signals from extra-cellular ligands binding with membrane receptors. Multiple 
extra-cellular growth factors lead to Ras activation via membrane receptors. These 
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include EGF, TGFβ, HGF and importantly IL-6 via the gp-130 receptor 
subunit245. 
 
Activation of Ras protein occurs with the conversion of inactive GDP-bound Ras 
to the active GTP-bound Ras. The first stage of Ras activation is tyrosine 
phosphorylation of one of the Ras subunits termed Shc. Ras localisation on the 
interior of the plasma membrane leads to rapid conversion of Ras from its GDP 
bound (inactive) state to its GTP bound (active) state. K-Ras mutation is one of 
the commonest involved in human cancer and in particular pancreatic cancer 
where it is mutated in 90% of patients with the disease. The K-Ras oncoprotein 
differs from the normal protein by a single amino acid substitution at a critical 
position. This substitution leads to constitutive activation of the Ras protein (GTP 
bound) and subsequent activation of the downstream Raf/MEK/ERK pathway244. 
 
1.4.1.2 Raf-1 
Raf-1 is the most extensively studied of the Raf proteins of which there are three 
forms, A-Raf, B-Raf and C-Raf (Raf-1)246. Raf-1 is a 72-76 kDa cytoplasmic 
protein with intrinsic serine-threonine kinase activity and is a direct effector of 
Ras. Once bound to active Ras at the cell membrane, Raf-1 proteins undergo 
activation via a complex series of events. Initially there is de-phosphorylation of 
an inhibitory site (serine 259) followed by the phosphorylation of a critical 
activating site (serine 338)247 . Activated Raf-1 then goes on to interact with MEK 
further downstream in the pathway. In contrast to Ras proteins, Raf-1 mutations 
are extremely rare. 
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The MEK’s are a family of protein serine/threonine kinases that have three 
isoforms in mammals- MEK-1a, MEK-1b and MEK-2248. Activation of MEK-1/2 
involves phosphorylation of two serine residues at positions 217 and 221 by 
activated Raf-1 protein in the cytoplasm. Once activated MEK-1/2 goes on to 
activate MAPK again in the cytoplasm.  
 
1.4.1.3 MAPK (ERK) 
There are three members of this group of protein kinases ERK-1, ERK-2 and an 
alternative spliced form of MAPK. ERK-1 and ERK-2 are generally considered 
together as they are functionally very similar. The activation of these kinases 
requires phosphorylation of both threonine and tyrosine residues for full 
activation, and the main mechanism for this process is phosphorylation at both 
sites by activated MEK 248. The phosphorylation at both sites has also been shown 
to be the main requirement for the translocation of ERK into the nucleus where it 
binds and regulates genes controlling cellular growth, proliferation, differentiation 
and apoptosis249 
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1.4.2 MAPK and Cancer 
It has been suggested that to survive and proliferate cancer cells have to acquire a 
number of capabilities: independence of proliferation signals, evasion of 
apoptosis, insensitivity to anti-growth signals, unlimited replicative potential, the 
ability to invade and metastasise and to attract and sustain angiogenesis250. 
Abnormalities within the MAPK pathway can give rise to most of these properties 
which is why it is such a crucial pathway in the development and propagation of 
cancer. In all, 30% of all cancers contain a mutation to one of the Ras oncogenes. 
Table 1.2 demonstrates the frequency of these mutations in various cancers. 
 
Table 1.2: Frequency of Ras mutation in human cancers247. 
Tumour type Percentage with Ras Mutation 
Pancreas 90% 
Lung adenocarcinoma (non-small cell) 35% 
Thyroid (follicular) 55% 
Thyroid (papillary) 60% 
Seminoma 45% 
Melanoma 15% 
Bladder 10% 
Liver  30% 
Kidney 10% 
Myelodysplastic syndrome 40% 
Acute myeloid leukaemia 30% 
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In the MAPK pathway it is the ligand-mediated activation of receptor tyrosine 
kinases that leads to the activation of Ras protein (GDP bound to GTP bound 
state) and subsequent recruitment of Raf-1 to the cell membrane followed by 
activation of the MAPK cascade. As previously stated, one of these ligands is IL-
6 which leads to activation of the Ras protein via receptor tyrosine kinases, a fact 
crucial to this report. The majority of cancer-associated lesions that go on to cause 
constitutive activation of the MAPK pathway occur early in the cascade247. The 
large number of mutations centred around Ras-Raf suggest that this is the key 
stage in regulation of the pathway, particularly in pancreatic cancer with 90% of 
these tumours harbouring Ras mutations.  
 
It is not surprising that the MAPK pathway has been the target for a number of 
potential cancer therapies. Sorafenib targets Raf kinases and was found to be well 
tolerated but with little anti-tumour activity in malignant melanomas, the intended 
target251. A number of MEK inhibitors have been trialled, firstly CI-1040 was 
found to be well tolerated but with little anti-tumour activity, a second MEK 1/2 is 
now involved in trials. In fact there have now been around 25 small molecule 
inhibitors aimed at the MAPK pathway that have reached early to late stage 
clinical trials in many different tumour types252. This fact alone signifies the 
importance of the MAPK pathway in cancer research. 
 
As discussed above, IL-6  is known to be an important ligand involved in the 
activation of receptor tyrosine kinases and subsequent activation of Ras protein253. 
IL-6 has been shown not only to be increased in the plasma of patients with 
pancreatic cancer but is produced in an autocrine manner by pancreatic cancer 
cells206-208. These two particular facts not only emphasise the potential importance 
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of the MAPK pathway in pancreatic cancer, but also link it with the JAK-STAT 
pathway. 
 
A number of studies in the published literature have shown the MAPK pathway to 
influence proliferation, mitosis and apoptosis in pancreatic tumours and cell lines. 
Tong et al showed that activation of the MAPK pathway was crucial for tumour 
proliferation in pancreatic cell lines254. Gysin et al looked at the role of the MAPK 
pathway on pancreatic cancer cell line proliferation by treating cell lines with a 
MEK inhibitor255. They were able to demonstrate that this inhibition led to a 
cessation of cellular proliferation and cell cycle arrest in all eight cell lines tested 
suggesting that the MAPK pathway may have a crucial proliferative role in 
pancreatic cancer cells. 
    
AURKA is a gene encoding a kinase crucial in the control of cellular mitosis. 
Using a known MAPK inhibitor and mapping the subsequently downregulated 
genes, Furukawa et al showed that AURKA is a downstream target of the MAPK 
pathway. Its overexpression in pancreatic cancer is induced by increased 
expression of the MAPK pathway, most likely via its constitutive activation 
secondary to KRas mutation256. 
 
Boucher et al looked at pancreatic cancer cell lines and looked at the role that 
ERK 1/2 had in cell survival257. By using a MEK inhibitor and studying the 
resulting changes in expression in genes known to have anti-apoptotic effects. 
They were able to demonstrate that activation of the MAPK pathway protects 
pancreatic cancer cells from apoptosis by regulating crucial genes involved in 
apoptosis such as Bcl-2, Bcl-x and Mcl-1. 
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The transcription factor NF-κB is of great importance in the inflammatory 
response, but increasingly it is being touted as a key player in carcinogenesis. A 
number of publications have shown that K-Ras may be one of the factors that is 
responsible for the activation of NF-κB and this will be explored later in this 
thesis. 
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Figure 1.5: Diagramatic Representation of JAK STAT and MAPK pathways 
(http://www.sigmaaldrich.com/Area_of_Interest/Life_Science/PathFinder.html) 
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1.5 Hypothesis and Aims 
The link between inflammation and cancer is now well established. When looking 
specifically at pancreatic cancer, an inflammatory response, as measured by CRP 
is associated with a poor outcome in patients with both operable and non-operable 
disease. As the main driver of plasma CRP, IL-6 is the likely cause of this 
inflammatory response, but is IL-6 responsible for this poor prognosis, and if so 
how does it exert its effect? The main intra-cellular pathway associated with IL-6 
signalling is the JAK-STAT pathway described above and it is known to induce 
cell growth, de-differentiation and inhibit apoptosis. IL-6 is a known activating 
ligand in the MAPK pathway also described above. The MAPK pathway is also 
known to be involved in the regulation of cellular growth, proliferation, 
differentiation and apoptosis and this thesis aims to explore the relationship 
between these two intracellular pathways and survival in patients with pancreatic 
cancer. 
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1.5.1 Hypothesis 
The presence of a systemic inflammatory response is associated with a 
particularly poor prognosis in pancreatic cancer. Pro-inflammatory cytokines, in 
particular IL-6, are known to induce CRP production and also may influence 
tumour growth and differentiation through well-described cellular pathways. 
Upregulation of IL-6 dependent pathways in tumour cells may explain the poor 
prognosis associated with a systemic inflammatory response. 
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1.5.2 Aims 
The ultimate aim of this thesis is to disprove the above hypothesis. Below are the 
ways in which this hypothesis will be tested: 
 
1/. Establish pancreatic cancer patient database with basic demographics, 
pathological and survival data. 
 
2/. Confirm the connection between a raised CRP and survival in pancreatic 
cancer in a larger cohort and establish if there is a relationship between CRP and 
non-pancreatic peri-ampullary cancers.  
 
3/. Simultaneously create a prospective database and establish the connection 
between CRP and survival in a prospective cohort. 
 
4/. Create tissue micro-arrays using tissue from the pancreatic cancer database to 
enable the efficient examination of relevant antibodies using standard 
immunohistochemical techniques. 
 
5/. Using immunohistochemistry, stain with antibodies from the JAK-STAT and 
MAPK pathways and establish whether poor survival in these patients with 
pancreatic cancer is associated with upregulation of these pathways. 
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2.0 MATERIALS & 
METHODS 
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2.1 Patients 
2.1.1 Retrospective Patients 
The author (SD) gained ethical approval from the trust Ethics committee and met 
the approval of the local Research & Development department. The author 
identified all patients who had undergone resection for pancreatic cancer by 
interrogating the pathology department database at Glasgow Royal Infirmary with 
the assistance of the mortician (AM). A search looking for the words ‘whipple’ or 
‘pancreaticoduodenectomy’ in all pathology reports was carried out by the author 
who went on to carefully examine each individual report. Only patients who had 
undergone a pancreatic resection for pancreatic cancer, cholangiocarcinoma, 
ampullary adenocarcinoma, duodenal adenocarcinoma and tumours termed by the 
pathologist as peri-ampullary adenocarcinoma were included. This left 148 
patients, 90 pancreatic cancers (PC) and 58 non-pancreatic peri-ampullary 
tumours (NPPC) made up of 35 ampullary adenocarcinomas, 15 distal 
cholangiocarcinomas, 3 duodenal adenocarcinomas and 5 that were described as 
peri-ampullary adenocarcinomas.  
 
With the pathology data, an anonymised database was created by the author for 
the 148 patients using their unique pathology numbers as identifiers. Basic patient 
demographics, pre-operative CRP values and survival data were retrieved to 
complete the database. All CRP values in this thesis were analysed in the 
biochemistry department of Glasgow Royal Infirmary. A fluorescence 
polarisation immunoassay was performed using an Abbott TDX analyser and 
Abbott reagents (Abbott Labs, Abbott Park, Il, USA). 
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2.1.2 Prospective Patients 
The author (SD) gained ethical approval from the trust Ethics committee and met 
the approval of the local Research & Development department. All patients 
undergoing a Whipple resection for either pancreatic cancer (PC) or non-
pancreatic peri-ampullary cancer at Glasgow Royal Infirmary whom gave written 
consent had blood taken pre-operatively by the author (SD) between 30/10/03 to 
05/05/05 (collection has continued by JL after this date as the author left the 
department).  
 
Blood was anonymously labelled and stored in the department of surgery at -
20oC. An anonymous prospective database was then created containing basic 
patient demographics, pathology data and survival data. The blood samples for the 
first 36 patients were analysed by an additional research fellow in the department 
of surgery at Glasgow Royal Infirmary (JL). Circulating concentrations of IL-6 
were measured by JL using a commercially available enzyme-linked immuno-
sorbent assay (ELISA) (R&D Systems Europe Ltd). 
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2.2 Creating Tissue Micro-Array’s (TMA’s) 
Prior to undertaking the slide retrieval process the author underwent a period of 
gastro-intestinal histology revision, with emphasis on pancreatic and hepato-
biliary histology under the guidance of a consultant pathologist (KO) within the 
pathology department of Glasgow Royal Infirmary. This revision included 
recognition of normal tissue but also on the recognition of pancreatic tumours and 
degrees of tumour differentiation. 
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2.2.1 Slide Retrieval, Identification of Tumour and Slide 
Marking 
After the identification of the 148 patients to be included in this study, the slide 
retrieval process began. As stated in section 2.1, the pathology numbers were used 
as unique identifiers and the author collected every haematoxylin and eosin 
stained slide from the pathology archive that corresponded to the pancreatic 
resection for each of the 148 patients. This resulted in approximately 40 slides for 
each of the 148 patients. Following the period of histology revision, the author 
(SD) looked at every H&E slide collected for the 148 patients under a microscope, 
marking areas of tumour and areas of normal pancreatic duct. Due to the 
heterogenous nature of pancreatic cancer, the author marked multiple areas of 
each tumour aiming to include areas of differing differentiation in addition to 
normal pancreatic ducts. A consultant pathologist (KO) checked a proportion of 
the marked slides, agreeing with the selected tumour and normal duct marking. 
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2.2.2 Planning the TMA’s 
A precise plan of the TMA’s was created by the author. A number of factors were 
taken into account when planning the TMA’s: the number and size of cores (3 
tumour and 2 normal ductal cores of 0.6mm for each of the 148 patients); control 
tissues; the ability to orientate around the TMA’s; the minimum safe distance 
between each core; the size of the recipient wax block. 
 
Three cores of tumour tissue and two cores of normal ductal tissue were planned 
for each of the 148 patients making a total of 740 cores. Two cores for each of 
nine control tissues (breast, testis, pancreatic ducts, pancreatic acinar tissue, 
pancreatic islets, bile duct, duodenum, liver and prostate) on every TMA were 
also planned for. The minimum distance between cores is accepted at 0.8mm but 
the author planned for a minimum of 1mm apart with regular larger gaps to enable 
easy core identification during analysis. A plan was then created using a 
spreadsheet with all these factors taken into account. Three TMA’s were 
necessary, each being asymmetrical and individually identifiable (Figures 2.1-
2.3). 
 
At this stage a practice TMA was also planned containing 40 cores. This would be 
used for the optimisation of antibodies, avoiding waste of the full TMA’s. 
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Figure 2.1: Plan of TMA  
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Figure 2.2: Plan of TMA 2 
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Figure 2.3: Plan of TMA 3 
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2.2.3 Making the TMA’s 
Following marking of the relevant H&E slides, the author collected all the 
corresponding paraffin embedded tissue blocks from the pathology archive of 
Glasgow Royal Infirmary. All the formalin fixed paraffin embedded tissue blocks 
paired with their corresponding pre-marked H & E slides were transferred to the 
pathology department of The Western Infirmary, Glasgow. The author then 
underwent a period of training at the Western Infirmary into the manufacturing of 
TMA’s under the guidance of a scientist (AK) within the department with years of 
experience in making TMA’s. A manual tissue arrayer (Beecher Instruments© 
Micro-array technology, figure 2.4) was used to create a number of practice lines 
of tissue cores. The quality of these practice runs were assessed by AK. The 
author then went onto create the formal practice pancreatic TMA. Following this 
the three full pancreatic TMA’s were manufactured by the author.  
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The following procedure was followed for the manufacturing of the TMA’s 
(shown in figure 2.5). 
 
1/. Blank wax block is fixed in position. 
  
2/. A core of wax from a pre-planned position is removed. 
 
3/. The coring mechanism is flipped on the arrayer. 
 
4/. A core of tissue (identified by the pre-marked H&E slide) is removed from the 
donor tissue block. The tissue core is slightly larger than the space to allow a tight 
fit. 
 
5/. The coring mechanism allows this process to occur without moving the wax 
block and the tissue core is placed precisely in the space on the recipient block. 
 
6/. Using the micrometer the coring mechanism is moved for extraction of the 
next wax core and the process is repeated until the TMA is completed. 
 
7/. Only after each core is inserted into the TMA is the pathology number of that 
core added to the formal TMA map which is used to identify cores for later 
scoring. 
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Figure 2.4: Beecher Instruments Manual Tissue Arrayer 
(www.beecherinstruments.com) 
 
Figure 2.5: Technique for creating TMA (www.tissue-array.org) 
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2.2.4 Preparation of Tissue Sections 
The manufacturing of the TMA’s was done entirely by the author (SD). The 
sectioning of the TMA’s was performed by an MLSO with extensive TMA 
sectioning experience using the following protocol. Before sectioning of the 
TMA’s could take place they were heated to 37o for 10 minutes to allow the wax 
from the block to bind with the wax in the tissue core to avoid shearing of the 
cores during sectioning. Prior to sectioning, tissue blocks were cooled to -10oC 
(Tissue Tec© cooler). Three micrometer thick sections were then cut from the 
blocks using a Leica© RM 2135 microtome. These sections were then floated onto 
a waterbath and heated to 45 oC allowing any tissue folds to flatten out. Following 
heating the sections were applied to aminopropyltriethoxysilane-treated 
(sialinised) slides (BDH 1.0mm thick, clear glass). These slides were sialinised to 
create greater adherence with the tissue using the following protocol: 
 
1. Slides placed in acetone for 5 minutes, followed by 2% silane (v/v 8ml in 
400ml). 
 
2. Slides then washed in running tap water for 5 minutes, before being bathed 
in tap water for a further 20 minutes before being dried overnight in a 
fume hood. 
 
Slides were then ready for immunohistochemical staining. 
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2.3 Antibodies and Antibody Specificity 
2.3.1 Antibodies 
Twelve antibodies were used in this study, six from the JAK-STAT pathway and 
six from the MAPK pathway. They were: 
 
1. Interleukin-6 Receptor (IL-6R)- (C20, SC-661, Santa Cruz) 
2. Jak-1- (#3332, Cell Signalling Technology, US) 
3. Phosphorylated.Jak-1- (New England Biolabs, UK) 
4. STAT-3- (#9132, Cell Signalling Technology, US) 
5. Phosphorylated.STAT-3Tyr 705- (#9131, Cell Signalling Technology, US) 
6. Phosphorylated.STAT-3Ser 727- (#9134, Cell Signalling Technology, US) 
7. K-Ras- (Sigma R3400 Clone 234-4.2) 
8. Raf-1- (E-10, Santa Cruz) 
9. Phosphorylated.Raf-1Ser 259- (#9421, Cell Signalling Technology, US) 
10. Phosphorylated.Raf-1Ser 338- (#05-538, Upstate) 
11. MAPK (p42/44)- (#9012, Cell Signalling Technology, US) 
12. Phosphorylated.MAPK (p42/44)- (#9101, Cell Signalling Technology, 
US). 
 115 
2.3.2 Antibody Specificity 
All antibodies except Phospho.JAK-1 were available in the laboratory of the 
University Department of Surgery, Glasgow Royal Infirmary. All eleven of the 
available antibodies had been used successfully within the same laboratory, the 
JAK-STAT proteins on prostatic tissue and the MAPK proteins on prostatic and 
breast tissue. The specificities of these eleven antibodies had all been established 
by Western Blotting within the same laboratory by previous students. The JAK-
STAT antibodies (IL-6R, JAK-1, STAT3, Phospho.STAT3 
Tyr705,Phospho.STAT3 Ser727) had Western Blotting performed by an MSc 
student (LT), demonstrating specificity in all five. The six MAPK antibodies (K-
Ras, RAF-1, Phospho.RAF-1 Ser259, Phospho.RAF-1 Ser338, MAPK, 
Phospho.MAPK) underwent Western Blotting by a PhD student (LM) and again 
all six had their specificity confirmed.  
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2.3.3 Western Blotting for Phospho.JAK-1 
The antibody Phospho.JAK-1 was not available nor had it been previously used 
within the laboratory. The author contacted Cell Signalling Technology who were 
able to supply a free sample of Phospho.JAK-1 antibody, but did state that this 
had not been used for immunohistochemistry before. Despite repeated attempts 
using a standard Western Blotting technique used successfully in the laboratory 
for other antibodies, the author was unable to demonstrate specificity for this 
antibody. After consultation with the senior scientist (JE) within the department, it 
was decided to perform immunohistochemical staining with the Phospho.JAK-1 
antibody sample. 
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2.4 Immunohistochemistry 
Protein expression was determined using immunohistochemistry (IHC). This is a 
staining technique which relies on the use of specific antibodies raised against 
epitopes of the protein antigens to be analysed. In this study a standard indirect 
immunoperoxidase technique was used to stain tissue sections. Slides contained 
3µm sections of tissue, cut from paraffin embedded tissue-blocks and required de-
waxing in xylene and progressive rehydration through graded alcohol solutions in 
order to remove any remaining paraffin. Some cells contain endogenous 
peroxidase enzymes which can interfere with the use of peroxidase-labelled 
antibodies later on during the procedure. Treatment with hydrogen peroxide (3%) 
is therefore required to destroy this pre-existing peroxidase within the tissue. 
 
The next stage is an antigen-retrieval process which is required to counteract the 
effects of formaldehyde fixatives. These fixatives react with basic amino-acids to 
form cross-links masking antigen from the antigen. The cross-links can be 
removed using a variety of methods (incubating slides in heated trypsinised 
solution or citrate buffer solution) depending on the particular antigen in question. 
Non-specific binding of antibody to protein can take place resulting in 
background staining. This makes subsequent scoring difficult as differentiating 
between specific and background staining is impossible. A blocking agent is 
therefore required and takes the form of serum, which is usually derived from 
horse. 
 
The addition of the antibody, which may be monoclonal or polyclonal is next. 
Polyclonal antibodies are by definition derived from several different clones of 
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plasma cells upon inoculation of protein, meaning they will react to different 
epitopes on the same antigen and can be used at low concentrations. This also 
means that they may also contain non-specific antibodies, leading to background 
staining. This effect can be minimised by titrating the most appropriate 
concentration of antibody. Monoclonal antibodies are produced from a single 
clone of B-cells and react with a specific epitope on the antigen and consequently 
leading to less background staining. 
 
Primary antibodies are incubated for varying lengths of time, ranging from 1 hour 
at room temperature to overnight at 40C dependent on the antibody used. 
Following this initial incubation period the addition of a secondary antibody is 
required as part of an indirect method of immunostaining. This takes place in two 
parts, initially using a biotinylated secondary antibody which links to a peroxide 
enzyme-streptavidin conjugate. Streptavidin has a low potential for non-specific 
binding which results in more sensitive staining. Endogenous biotin may however 
result in non-specific binding of secondary antibody which may be reduced by the 
addition of a biotin block. 
 
The next stage is staining which is achieved by the addition of 3,3-diamino-
benzidine tetrahydrochloride (3,3-DBT). In the presence of peroxidase at the site 
of the antigen DBT polymerises to form a visible brown reaction product. 
Following this, the nuclei are counterstained blue with haematoxylin and Scotts 
tap water substitute. The final stage involves dehydration of the sections in graded 
alcohol solutions before clearing in xylene. Finally DPX resin-coated coverslips 
are added and the slides are ready for scoring. 
 
 119 
All immunohistochemistry was performed by the author using a number of 
protocols. All protocols involved a number of similar steps which are described 
below. The individual variations between antibodies are summarised in Table 2.1. 
 
2.4.1 De-waxing and Rehydration 
1. Xylene (Fisher Laboratories, UK) for 5 mins x2 
2. 100% alcohol (Fisher Laboratories, UK) for 5 mins 
3. 90% alcohol for 2 mins 
4. 70% alcohol for 2 mins 
5. Rinse in tap water  
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2.4.2 Antigen Retrieval 
Formalin fixation causes cross-linking within the sections, causing alteration of 
the tertiary structure of the protein and may therefore mask the antigenic site in 
the protein that the antibody has been raised to. Antigen retrieval is necessary to 
break these bonds and unmask the antigen and involves a process with enough 
energy to break the disulphide bonds without destroying the intrinsic protein 
structure. In this study the author used two methods depending on the antibody 
used: 
Microwave under pressure: 
 
1. Add 0.55g TRIS (VWR International LTD, UK) and 0.37g EDTA (BDH 
Laboratory Supplies, UK) to 1L of distilled water. 
2. Microwave under pressure for 5 mins 
3. Allow slides to cool for 20 mins 
4. Rinse in tap water 
 
Citrate buffer incubation: 
 
1. Incubate in Citrate buffer solution (Epitope Retrieval Solution x10, K-
5205, Dakocytomation, Denmark) diluted in distilled water (72:8) at 960C 
in a calibrated water bath for 20 mins 
2. Allow slides to cool for 20 mins 
3. Rinse in tap water 
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2.4.3 Block of Endogenous Peroxidase Activity 
Many human tissues contain endogenous peroxidase. All twelve antibodies 
underwent treatment hydrogen peroxidase to irreversibly inactivate endogenous 
peroxidase. This was done as described below, either before or after antigen 
retrieval depending on the individual antibody protocol: 
 
1. H2O2 (VWR International LTD, UK) 0.3% 400mls for 10 mins 
 
2. Rinse in tap water 
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2.4.4 Block of Non-specific Background Staining 
Non-specific background staining can cause problems during analysis and 
requires blocking. In the majority of cases this was done using 1.5% v/v normal 
horse serum (S-2000, Vector Laboratories Inc. Burlingame CA 94010) in tri-
phosphate buffered saline (TBS). This was done using the following protocol: 
 
- Block with 15uL horse serum (Vector, US) per 1ml of TBS for 20 mins, then 
blot. 
 
In addition to horse serum some antibodies required further blocking using Avidin 
and Biotin block as described below: 
 
1. Add Avidin block (Vector Laboratories, US) for 15 mins 
2. Wash in TBS for 5 mins 
3. Add Biotin block (Vector Laboratories, US) for 15 mins 
4. Wash in TBS for 5 mins 
 
A number of antibody protocols did not use horse serum and instead background, 
non-specific staining was blocked using the below protocol: 
 
- Incubate with ‘Power Block’ – 1xCasein (diluted in TBS) for 10 minutes, then 
blot. 
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2.4.5 Incubation with Primary Antibody 
The primary antibody was then added to the sections. For each antibody a number 
of different concentrations were tried on the practice TMA. The optimum 
concentration was chosen as the one that gave the least amount of background 
staining with clear tumour staining. All antibodies were diluted using DAKO 
antibody dilutent (S-0809, Dakocytomation, Denmark) and incubated overnight at 
either room temperature or 40C in a moisture chamber. See Table 1 for 
concentrations of each antibody.  
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2.4.6 Visualisation Method 
Once the antibody has bound to its target protein, a visualisation method is needed 
to identify the location and intensity of the antibody. In the twelve antibodies used 
in this study three different methods were used depending on the individual 
protocols, each being described below. 
 
Following each of the three visualisation methods described below 3,3-
diaminobenzidine (DAB) solution is added. DAB binds to the peroxidase domain 
leaving an insoluble brown stain at the site of cleaving. The addition of DAB is 
common to all twelve antibodies using the protocol described below and follows 
each of methods 1, 2 and 3. 
 
Method 1: 
1. Add secondary antibody (K-0690, Dakocytomation, Denmark). Leave for 
15 minutes 
2. Wash in TBS for 5 mins x2 
3. Add Biotinylated Streptavadin-HRP complex (K-0690, Dakocytomation, 
Denmark). Leave for 15 mins 
4. Wash in TBS for 5 mins 
 
Method 2: 
1. Add Envision block (Dakocytomation, Denmark) for 30 minutes 
2. Wash in TBS for 5 mins 
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Method 3: 
1. Incubate slides with ‘SuperBlock Reagent’ (HK518-06K, BioGenex) for 
20 mins 
2. Wash in TBS for 5 mins x2 
3. Incubate slides with ‘Poly-HRP Reagent’ (HK519-06K, BioGenex) for 30 
mins 
4. Wash in TBS for 5 mins x2 
 
DAB protocol (follows each of the above methods 1-3): 
 
1. DAB (SK-4100, Vector Laboratories, Burlingame, CA 94010, US) Kit 
contains separate H2O2, DAB reagent and buffer (pH 7.5) - 2 drops buffer: 
4 drops DAB: 2 drops H2O2 in 5mls distilled water. 
2. Leave for 2-10 minutes until brown staining evident. 
3. Rinse in tap water for 10 minutes. 
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2.4.7 Counterstaining 
Counterstaining is essential to stain areas on the section that do not contain the 
antibody so that all cells and stroma on the section can be visualised. All twelve 
antibodies underwent the following protocol: 
 
1. Stain in haematoxylin (Thermoshandon) for 90secs 
2. Rinse in tap water 
3. Add to Scotts Tap water (Magnesium Sulphate 7-hydrate and Na, H+ 
Carbonate , BDH Laboratory Supplies, UK) until blue staining 
4. Rinse in tap water 
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2.4.8 Dehydration and Mounting 
Following staining the slides undergo dehydration through increasing 
concentrations of alcohol and then xylene before being mounted on a coverslip to 
preserve the tissue and allow examination under a microscope. All twelve 
antibodies underwent the following protocol: 
 
1. 1 min 70% alcohol 
2. 1 min 90% alcohol 
3. 1 min 100% alcohol x2 
4. 1 min xylene x2 
5. Mount in DPX (a mixture of distyrene (a polystyrene), tricresyl phosphate 
(a plasticizer) and xylene). DPX has the same refractive index of glass and 
enables visualisation via light microscopy. 
 
The above protocols were based on work done on prostate tissue for the JAK-
STAT pathway and breast tissue for the MAPK pathway. They were developed 
for pancreatic tissue using the practice TMA described earlier until adequate 
quality of staining was achieved. The new protocol was then used upon the three 
pancreatic TMA’s. The variables in IHC for each antibody are summarised in 
Table 2.1. 
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Table 2.1: Variations in IHC for each of the twelve antibodies. 
Antibody Antibody 
dilution 
Antigen 
retrieval 
 method 
Blocking of 
peroxidase 
activity 
(before/after 
antigen 
retrieval) 
Blocking of 
non-specific 
background 
staining 
Incubation 
with 
primary 
antibody 
Visualisation 
method 
IL-6R 1:500 Citrate 
buffer 
Before Horse serum 40C 20 antibody 
& biotin 
Jak-1 1:200 Microwave After Horse serum 
(+avid & 
biotin) 
Room 
temp 
20 antibody 
& biotin 
pJak-1 1:25 Microwave After Horse serum Room 
temp 
Envision 
STAT-3 1:100 Citrate 
buffer 
Before Horse serum 40C 20 antibody 
& biotin 
pSTAT-
3Tyr 705 
1:50 Microwave After Horse serum Room 
temp 
20 antibody 
& biotin 
pSTAT-
3Ser 727 
1:50 Microwave After Horse serum Room 
temp 
20 antibody 
& biotin 
K-Ras 1:10 Microwave After Power block 40C Super-block 
& Poly-HRP 
Raf-1 1:80 Citrate 
Buffer 
After Horse serum 40C Super-block 
& Poly-HRP 
pRaf-
1Ser259 
1:10 Citrate 
buffer 
After Power block 40C Envision 
pRaf-
1Ser338 
1:250 Microwave After Power block 40C Envision 
MAPK 1:200 Citrate 
buffer 
After Horse serum 40C Envision 
pMAPK 1:50 Microwave After Horse serum Room 
temp 
Envision 
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2.5 Scoring 
Scoring was performed using the weighted histoscore. When scoring each 
core/slide, the investigator multiplies the proportion of cells staining by the 
intensity of that staining to give on overall histoscore out of 300 for each part of 
the cell, the membrane, the cytoplasm and the nucleus. The proportion of cells 
staining is given as a percentage and the intensity is based upon a scale of 0-3, 
where 0 is no staining, 1 is weak staining, 2 is moderate staining and 3 is strong 
staining. The total score out of 300 is achieved by adding the following: (0 x 
percentage not staining) + (1 x percentage weakly staining) + (2 x percentage 
moderately staining) + (3 x percentage strongly staining). For example, a section 
with 50% of tumour staining with an intensity of 1; 25% staining with intensity of 
2 and 25% staining with an intensity of 3 would have a total histoscore of: 
 
(50x1) + (25x2) + (25x3) = 175 
 
All 12 of the antibodies were double scored (a 10% sample of each antibody) by 
the senior scientist (JE) within the department of surgery with years of experience 
and scoring consistency was confirmed using the Intra-class correlation 
coefficient (ICCC). If there was a difference of 50 or greater for any score then 
the two observers looked at the core again and came to an agreement about the 
appropriate score. 
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2.6 Statistical Analysis 
All statistical analysis in this thesis was performed using SPSS 11&15 (SPSS Inc, 
Chicago, Illinois) by the author (SD) with advice from a statistician (WA) in the 
University Department of Surgery, Glasgow Royal Infirmary The statistics in 
Section 3.4.6 (Further Statistical Analysis) were performed entirely by a 
statistician (JP) within the Beatson Oncology Centre, Gartnavel General Hospital, 
Glasgow, using his own statistical package and are reproduced in this thesis with 
his kind permission. 
 
In section 3.1.2 (Patient Demographics) median age and range was calculated by 
analysing the basic patient demographics and using descriptive statistics followed 
by frequencies. Section 3.1.3 (Clinical and Pathological Prognostic Factors) 
involved the analysis of a number of factors against survival. The database 
contained survival data for all of the 148 patients and survival analysis was 
performed using Kaplan Meier curves and the log-rank test for significance. The 
event in the analysis was death and for each of the variables the patients were split 
into groups before the survival analysis was performed: pancreatic cancer and 
NPPC (Section 3.1.3.1); tumours >2cm and <2cm (Section 3.1.3.2); N0 and N1 
tumours (Section 3.1.3.3); tumour differentiation (Section 3.1.3.4); R0 and R1 
tumours (Section 3.1.3.5). 
 
Section 3.2 dealt with CRP and for the statistics the tumours were again separated 
into Pancreatic cancer and NPPC. Before survival analysis, again with Kaplan 
Meier curves and the log-rank test, the patients were divided into two groups 
depending whether their pre-operative CRP was raised or not. A CRP of 
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>10mg/ml was taken as a raised CRP, again analysing against survival with death 
being the event. Following univariate analysis of all clinical and pathological 
prognostic factors, all statistically significant factors were entered into a Cox’s 
regression analysis, again with length of survival and death as the event to 
establish significant factors following multivariate analysis. 
 
The author scored all of the antibody staining and 10% of this scoring was 
repeated independently by the senior scientist within the laboratory (JE) to check 
scoring consistency. This consistency was analysed using the ICCC via scale and 
then reliability analysis. 
 
The frequency histograms plotted in section 3.4.4 (Protein Expression) were 
produced by analysis and descriptive statistics to give a visual representation of 
the distribution of scoring for each antibody in each cellular compartment and are 
displayed in full in Appendix 1 and Appendix 2 (for the JAK-STAT and MAPK 
pathways respectively). 
 
These frequency histograms demonstrate skewing to the right in the vast majority 
of cases in both the JAK-STAT and MAPK pathways and after consultation with 
the unit statistician (WA) it was decided that the optimum cut-off between what 
was considered low and high scoring should be the upper quartile. This was used 
to again plot Kaplan Meier curves with the log-rank test to assess significance for 
each of the twelve antibodies in each cellular compartment. 
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3.0 RESULTS 
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3.1 Patients 
3.1.1 The Retrospective Database 
Ethical approval was achieved from the trust Ethics committee and met the 
approval of the local Research & Development department. Identification of all 
patients who had undergone resection for pancreatic cancer was achieved using 
the pathology department database at Glasgow Royal Infirmary under the 
guidance of Mr Alan Moffat (mortician, Glasgow Royal Infirmary). The start date 
for this search was June 1992, when the pathology department database was 
created. A search looking for the terms ‘whipple’ or ‘pancreaticoduodenectomy’ 
in all pathology reports was carried out. All of the identified reports were then 
examined on a computer, those patients with Whipples disease biopsy results 
being excluded, leaving only those who had undergone a Whipple operation or 
pancreaticoduodenectomy. Each report was then carefully examined and only 
patients who had resection for either pancreatic cancer (PC) or non-pancreatic 
peri-ampullary cancer (NPPC) were included (neuro-endocrine tumours were 
excluded). This left 148 patients, 90 PC and 58 NPPC. The NPPC group was 
made up of 35 ampullary adenocarcinomas, 15 distal cholangiocarcinomas, 3 
duodenal adenocarcinomas and 5 that were described as peri-ampullary 
adenocarcinomas on the pathology report.  
 
Patient demographics were entered onto an anonymised database using pathology 
and hospital numbers as identifiers along with their pathological details. Further 
information including pre-operative CRP and survival data was gained from 
hospital records and added to the database. 
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3.1.2 Patient Demographics 
Between June 1992 and July 2004, 148 patients underwent a Whipple procedure 
for malignant disease and were included in this study. During the first 6 years 
(June 1992- June 1998) of this period only 23 resections were performed by a 
single surgeon. The increase in resections over the latter six years (July 1998- July 
2004) reflects the centralisation of pancreatic services in the West of Scotland, 
with three surgeons performing resections.  
 
Overall median age was 63.5 years (range 38-77), in the PC group 63.5 years 
(range 38-77) and in the NPPC group median age was 64 years (range 42-77) 
(Table 3.1). 
 
Table 3.1: Basic Patient Demographics 
 
Variable Overall group 
(N=148) 
PC group (N=90) NPPC group(N=58) 
Median Age 63.5 years (38-77) 63.5 years (38-77) 64 years (42-77) 
Male: Female 77:71 45:45 32:26 
Median 
Survival 
477 days (7-3851) 374 days (8-2873) 618 days (7-3851) 
Alive: Dead 27:121 11:79 16:32 
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3.1.3 Clinical and Pathological Prognostic Factors 
There are a number of clinical factors that are known to influence survival in 
resectable pancreatic cancers (see introduction). These include: histological 
tumour type; tumour size; lymph node status; tumour differentiation; resection 
margin status. As this thesis discusses CRP as a prognostic factor, the prognostic 
indicators above are discussed individually below. 
 
3.1.3.1 Histological Tumour Type 
The histological origin of the tumour is known to be crucial to post-operative 
survival, PC patients doing poorly when compared to NPPC5. In this cohort 
overall median survival was 477 days (range 7-3851) with 27 patients alive at the 
end of the study period. When patients were divided into PC and NPPC groups, 
using Kaplan Meier curves and the log rank test for statistical significance the 
median survival times were 374 days (range 8-2873) and 618 days (range 7-3851) 
respectively (p=0.003) (Figure 3.1). 
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Figure 3.1: Kaplan Meier Curve of PC versus NPPC post-op survival.  
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3.1.3.2 Tumour Size 
In the current TNM classification of pancreatic cancers, tumours are separated 
into those less than and those greater than 2cm to differentiate between T1 and T2 
tumours respectively. Tumour size is, as mentioned above another known 
prognostic factor, with larger tumours associated with poorer survival11. In the 
analysis of tumour size against survival, 2cm (maximum diameter) was used as 
the cut off before analysis using Kaplan Meier curves and the log rank test for 
statistical significance. Analysis revealed a significant difference in survival when 
the group was analysed as a whole, but not when separated in PC and NPPC 
groups (Table 3.2). 
 
Table 3.2:  Survival analysis of tumour size. 
Tumour Type Size Median Survival (days)  Range P-Value 
T1 655 17-3460  
OVERALL T2 381 7-3851 
 
0.0088 
T1 430  79-2710  
PC T2 345  8-2873 
 
0.3469 
T1 817  17-3460  
NPPC T2 477  7-3851 
 
0.2045 
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Figure 3.2: Kaplan Meier curve of tumour size and survival in overall group. 
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3.1.3.3 Lymph Node Status 
The presence of tumour within lymph nodes following resection is associated with 
a negative impact on survival13. In the current TNM classification N0 and N1 are 
used to described tumours without and tumours with regional lymph node 
invasion respectively. Using lymph node status from post-operative resection 
specimens, Kaplan Meier curves and the log rank test for statistical significance 
were used to establish if lymph node positivity had an impact on survival in this 
patient cohort. 
 
Following analysis, N1 disease was associated with significantly poorer survival 
when compared with N0 disease when all patients were analysed together and 
when separated into PC and NPPC patients (Table 3.3 & figures 3.3-3.5). In the 
PC group the Kaplan Meier curve (figure 3.4) illustrates the poorer survival with 
N1 disease but the median survival is actually longer than N0 patients. This is due 
to half of the patients in both groups dying in the first year, where the two curves 
are close. After the first year there is separation of the two curves as a number of 
N0 patients are long-term survivors. In the NPPC group, N1 disease is associated 
with significantly poorer survival (P<0.0001) (Figure 3.5). 
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Table 3.3:  Survival Analysis of Lymph Node Status 
Tumour Type Nodal Status Median Survival (days)  Range P-Value 
N0 1055 7-3851  
OVERALL N1 411 8-2713 
 
<0.0001 
N0 304 9-2873  
PC N1 389 8-1461 
 
0.04 
N0 1659 7-3851  
NPPC N1 494 12-2713 
 
<0.0001 
 
 
Figure 3.3: Kaplan Meier Curve of lymph node status and post-op survival in all 
patients. 
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Figure 3.4: Kaplan Meier Curve of lymph node status and post-op survival in PC 
patients.  
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Figure 3.5: Kaplan Meier Curve of lymph node status and post-op survival in 
NPPC patients.  
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3.1.3.4 Tumour Differentiation 
The differentiation of tumours significantly affects outcome after curative 
resection for pancreatic tumours, poorly differentiated tumours having a 
significantly poorer outcome compared to well or moderately differentiated 
tumours9. Patients were divided into PC and NPPC groups before analysis using 
Kaplan Meier curves and the log rank test for statistical significance. When all 
patients were analysed together, patients with poorly differentiated tumours 
survived a shorter period (p=0.028) (figure 3.6). In the PC group, tumour 
differentiation was a significant prognostic factor, patients with a poorly 
differentiated tumour surviving for a shorter period (p=0.0091) (figure 3.7). There 
was no significant difference in the NPPC group (p=0.34). 
 
Table 3.4: Survival analysis of tumour differentiation 
Tumour Type Differentiation Median Survival (days) Range P-value 
Well 589 8-2710 
Moderate 552 10-3851 
 
OVERALL 
Poor 290 7-2434 
 
0.0281 
Well 589 8-2710 
Moderate 467 10-2653 
 
PC 
Poor 208 10-2434 
 
0.0091 
Well 1301 356-1988 
Moderate 618 17-3851 
 
NPPC 
Poor 443 7-1515 
 
0.3409 
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Figure 3.6: Kaplan Meier curve of tumour differentiation and post-op survival in 
the overall group (p=0.0281). 
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Figure 3.7: Kaplan Meier curve of tumour differentiation and post-op survival in 
the PC group (p=0.0091). 
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3.1.3.5 Resection Margin Status 
The presence of tumour at the resection margins following potentially curative 
resection for pancreatic cancer causes a significant reduction in post-operative 
survival9. As with other clinical parameters, patients were split in to PC and 
NPPC groups prior to analysis using Kaplan Meier curves and the log rank test for 
statistical significance. 
 
Following analysis a positive resection margin is significantly associated with 
poor survival when all patients are analysed together (figure 3.8), but appears to 
have no significant affect on survival in PC patients in this cohort (Table 3.5). In 
the NPPC group, positive resection margins were associated with significantly 
shorter survival than patients with a R0 resection (Figure 3.9) (p<0.001).  
 
 Table 3.5: Survival Analysis of Resection Margin Status 
Tumour Type Resec.Margin Median Survival (days)  Range P-Value 
R0 655 7-3851  
OVERALL R1 370 10-1460 
 
<0.0001 
R0 589 8-2873  
PC R1 345 10-2710 
 
0.16 
R0  779 7-3851  
NPPC R1  379 47-826 
 
0.001 
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Figure 3.8: Kaplan Meier Curve of resection margin status and post-op survival 
in all patients. 
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Figure 3.9: Kaplan Meier Curve of resection margin status and post-op survival 
in NPPC patients.  
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3.2 C-reactive Protein 
3.2.1 Retrospective CRP 
Overall 118 of the 148 patients had pre-operative CRP measurements available, 
83 of these were in the PC group and 35 in the NPPC group. Of the 83 PC patients 
with pre-op CRP available 38 had a raised CRP level (>10mg/l). In the NPPC 
group15 out of the 35 CRP values available were raised (Table 3.6). 
 
Table 3.6: Available CRP measurements/ proportion of patients with raised CRP. 
Group Pre-op CRP Available Pre-op CRP >10mg/l 
Overall (No-148) 118/148 53/118 
PC (No-90) 83/90 38/83 
NPPC (No-58) 35/58 15/35 
 
The two groups (PC and NPPC) were separated and survival analysis using 
Kaplan Meier curves and the log rank test for statistical significance was 
performed using a CRP of 10mg/l as the cut off between normal and raised levels. 
An elevated pre-operative CRP was associated with poor survival (p=0.0001) 
(Figure 3.10). Those patients in the PC group with an elevated pre-operative CRP 
(>10mg/l) had a median survival of 262 days compared with 594 days in those 
with a normal CRP. In the NPPC group, pre-operative CRP was not significantly 
associated with survival (p=0.225). 
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Figure 3.10: Kaplan Meier curve of pre-op CRP levels and post-op survival in the 
PC group (p=0.0001). 
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3.2.1.1 Multivariate Analysis 
All clinical variables found to be statistically significant on univariate analysis in 
the PC group (p<0.05) (pre-operative CRP, tumour differentiation, nodal status) 
were entered into Cox’s regression analysis. Following analysis only pre-
operative CRP retained statistical significance (p=0.009). 
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3.2.2 Prospective Cohort 
Ethical approval was granted by the trust Ethics committee meeting the approval 
of the local Research & Development department for a prospective study. All 
patients undergoing a Whipple resection for either pancreatic cancer (PC) or non-
pancreatic peri-ampullary cancer at Glasgow Royal Infirmary whom gave written 
consent had blood taken pre-operatively by the author (SD) between 30/10/03 to 
05/05/05 (collection has continued by JL after this date as the author left the 
department).  
 
The blood was then anonymously labelled and stored in the department of surgery 
at -20oC. An anonymous prospective database was then created containing basic 
patient demographics, pathology data and survival data. The blood samples for the 
first 36 patients were analysed by an additional research fellow in the department 
of surgery at Glasgow Royal Infirmary (JL). 
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3.2.2.1 Patient Demographics 
Between 30/10/03 and 05/05/05, 36 patients underwent a Whipple procedure for 
malignant disease and were included in an anonymous, prospective database. Pre-
operative blood samples were collected by the author (SD) and analysed by 
another research fellow in the department of surgery (JL). The resections were 
performed by three consultant surgeons. 
 
Overall median age was 64.5 years (range 41-76), in the PC group 66 years (range 
41-76) and in the NPPC group median age was 59 years (range 42-76) (Table 
3.7). The patients were split into PC and NPPC groups and survival analysis using 
Kaplan Meier curves and the log rank test for statistical significance was 
performed (Figure 3.11). Despite the small numbers in this prospective cohort, a 
statistically significant difference in survival is seen between the two groups. 
Patients with PC had a median survival of 564.5 days (range 163-1013) and those 
with NPPC 760 days (range 347-1135) (P=0.03). 
 
Table 3.7: Basic Patient Demographics 
Variable Overall group (N=36) PC group (N=20) NPPC group(N=16) 
Median Age 64.5 years (41-76) 66 years (41-76) 59 years (42-76) 
Male: Female 19:17 11:9 8:8 
Median 
Survival 
637.5 days (163-
1135) 
564.5 days (163-1013) 760 days (347-1135) 
Alive: Dead 14:22 4:16 10:6 
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Figure 3.11: Kaplan Meier curve of PC and NPPC and survival in prospective 
group. 
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3.2.2.2 Prospective CRP 
All of the 36 patients had pre-operative CRP measurements available. A CRP of 
>10mg/l was used as the cut-off for an inflammatory response. Of the 36 patients 
8 had a raised CRP level (>10mg/l). In the PC group 5 out of the 20 CRP values 
available were raised compared with 3 out of 16 in the NPPC group (Table 3.8). 
 
Table 3.8 : Available CRP measurements/ proportion of patients with raised CRP. 
Group Pre-op CRP >6mg/l 
Overall (No-36) 8/36 
PC (No-20) 5/20 
NPPC (No-16) 3/16 
 
All 36 patients were analysed together before separating into two groups (PC and 
NPPC) and survival analysis using Kaplan Meier curves and the log rank test for 
statistical significance was performed. No significant difference in survival was 
seen between patients with and without an inflammatory response when all 36 
were analysed together or when patients were separated into PC and NPPC groups 
(Table-3.9).  
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Table 3.9: CRP levels and survival in prospective group  
Tumour Type CRP Level Median Survival (days) Range (days) P-Value 
<10mg/L 727 163-1135  
Overall >10mg/L 493 394-922 
 
0.739 
<10mg/L 589 163-1013  
PC Group >10mg/L 493 402-922 
 
0.970 
<10mg/L 787 347-1135  
NPPC Group >10mg/L 593 394-803 
 
0.917 
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3.2.2.3 Interleukin-6 and Survival 
Using the prospectively collected blood samples, plasma levels of IL-6 were 
obtained by JL using a commercially available ELISA kit (R & D Systems Europe 
Ltd). All 36 patients were analysed together before separating into two groups 
(PC and NPPC) and survival analysis using Kaplan Meier curves and the log rank 
test for statistical significance was performed. Previous papers using an identical 
ELISA kit used an IL-6 level of 4pg/ml as the cut off between normal and raised 
levels and this value was employed by the author (Table 3.10)258. 
 
When all of the 36 patients were analysed together there was a statistically 
significant difference in survival between patients with low levels of plasma IL-6 
and those with higher levels (Figure 3.12). Median survival in patients with low 
levels of IL-6 was 799 days (range 230-1013) compared with 537 days (range 
163-1135) in those with higher levels (P=0.002). 
 
When patients are separated into PC and NPPC groups there was no significant 
difference in survival in the PC group.  In this group, median survival in those 
with lower levels of IL-6 was 902 days (range 230-1013) compared with 540 days 
(range 163-1002) in those with higher IL-6 levels (P=0.104). In the NPPC group 
there was a significant difference in survival. Those patients with low IL-6 levels 
had a median survival of were 766 days (range 398-1013) and 537 days (range 
347-1135) in those without and those with an inflammatory response respectively 
(P=0.027). As with the prospective CRP results, the numbers in this IL-6 analysis 
are extremely small, with only 5 patients in the NPPC group actually having high 
levels of IL-6. These results represent the initial trends as data collection 
continues. 
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Table 3.10: IL-6 levels and survival in prospective group 
Tumour Type IL-6 Level Median Survival (days) Range (days) P-Value 
Low 799 230-1013  
Overall High 540 163-1135 
 
0.002 
Low 902 230-1013  
PC Group High 540 163-1002 
 
0.104 
Low 766 398-1013  
NPPC Group High 537 347-1135 
 
0.027 
 
Figure 3.12: Kaplan Meier curve of Normal v Elevated IL-6 and Survival in 
Overall Prospective Group.   
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3.2.2.4 Correlation Between CRP and IL-6 Levels 
If the hypothesis stated in the introductory chapter to this thesis is correct then 
there should be a correlation between the plasma levels of IL-6 and CRP as the 
main driver of plasma CRP is IL-6. To analyse possible correlations, Spearmans 
test for two data sets with non-linear distribution was used (Figure 3.13). This 
revealed a statistically significant relationship between plasma CRP and plasma 
IL-6 (P=0.031). 
 
Figure 3.13: Analysis of correlation between plasma IL-6 and CRP. 
 Correlations 
 
      CRP IL-6 
Correlation Coefficient 1.000 .360(*) 
Sig. (2-tailed) 
. .031 
CRP 
N 36 36 
Correlation Coefficient 
.360(*) 1.000 
Sig. (2-tailed) 
.031 . 
Spearman's rho 
il6elisa 
N 36 36 
*  Correlation is significant at the 0.05 level (2-tailed). 
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3.3 Tissue Micro-Arrays (TMA’s) 
3.3.1 Planning the TMA’s 
Before embarking on the creation of TMA’s a period of planning took place. One 
of the key factors when planning the TMA’s was the distance between cores. The 
accepted minimum between cores is 0.8mm, below that and the wax blocks are 
likely to disintegrate during coring. For the TMA’s in this thesis 1mm gaps 
between cores were chosen. To gain representation of pancreatic tumours, 3 cores 
of tumour tissue were taken for each patient along with 2 cores of normal 
pancreatic ductal tissue, a total of 5 cores for each patient. For the 148 patients 
this meant a total of 740 cores. A number of control tissues were also required. A 
literature review was carried out by the author to select control tissues that have 
previously been shown to give positive immunohistochemical staining in the 
relevant antibodies. Table 3.11 below shows each of the antibodies, tissues they 
have previously been shown to stain and the relevant references. In addition to 
pancreatic ducts, acinar tissue, islet tissue, bile duct tissue and duodenal tissue, 
breast, testis, liver and prostate tissue were also included on the control panel. 
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Table 3.11: Selected tissue for positive controls.  
ANTIBODY TISSUE REFERENCES 
IL-6R Prostate, Liver Tam259, Rose260 
JAK1 Prostate Tam259 
Phospho.JAK1 Prostate, Breast Tam259, Yeh261 
STAT3 Prostate, Liver, Breast Tam259, Levy262 
Phospho.STAT3 Tyr705 Prostate, Liver Tam259, Yang263 
Phospho.STAT3 Ser727 Prostate, Breast Tam259, Yeh264 
KRas Breast, Prostate, Testis McGlynn265, 
Mukhergee266, 
Traynor267, Yanagihara268 
RAF-1 Breast, Prostate McGlynn265, 
Mukhergee266 
Phospho.RAF-1 Ser259 Breast, Prostate McGlynn265, 
Mukhergee266 
Phospho.RAF-1 Ser338 Breast, Prostate McGlynn265, 
Mukhergee266 
MAPK Breast, Prostate McGlynn265, 
Mukhergee266 
Phospho.MAPK Breast, Prostate McGlynn265, 
Mukhergee266 
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Using standard sized wax recipient blocks, it was calculated that 3 TMA’s would 
be required for the 740 cores in addition to 18 control cores on each TMA (2 cores 
of each control tissue). The other crucial factor when planning TMA’s is 
orientation. Each of the three TMA’s had to be unique to allow identification and 
to make analysis easy, each TMA was asymmetrical. In addition to the 1mm gap 
between cores, larger gaps were made after 6, 6 and 8 cores in the horizontal 
plane and every 4 cores in the vertical plane creating 9 sections of cores on each 
TMA in addition to the panel of controls. This made orientation and subsequent 
scoring significantly easier. The construction of the TMA’s is described in chapter 
2. 
 
For the purpose of antibody optimisation, a practice TMA was created with a total 
of 40 cores. The cores were made up of a selection of tumour and normal tissue to 
avoid using a significant number of slides from the actual TMA’s. 
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3.3.2 TMA Quality 
During the manufacturing of TMA’s there is some inevitable loss of cores. This 
can occur at a number of stages and is the reason why a number of cores are taken 
for each patient. If the donor tissue block is thin then a number of cores will be 
required to fill the recipient block, often referred to as double or triple stacking. 
This inevitably creates gaps in the TMA which will manifest themselves as lost 
cores on subsequent sections. During sectioning it is also generally accepted that 
some cores will be lost, those at the peripheries being more vulnerable. Another 
potential problem that can arise with TMA’s occurs before manufacturing has 
taken place in the selection of tissue. If the original tissue selection is incorrect 
then a good quality TMA will simply show cores of unwanted tissue that should 
be excluded at the scoring stage. 
 
During the scoring of the 12 antibodies analysed in this thesis a record was kept of 
the number of lost or damaged cores and the number of cores of inappropriate 
tissue that had been stained for both tumour and normal pancreatic tissue. 
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3.3.2.1 JAK STAT Lost cores 
There were a total of 740 cores that underwent staining for 6 antibodies 
(excluding control cores) making a total of 4440 cores that underwent scoring for 
the JAK-STAT pathway. Of those 4440, 2664 were tumour and the remaining 
1776 were normal ductal tissue. The numbers of lost and incorrect cores are 
displayed below (Table 3.12). 
 
Table 3.12: Numbers of cores excluded from JAK-STAT analysis. 
 Total Cores Lost/Damaged % Lost Incorrect Tissue % Incorrect 
Overall 4440 74 1.7 812 18.3 
Tumour 2664 32 1.2 174 6.5 
Normal 1776 42 2.36 638 35.9 
 
 161 
3.3.2.2 MAPK Lost Cores 
As in the JAK-STAT analysis there were a total of 4440 cores with 2664 tumour 
and 1776 normal ductal cores. The table below (Table 3.13) displays the 
breakdown of lost cores for the MAPK pathway. 
 
Table 3.13: Numbers of cores excluded from MAPK analysis. 
 Total Cores Lost/Damaged % Lost Incorrect Tissue % Incorrect 
Overall 4440 108 2.4 1512 34.1 
Tumour 2664 75 2.8 576 21.6 
Normal 1776 33 1.9 936 52.7 
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3.4 The JAK STAT Pathway 
3.4.1 Antibody Selection 
For a detailed literature review of the JAK-STAT pathway see section 1.3, a brief 
summary follows. The cytokine Interleukin-6 (IL-6) binds to its cell surface 
receptor IL-6R. Ligand binding leads to dimerisation of the gp130 receptor 
subunit, followed by receptor phosphorylation211. This phosphorylation causes 
internalisation of the ligand-receptor complex allowing cytoplasmic parts of the 
receptor to bind cytoplasmic JAK proteins.  
 
Following receptor phosphorylisation JAK proteins bind to the receptor and auto-
phosphorylate causing JAK activation269. A number of JAK proteins can be 
activated by IL-6, but JAK-1 is dominant in IL-6 signal transduction270. The 
receptor-bound active JAK-1 proteins then cause phosphorylisation of tyrosine 
residues on the cytoplasmic region of the IL-6R which creates binding sites for 
STAT proteins. Although a number of STAT proteins can be activated in this 
process, STAT3 is the dominant protein in IL-6 signalling191.  
 
Once bound to the IL-6R complex STAT3 proteins are phosphorylated by the 
active JAK-1 proteins and these active STAT3 proteins form dimers in the 
cytoplasm, before transportation to the nucleus by unknown mechanisms to bind 
with DNA. 
 
The most suitable antibodies (IL-6R, JAK-1, Phospho.JAK-1, STAT3, 
Pospho.STAT3 Tyr705, Phospho.STAT3 Ser727) for testing the stated hypothesis 
were chosen (Table 3.7). Five of these antibodies (all but Phopsho.JAK-1) were 
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already available for use, their specificity having been established within the 
laboratory as described in section 2.3.2. Each of these five antibodies had all been 
successfully used in immunohistochemistry with prostate tissue in the same 
laboratory. Phospho.JAK-1 antibody had not been previously used within this 
laboratory nor had it been approved for use in immunohistochemistry. A suitable 
product was identified (Phospho.JAK-1, New England Biolabs), but despite 
repeated attempts antibody specificity could not be established (described in 
section 2.3.3). It was decided that despite the lack of evidence of specificity, that 
optimisation of Phospho.JAK-1 should still take place. 
 
Table 3.14: Antibodies Used in Analysis of JAK STAT Pathway 
 
Antibody Manufacturing Company 
Il-6R Santa Cruz 
JAK-1 Cell Signalling 
Phospho.JAK-1 Tyr1022/1023 New England Biolabs 
STAT3 Cell Signalling 
Phospho.STAT3 Tyr705 Cell Signalling 
Phospho.STAT3 Ser727 Cell Signalling 
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3.4.2 Optimisation of Antibodies 
As stated in section 3.4.1, five of the antibodies had been previously used for 
immunohistochemistry on prostate tissue within The University Department of 
Surgery Laboratory, Glasgow Royal Infirmary. The IHC protocols used for 
prostate tissue were taken as the starting point for IHC protocols by the author of 
this thesis (SD) and used on the pancreatic TMA’s with permission of author LT. 
Using a practice TMA described earlier in this thesis, key variables, primary 
antibody dilution, blocking agents and epitope retrieval method were altered until 
optimal staining was achieved. Once optimal staining was achieved on the 
practice TMA, the protocol was repeated on the actual TMA’s.  
 
With every IHC run, a practice TMA slide was included that underwent the same 
protocol but without incubation with the primary antibody as a negative control. 
Positive control cores were already incorporated onto the TMA’s as described 
earlier. The quality of the staining for each antibody was assessed by the author 
(SD) and confirmed by the senior scientist within the laboratory (JE). 
Representative immunohistochemical staining patterns for each of the antibodies 
are shown in figure 3.14. 
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3.4.2.1 IL-6R 
The IL-6R rabbit polyclonal antibody (Santa Cruz) was used on the practice TMA 
initially with a protocol successfully used on prostate tissue. This protocol used 
citrate buffer and an antibody dilution of 1:500 and optimal staining was achieved 
on the first run with no staining on the negative control. This was successfully 
repeated on the actual TMA’s. Staining was expected in both the cytoplasm and 
the membrane cellular compartments according to the product datasheet, but in 
this study staining was seen in all 3 cellular compartments.  
 
3.4.2.2 JAK-1 
The rabbit polyclonal JAK-1 antibody (Cell Signalling) was used on the practice 
TMA using a previously successful IHC protocol for prostate tissue. This 
antibody detects total JAK-1 staining. Antigen retrieval was with EDTA buffer 
and an initial antibody dilution of 1:200 was used. The initial staining run was 
successful and was repeated exactly on the TMA’s with a negative control. 
Optimal staining was achieved. Staining was seen in the cytoplasm and to a lesser 
degree at the membrane. 
 
3.4.2.3 Phospho.JAK-1 Tyr 1022/1023 
As stated earlier the, rabbit polyclonal P.JAK-1 antibody (Cell Signalling) was 
obtained but had not been used for immunohistochemistry in the past. This 
antibody only detects levels of JAK1 when it is phosphorylated at Tyrosine 
residues 1022 and 1023. As this antibody had not been worked up in the past, the 
successful staining protocol for JAK-1 was used as a starting point with EDTA 
buffer and dilution of 1:200. This resulted in very weak staining and the protocol 
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was repeated with dilutions of 1:100, 1:50 and 1:25. Despite increasing 
concentrations of primary antibody, staining was extremely weak. Following 
discussion with the senior scientist within the laboratory (JE) the blocking agent 
was changed from Avidin and Biotin block (Vector Laboratories) to Envision 
block (Dakocytomation, Denmark). The protocol was otherwise unchanged and 
dilutions of 1:50 and 1:25 were performed on the practice TMA’s, again with 
negative controls. Optimal staining was achieved with 1:25 and this was repeated 
successfully on the pancreatic TMA’s. As P.JAK-1 had not been used for IHC the 
datasheet did not contain any information on expected staining, but staining was 
seen in all three cellular compartments on the pancreatic TMA’s. 
 
3.4.2.4 STAT3 
The starting point for staining was a previously used protocol used successfully on 
prostate tissue with the same antibody. This STAT3 antibody detects total levels 
of STAT3 protein. This protocol used a citrate buffer and initial dilution of 1:100 
and was followed successfully on the practice pancreatic TMA. This was then 
repeated on the 3 TMA’s and optimal staining was achieved without staining of 
the negative control. The antibody datasheet showed staining in the cytoplasm and 
nucleus, however on the pancreatic TMA’s staining was seen in the cytoplasm 
and at the cell membrane but not in the nucleus. 
 
 
 
 
 167 
3.4.2.5 Phospho.STAT3 Tyr705 
The IHC protocol previously used successfully on prostate tissue was used on the 
practice pancreatic TMA with EDTA buffer and a 1:50 dilution of the rabbit 
polyclonal antibody P.STAT3 Tyr705. This antibody only detects levels of 
STAT3 when it is phosphorylated at tyrosine 705 residue. This protocol resulted 
in excellent staining and was repeated successfully on the full pancreatic TMA’s 
without any staining on the negative controls. Staining was seen in the cytoplasm 
and the nucleus. 
 
3.4.2.6 Phospho.STAT3 Ser727 
The same protocol used successfully on P.STAT3 Tyr705 was used on this rabbit 
polyclonal antibody which detects levels of STAT3 only when phosphorylated at 
Serine 727. Good staining was achieved on the practice run and repeated on the 
full pancreatic TMA’s with excellent results and no staining on the negative 
control. Staining was seen in both the cytoplasm and the nucleus. 
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Figure 3.14: Representative Immunohistochemical Staining of JAK-STAT 
Proteins (0=no staining, 1=pale staining, 2=moderate staining, 3=strong staining) 
IL-6R Staining 
 
0   1   2 
JAK-1 Staining 
 
0   1   2 
Phospho.JAK-1 Staining 
 
0   1   2   3 
STAT3 Staining 
 
0   1   2   3 
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Phospho.STAT3 Tyr705 Staining 
 
0   1   2 
Phospho.STAT3 Ser727 Staining 
 
0   1   2 
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3.4.3 Variation in Scoring 
The weighted histoscore (discussed in section 2.5) was used for all of the 
immunohistochemical staining. As discussed earlier, all scoring was performed by 
the author of this thesis (SD). The senior scientist within The University 
Department of Surgery, Glasgow Royal Infirmary (JE) independently double-
scored 10% of the cores. The variation in observer scoring was calculated by the 
interclass correlation coefficient (ICCC). An ICCC of 0.7 or greater is considered 
excellent with an ICCC of 1 indicating identical scores. Table 3.15 below shows 
the individual ICCC scores for each of the antibodies. 
 
Table 3.15: ICCC scores for JAK-STAT IHC scoring. 
Antibody         ICCC score (>0.7 excellent).  
IL-6R 0.7284 
JAK-1 0.8757 
P.JAK-1 0.9377 
STAT3 0.8390 
P.STAT3 Tyr705 0.9325 
P.STAT3 Ser727 0.7059 
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3.4.4 Protein Expression 
For the six JAK-STAT proteins examined in this study, expression was seen in all 
three cellular compartments in IL-6R, and Phospho.JAK 1. Cytoplasmic and 
membrane expression only was seen for JAK1 and non-activated STAT3. Both 
active forms of STAT 3 (Phospho.STAT3 Tyr705 and Phospho.STAT3 Ser727) 
had protein expression observed in the cytoplasmic and nuclear compartments 
only. The distribution of scoring for each of the antibodies in each of the cellular 
compartments was then examined. The distribution of scoring was demonstrated 
by plotting frequency histograms (SPSS 15.0, Chicago). These histograms are 
shown in full in Appendix 1.  
 
When these histograms are analysed the majority of these graphs demonstrate 
skewing to the right. Before further statistical analysis took place the continuous 
data needed to be dichotomised, splitting the data in to high and low staining 
before survival analysis could take place. Following statistical advice the upper 
quartile was chosen as the cut-off between high and low scoring. Table 3.16 
shows the median and inter-quartile ranges of each antibody in each cellular 
compartment and hence the cut-off values used for subsequent survival analysis.  
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Table 3.16: Median histoscores and interquartile range 
Protein Median Histoscore Interquartile range 
(Lower Quartile to 
Upper Quartile) 
Cyto 16.67 5.42-30.00 
Mem 6.67 0.0-20.00 
 
IL-6R 
Nuc 6.67 0.0-20.00 
Cyto 53.33 26.67-83.33 
Mem 0.00 0.0-16.67 
 
JAK 1 
Nuc - - 
Cyto 83.33 56.67-100.00 
Mem 60.00 30.00-86.67 
 
P.JAK 1 
Nuc 120.00 83.33-145.00 
Cyto 93.33 56.67-123.33 
Mem 40.00 17.50-71.67 
 
STAT 3 
Nuc - - 
Cyto 23.33 6.67-54.58 
Mem - - 
 
P.STAT3 
Ser727 
Nuc 43.33 23.75-80.00 
Cyto 13.33 3.75-26.67 
Mem - - 
 
P.STAT3 
Tyr705 
Nuc 66.67 26.67-126.67 
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3.4.5 Protein Expression and Survival 
To assess whether expression levels of proteins in the JAK-STAT pathway were 
associated with poorer survival in pancreatic cancer, Kaplan-Meier graphs were 
plotted for patients expressing low levels (below cut off)and high levels (above 
cut off) of staining in both the PC and NPPC groups and were compared using the 
log rank test. Table 3.17 shows survival in patients with PC for both low and high 
levels of staining for each of the tested antibodies in each of the cellular 
compartments. Table 3.18 shows the corresponding values for patients with NPPC 
tumours. 
 
At first glance there appear to be statistically significant results in both the PC and 
NPPC patients (cytoplasmic STAT3 and nuclear Phospho.STAT3 Tyr 705 
respectively). However when multiple testing is taken into account using 
Bonferroni correction, there are no statistically significant results in either the 
ductal or non-ductal groups at the 5% level271. 
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 Table 3.17: Difference in survival between low and high protein expression in 
the PC group. 
 
Median Survival (days)  
               Protein Low 
expression 
High 
expression 
 
P-value 
Cyto 345 370 0.6988 
Mem 430 279 0.0549 
 
IL-6R 
Nuc 430 304 0.3769 
Cyto 405 339 0.6106 
Mem 405 345 0.4487 
 
JAK 1 
Nuc - - - 
Cyto 407 339 0.2498 
Mem 374 345 0.3382 
 
P.JAK 1 
Nuc 407 267 0.0853 
Cyto 345 801 0.0286 
Mem 370 512 0.5725 
 
STAT 3 
Nuc - - - 
Cyto 411 304 0.847 
Mem - - - 
 
P.STAT3 
Ser727 
Nuc 430 304 0.1894 
Cyto 389 345 0.5874 
Mem - - - 
 
P.STAT3 
Tyr705 
Nuc 407 271 0.2428 
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Table 3.18: Difference in survival between low and high protein expression in the 
NPPC group. 
 
Median Survival (days)  
               Protein Low 
expression 
High 
expression 
 
P-value 
Cyto 572 618 0.2931 
Mem 582 1432 0.2924 
 
IL-6R 
Nuc 582 848 0.3263 
Cyto 572 811 0.2669 
Mem 572 1423 0.0623 
 
JAK-1 
Nuc - - - 
Cyto 618 811 0.5617 
Mem 618 1055 0.9913 
 
P.JAK-1 
Nuc 618 582 0.8709 
Cyto 477 1423 0.0528 
Mem 572 1055 0.1982 
 
STAT 3 
Nuc - - - 
Cyto 582 618 0.9536 
Mem - - - 
 
P.STAT3 
Ser727 
Nuc 632 618 0.2880 
Cyto 572 655 0.1878 
Mem - - - 
 
P.STAT3 
Tyr705 
Nuc 529 848 0.0446 
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3.4.6 Further Statistical Analysis 
The analysis above was carried out by the author (SD) turning what is continuous 
data (a histoscore of between 0 and 300) into binary data by creating cut-off 
points to differentiate between high and low levels of scoring. Although this is an 
accepted method of statistical analysis the author was keen to explore ways in 
which the data could be analysed in a continuous way. The raw scoring data from 
each of the JAK STAT proteins for the 90 PC patients was sent to JP a statistician 
at the Beatson Oncology unit in Glasgow who prepared the following analysis. 
 
The fractional polynomial approach was used in the analysis to establish the best 
shape of relationship between the protein measurements and survival272.  
Fractional polynomials explore a wide range of plausible polynomial relationships 
between the predictor and outcome in a statistically controlled manner which 
avoids the problems of exploring arbitrarily chosen cut-off levels.  Because of the 
large number of variables assessed, the false discovery rate has been used to 
assess the final level of statistical significance273. 
 
When the data is analysed in this fashion on first inspection there appears to be a 
number of significant results (Table 3.19). However when taking into account the 
number of variables assessed, none are significant. 
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Table 3.19: Results of fractional polynomial modelling with Cox regression. 
 
               Protein 
 
Hazard 
Ratio(*) (HR) 
95%  
Confidence 
Interval for 
HR 
 
P-value(**) 
Cyto 6.3 1.22-32.60 0.037 
Mem 1.014 0.999-1.029 0.085 
 
IL-6R 
Nuc 1.017 1.002-1.033 0.037 
Cyto 1.004 0.997-1.011 0.245 
Mem 1.004 0.996-1.012 0.321 
 
JAK-1 
Nuc 1.001 0.989-1.014 0.827 
Cyto 1.004 0.997-1.011 0.246 
Mem 1.002 0.996-1.008 0.477 
 
P.JAK-1 
Nuc 1.003 0.998-1.009 0.217 
Cyto 0.995 0.990-1.000 0.035 
Mem 1.000 0.994-1.007 0.930 
 
STAT 3 
Nuc - - - 
Cyto 1.001 0.993-1.009 0.839 
Mem - - - 
 
P.STAT3 
Ser727 
Nuc 1.003 0.996-1.011 0.361 
Cyto 0.997 0.983-1.011 0.676 
Mem 0.995 0.952-1.039 0.807 
 
P.STAT3 
Tyr705 
Nuc 1.002 0.998-1.006 0.352 
 
*- Relative change in hazard for unit change in the best fitting polynomial. 
**- Adjusting for multiple comparisons none using the false discovery rate of 
these are statistically significant at 5%. 
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3.5 The MAPK Pathway 
3.5.1 Antibody Selection 
For a review of the MAPK pathway see section 1.4, a short summary follows. 
Inactive Ras protein is anchored to the cellular membrane hence its ability to take 
part in cellular signalling. Ras is activated by multiple extra-cellular growth 
factors including IL-6. Ras activation occurs via interaction with the membrane 
bound gp130 receptor subunit with phosphorylation, causing Ras to change from 
its inactive GDP-bound state to its active GTP-bound state274. Active Ras then 
binds to Raf-1 at the cell membrane and undergoes a complex series of events 
leading to Raf-1 activation. The first stage of activation involves de-
phosphorylation of an inhibitory site (serine259), followed by phosphorylation at 
serine338 which is crucial for Raf-1 activation247. 
 
Activated Raf-1 then interacts with MEK, a protein serine/threonine kinase in the 
cytoplasm that has three isoforms (MEK 1a/MEK 1b/MEK 2)248. Activated 
(phosphorylated) Raf-1 goes on to phosphorylate MEK 1/2 at 2 serine residues. 
Activated MEK 1/2 then goes on to interact with MAPK (sometimes known as 
ERK). There are three members of this group of protein kinases, but are generally 
considered together as they are functionally similar. MAPK activation requires 
phosphorylation at threonine and tyrosine residues and this is accomplished by 
interaction with activated MEK, again in the cytoplasm248. Phosphorylation of 
MAPK is the main requirement for its translocation to the nucleus where it 
regulates genes controlling growth, proliferation, differentiation and apoptosis249. 
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The most suitable antibodies to test the hypothesis were chosen (KRas, Raf-1, 
Phospho.Raf-1 Ser259, Phospho.Raf-1 Ser338, MAPK, Phospho.MAPK). These 
antibodies were also chosen as they had been used successfully for 
immunohistochemical analysis of the MAPK pathway in breast and prostate tissue 
within the same laboratory and were all available (Table 3.20). In addition the 
specificity of all of these antibodies was confirmed within the same laboratory by 
Western Blotting (see section 2.3.2). 
 
Table 3.20: Antibodies Used in Analysis of MAPK Pathway 
Antibody Manufacturing Company 
K-Ras Sigma 
Raf-1 Santa Cruz 
Phospho.Raf-1 Ser259 Cell Signalling 
Phospho.Raf-1 Ser338 Upstate 
MAPK Cell Signalling 
Phospho.MAPK Cell Signalling 
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3.5.2 Optimisation of Antibodies 
As stated in section 3.5.1, all six of the antibodies had been previously used for 
immunohistochemistry on breast and prostate tissue within The University 
Department of Surgery Laboratory, Glasgow Royal Infirmary. The IHC protocols 
used for breast tissue were taken as the starting point for IHC protocols by the 
author of this thesis (SD) and used on the pancreatic TMA’s with permission of 
author LM. 
 
Using a practice TMA described earlier in this thesis, key variables, primary 
antibody dilution, blocking agents and epitope retrieval method were altered until 
optimal staining was achieved. Once optimal staining was achieved on the 
practice TMA, the protocol was repeated on the actual TMA’s. With every IHC 
run, a practice TMA slide was included that underwent the same protocol but 
without incubation with the primary antibody as a negative control. Positive 
control cores were already incorporated onto the TMA’s as described earlier. The 
quality of the staining for each antibody was assessed by the author (SD) and 
confirmed by the senior scientist within the laboratory (JE). Representative 
immunohistochemical staining patterns for each of the antibodies is shown in 
figure 3.15. 
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3.5.2.1 K-Ras 
This K-Ras monoclonal mouse antibody (Sigma) had been previously used 
successfully on breast tissue and this protocol was followed exactly using the 
practice pancreatic TMA. This protocol used EDTA buffer and 1:10 dilution and 
gave excellent results and was therefore repeated exactly on the full TMA’s with 
no staining seen on the negative control slide. Staining was seen in all three 
cellular compartments. 
 
3.5.2.2 Raf-1 
The Raf-1 antibody used was a mouse monoclonal antibody that had been used 
successfully in the same laboratory on breast and prostate tissue. The author (SD) 
used the breast protocol as a starting point with the practice TMA. This protocol 
involved citrate buffer and 1:40 antibody dilution. The staining was extremely 
strong and a second identical run took place but with 1:60 dilution of the primary 
antibody. Again the staining was strong and a further run with 1:80 dilution took 
place using the practice TMA. This gave excellent staining and was repeated 
using the full pancreatic TMA’s. Results were good with staining seen in the 
cytoplasm and at the membrane and there was no staining seen on the negative 
control slide. The datasheet for the antibody stated that cytoplasmic and 
membrane staining was expected. 
 
 182 
3.5.2.3 Phospho.Raf-1 Ser259 
A protocol previously used on breast tissue with citrate buffer and a 1:25 dilution 
of the monoclonal rabbit Phospho.Raf-1 Ser259 antibody. Although specific 
staining was seen it was extremely weak and a second run with 1:10 dilution was 
performed. Excellent staining was achieved and the protocol repeated on the full 
TMA’s. Staining was excellent and seen in the cytoplasm only with no staining on 
the negative control. 
 
3.5.2.4 Phospho.Raf-1 Ser338 
A previously used breast protocol was again used as the starting point for staining 
using Phospho.Raf-1 Ser338 (Upstate), a monoclonal mouse antibody. EDTA 
buffer along with antibody dilution of 1:250 was used on the practice TMA with 
excellent results. This protocol was repeated on the full TMA’s but one of the 
TMA’s (TMA 2) showed no staining at all. This was thought to be a technical 
error and was repeated, however on this run the negative control slide showed 
evidence of staining. Again this was thought to be due to a technical error and a 
repeat run took place without any changes to the protocol. Satisfactory staining 
was seen in all three cellular compartments and crucially not on the negative 
control slide. 
 
3.5.2.5 MAPK 
The previously used breast protocol employing citrate buffer and a 1:200 dilution 
of the monoclonal rabbit MAPK antibody was used on the practice TMA. Very 
weak staining was seen and therefore the protocol was repeated with a dilution of 
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1:100. The staining was still very pale and was considered very difficult to score 
so a repeat run with 1:50 dilution was performed. On analysis of the 1:50 run 
staining was still pale so the author (SD) consulted the senior scientist in the 
laboratory (JE) and a change of buffer was used. When EDTA buffer was used 
with a 1:50 antibody dilution good staining was seen and a repeat run on the full 
TMA’s took place. Good staining was seen in all three cellular compartments, 
however the datasheet showed expected staining in only the cytoplasm and the 
nucleus. No staining was seen on the negative control slide. 
 
3.5.2.6 Phospho.MAPK 
As a starting point a protocol used on breast tissue was again used. Citrate buffer 
along with an antibody dilution of 1:200 gave very pale staining and the protocol 
was repeated with dilution of 1:100. The stronger antibody gave improved results 
but staining was still pale and the dilution was changed to 1:50 for a third run. 
This third run gave stronger staining but it was patchy and after discussion with 
JE a change of buffer was used. When EDTA buffer was used with a 1:50 
antibody dilution good, specific staining was seen and the full TMA’s underwent 
the same protocol. Although the datasheet showed expected staining in the 
cytoplasm and the nucleus, staining was seen in all three cellular compartments 
but not on the negative control slide. 
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Figure 3.15: Representative Immunohistochemical Staining of  MAPK Proteins 
(0=no staining, 1=pale staining, 2=moderate staining, 3=strong staining) 
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3.5.3 Variation in Scoring 
The weighted histoscore (discussed in section 2.5) was used for all of the 
immunohistochemical staining. As discussed earlier, all scoring was performed by 
the author of this thesis (SD). The senior scientist within The University 
Department of Surgery, Glasgow Royal Infirmary (JE) independently double-
scored 10% of the cores. The variation in observer scoring was calculated by the 
interclass correlation coefficient (ICCC). An ICCC of 0.5-0.6 is considered 
acceptable, 0.6-0.7 good and >0.7 is considered excellent with an ICCC of 1 
indicating identical scores. Table 3.21 below shows the individual ICCC scores 
for each of the antibodies. 
 
Table 3.21: ICCC scores for MAPK IHC scoring.   
Antibody         ICCC score  
K-Ras 0.82 
RAF-1 0.637 
P.RAF-1 Ser259 0.904 
P.RAF-1 Ser338 0.809 
MAPK 0.532 
P.MAPK 0.872 
 
 187 
3.5.4 Protein Expression 
For the six MAPK proteins included in this study staining was seen in all three 
compartments in four antibodies (K-Ras, Phospho.Raf-1 Ser338, MAPK and 
Phospho.MAPK). Raf-1 showed staining in the cytoplasm and membrane only 
and Phospho.Raf-1 Ser259 showed staining only in the cytoplasm. The 
distribution of scoring for each of the antibodies in each of the cellular 
compartments was then examined. The distribution of scoring was demonstrated 
by plotting frequency histograms (SPSS 15.0, Chicago). These histograms are 
shown in full in Appendix 2. 
 
When these histograms are analysed the majority of these graphs demonstrate 
skewing to the right. Before further statistical analysis took place the continuous 
data needed to be dichotomised, splitting the data in to high and low staining 
before survival analysis could take place. Following statistical advice the upper 
quartile was chosen as the cut-off between high and low scoring. Table 3.23 
shows the median and inter-quartile ranges of each antibody in each cellular 
compartment and hence the cut-off values used for subsequent survival analysis.  
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Table 3.22: Median histoscores and interquartile range 
 
Protein Median Histoscore Interquartile range 
(Lower Quartile to 
Upper Quartile) 
Cyto 63.33 30.00-96.667 
Mem 20.00 6.667-50.00 
 
K-Ras 
Nuc 33.33 6.667-76.667 
Cyto 100.00 56.667-140.00 
Mem 30.00 10.00-60.00 
 
Raf-1 
Nuc - - 
Cyto 30.00 10.00-56.667 
Mem - - 
 
P.Raf-1 
Ser259 
 
Nuc                       - - 
Cyto 70.00 43.33-100.00 
Mem 30.00 15.00-63.33 
 
P.Raf-1 
Ser338 
Nuc 135.00 86.667-175.00 
Cyto 50.00 20.00-85.833 
Mem 40.00 20.00-60.00 
 
MAPK 
Nuc 70.00 40.00-109.167 
Cyto 13.33 3.75-30.00 
Mem 3.33 0-16.25 
 
P.MAPK 
Nuc 95.833 50.833-139.167 
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3.5.5 Protein Expression and Survival 
To assess whether expression levels of proteins in the MAPK pathway were 
associated with poorer survival in pancreatic cancer, Kaplan-Meier graphs were 
plotted for patients expressing low levels (below cut off)and high levels (above 
cut off) of staining in both the PC and NPPC groups and were compared using the 
log rank test. Table 3.23 shows survival in patients with PC for both low and high 
levels of staining for each of the tested antibodies in each of the cellular 
compartments. Table 3.24 shows the corresponding values for patients with 
NPPC. 
 
At first glance there appear to be two statistically significant results in the patients 
with ductal tumours. Differences in cytoplasmic MAPK and cytoplasmic 
phosphorylated MAPK staining appear to have a significant effect on survival 
(p=0.0229 and p= 0.0342 respectively). However when multiple testing is taken 
into account using Bonferroni correction, there are no statistically significant 
results in the PC group at the 5% level271. In those patients with NPPC there were 
no significant effects on survival. 
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 Table 3.23: Difference in survival between low and high protein expression in 
the PC group. 
 
Survival (days)  
               Protein Low 
expression 
High 
expression 
 
P-value 
Cyto 405 150 0.1340 
Mem 330 411 0.8597 
 
K-Ras 
Nuc 339 389 0.5168 
Cyto 389 370 0.9712 
Mem 407 374 0.1065 
 
Raf-1 
 Nuc - - - 
Cyto 345 430 0.3245 
Mem - - - 
 
Raf-1 
Ser259 
Nuc - - - 
Cyto 407 339 0.9915 
Mem 407 345 0.5337 
 
Raf-1 
Ser338 
Nuc 444 279 0.2194 
Cyto 339 635 0.0229 
Mem 405 312 0.4514 
 
MAPK 
Nuc 407 253 0.0777 
Cyto 370 389 0.0342 
Mem 370 389 0.4046 
 
P.MAPK 
Nuc 405 304 0.6661 
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Table 3.24: Difference in survival between low and high protein expression in the 
NPPC group. 
Survival (days)  
               Protein Low 
expression 
High 
expression 
 
P-value 
Cyto 572 622 0.4099 
Mem 618 811 0.5926 
 
K-Ras 
Nuc 618 632 0.9215 
Cyto 618 582 0.6924 
Mem 618 398 0.6478 
 
Raf-1 
 Nuc - - - 
Cyto 582 618 0.5205 
Mem - - - 
 
Raf-1 
Ser259 
Nuc - - - 
Cyto 572 811 0.3583 
Mem 618 535 0.2800 
 
Raf-1 
Ser338 
Nuc 618 582 0.6425 
Cyto 582 1659 0.3169 
Mem 572 1423 0.4355 
 
MAPK 
Nuc 582 826 0.3885 
Cyto 826 529 0.1891 
Mem 582 655 0.6657 
 
P.MAPK 
Nuc 655 494 0.7049 
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4.0 DISCUSSION 
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HYPOTHESIS 
The presence of a systemic inflammatory response is associated with a 
particularly poor prognosis in pancreatic cancer. Pro-inflammatory cytokines, in 
particular IL-6, are known to induce CRP production and also may influence 
tumour growth and differentiation through well-described cellular pathways. 
Upregulation of IL-6 dependent pathways in tumour cells may explain the poor 
prognosis associated with a systemic inflammatory response. 
 
 At the start of this thesis a number of aims were stated to allow testing of the 
above hypothesis. These aims included:  
 
1/. Establish pancreatic cancer patient database with basic demographics, 
pathological and survival data. 
2/. Confirm the connection between a raised CRP and survival in pancreatic 
cancer in a larger cohort and establish if there is a relationship between CRP and 
non-pancreatic peri-ampullary cancers.  
3/. Simultaneously create a prospective database and establish the connection 
between CRP and survival in a prospective cohort. 
4/. Create tissue micro-arrays using tissue from the pancreatic cancer database to 
enable the efficient examination of relevant antibodies using standard 
immunohistochemical techniques. 
5/. Using immunohistochemistry, stain for antibodies from the JAK-STAT and 
MAPK pathways and establish whether poor survival in these patients with 
pancreatic cancer is associated with upregulation of these pathways. 
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4.1 CRP: Results Summary 
This thesis has confirmed that pre-operative CRP is a significant prognostic 
indicator in resectable pancreatic cancer in the largest series to date. Multivariate 
analysis has revealed that a raised CRP is the only prognostic factor that retains 
statistical significance, making it more important in outcome in this cohort of 
patients than the traditional, pathological factors associated with poor survival 
discussed in section 1.1.7.2. This is highly significant and raises the issue of 
whether patients with a raised pre-operative inflammatory response who are 
otherwise found to be operable should be offered curative resections. More 
information is needed regarding the pathophysiology behind this response and the 
effects of pharmacologically reducing it however, it is conceivable that CRP may 
be included in staging of these patients in the future. 
 
This thesis also shows in a prospective group that high levels of plasma IL-6 are 
associated with poorer post-operative survival and show a statistically significant 
correlation with plasma CRP levels. This adds to the body of evidence describing 
an IL-6 driven inflammatory response. 
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4.2 JAK-STAT Pathway: Results Summary 
When the results were analysed by creating cut-off points (Kaplan Meier) and 
analysing the data in a continuous fashion (fractional polynomial approach), there 
appears to be no relationship between JAK STAT staining and survival taking into 
account the multiple tests performed. The IHC in this thesis demonstrates staining 
in the JAK STAT pathway but crucially this staining does not appear to 
significantly influence survival in this patient group and therefore the author 
cannot reject the null hypothesis. 
 
A number of studies looked at STAT3 and its role in pancreatic cancer. Huang et 
al looked at the effects of blocking JAK proteins and was able to show a resulting 
decrease in phosphorylation of STAT3 in addition to a reduction in tumour 
invasion and metastases275. Wei et al showed constitutive STAT3 activation and 
resulting increased growth and metastatic potential238. Both of these studies 
however were in-vitro studies on pancreatic cancer cell lines and the value of their 
results is therefore limited. Greten et al were able to demonstrate that activation of 
STAT3 appeared to inhibit apoptosis, but this was a study on mice and there was 
no mention of a resulting effect on survival239. There are no studies in the 
published literature that can provide any evidence for the JAK STAT pathway 
influencing outcome in pancreatic cancer. The vast majority of studies that 
suggest that the JAK STAT pathway may have a role to play in pancreatic cancer 
are experimental, often in-vitro or are they are performed on animals. No real 
conclusions can be drawn about the role that this pathway plays in human 
pancreatic cancer from these studies and the results of this thesis demonstrate that 
although there is activity in human pancreatic cancer cells, it is not responsible for 
poor outcome. 
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.4.3 MAPK Pathway: Results Summary 
As with the JAK STAT pathway, there are no significant differences in survival 
between low and high levels of staining in any of the MAPK antibodies stained in 
this thesis. Similar to the JAK STAT pathway, there are a multitude of studies that 
show that the MAPK pathway may have a role to play in pancreatic cancer but 
these results do not appear to be bourne out by results of clinical trials on humans. 
As described in section 1.4.2, at least 25 potential therapies aimed at various 
proteins in the MAPK pathway have been trialed and none have yet to show any 
significant difference in outcome, supporting the results described here252.  
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4.4 Justification of Methods 
4.4.1 Tissue Microarrays 
The completion of the human genome sequence has provided a colossal amount of 
information about human gene structure. To go along with this explosion in 
genetic information cDNA microarrays have been developed, allowing 
simultaneous expression analysis of thousands of genes in one experiment276. 
Performing traditional methods of molecular pathology in large scale analyses are 
in comparison incredibly slow and labour intensive meaning that valuable human 
tissue resources are rapidly exhausted. A method of analyses that preserved 
human tissue and allowed large cohorts of patient specimens to be analysed 
quickly was required. 
 
In 1998 Kononen and colleagues developed the tissue microarray (TMA) for the 
high throughput molecular profiling of tumour samples277. This technique is now 
standard and described in detail in section 2.2. 
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4.4.2 Advantages of TMA’s. 
Other than the obvious major advantage of human tissue preservation, there are a 
number of other advantages associated with the use of TMA’s. As all tissue 
samples on the TMA are treated at the same time they are all exposed to identical 
conditions during immunohistochemical analysis enabling standardisation of 
testing. With conventional techniques sections are exposed to a multitude of slide 
to slide variations including reagent concentrations, incubation times, 
temperatures and wash conditions as well as antigen retrieval. Using TMA’s 
means every tissue sample is treated in an identical manner. With the use of 
TMA’s only a small amount of reagent is required to analyze an entire cohort of 
samples. 
 
There were initial concerns about the preservation of antigenicity in samples 
preserved over long periods of time in paraffin. A number of studies have looked 
at this potential problem. Camp et al showed that there was no significant 
decrease in antibody staining in blocks from pathology archives up to 68 years 
old278. Another study by Rhodes again showed no deterioration in antigenicity of 
samples dating back to the 1930’s279. 
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4.4.3 Limitations of TMA’s 
The major potential limitation of TMA’s is the lack of tissue volume used for 
analyses. Sceptics claim that the tiny amount of tissue used is too small to be 
representative of an entire tumour, particularly those tumours that exhibit 
heterogeneity. It is not known how much tissue however is required to be truly 
representative of a tumour. This problem is normally addressed by taking multiple 
cores from each tumour block when making up the TMA. There has to be a trade 
off however between taking increasing numbers of cores to be representative of 
the whole tumour and enjoying the advantages of TMA technology. So how many 
cores are needed to be representative of a tumour? 
 
There have been a number of studies validating the use of TMA’s and suggesting 
the optimal number of cores. Hoos et al showed that three cores (of 0.6mm 
diameter) showed concordance with standard techniques in more than 90% of 
cases when they examined breast tumours staining with a number of antibodies280. 
Camp et al took 38 cases of breast carcinoma and compared the staining of three 
common antigens on 2-10 microarray discs and the whole tissue section from 
which they were derived278. With one microarray disc only there was over 90% 
accuracy for all three antigens. When three discs were analyzed, accuracy 
increased to over 97% for all three antigens when compared to the full tissue 
section. These studies suggest that although the tissue used in microarrays is 
small, it is enough to be representative of the tumour when compared to standard 
tissue sections. 
 
 200 
Other potential drawbacks of using TMA technology are core loss or damage and 
a lack of identifiable tumour in the core. This can occur during sectioning if a 
section passes through a gap in a core (gaps can occur if the original paraffin 
block is thin meaning multiple thin cores are placed on top of each other to fill the 
space in the recipient block) or due to sub-optimal sectioning technique. The 
impact of these problems can be overcome by including multiple tissue cores and 
careful technique.  
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4.4.4 TMA’s and Pancreatic Tumours 
Pancreatic and biliary tumours are commonly heterogeneous and often associated 
with a significant surrounding desmoplastic stromal reaction. It is now widely 
accepted that pancreatic cancers originate from the ductal cells of the pancreas 
and not the more abundant acinar tissue.  
 
Swierczynski et al looked at novel tumour markers in pancreatic and biliary 
tumours281. Prior to the main analysis they used 8 markers shown to be over-
expressed in whole tissue sections of pancreatic adenocarcinoma and compared 
them to their own TMA’s. The labelling of these markers on the TMA’s was 
concordant with the whole tissue sections but used far fewer slides and reagents. 
Maitra et al looked at pancreatic intraepithelial neoplastic (PanIN) lesions using 
TMA’s whilst analysing the multistep progression model for pancreatic cancer39.  
They found that when compared with previous data published using routine 
histology sections, their results on the PanIN specimens using TMA’s were 
comparable. These studies suggest that analyzing pancreatic tissue using TMA’s 
gives comparable results to standard histology sections with all of the advantages 
already mentioned above. 
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4.4.5 TMA Quality in this Thesis 
There is adequate evidence to justify the use of TMA’s in immunohistochemical 
analysis. However, successful use of TMA’s does depend on their construction 
and more specifically the quality of that construction. There is an accepted loss of 
cores during the manufacturing of TMA’s that occurs usually during sectioning 
but can less commonly occur as a consequence of double or triple stacking 
(described earlier). This loss has been described by a number of authors looking at 
the validity of TMA use in immunohistochemistry and cancer research282,283. Both 
studies describe a loss of 5-10% of cores during sectioning when the cores are 
0.6mm in diameter (as they are in this thesis). During scoring of the TMA sections 
in this thesis a record was kept of the number of missing or damaged cores that 
could not be scored. Out of a total of 8880 cores 182 (2%) were missing or 
damaged, comparing favourably with accepted losses in the literature.  
 
Not mentioned in the papers described above however were the cores that were 
included on the TMA’s that did not contain the required tissue. If the initial cores 
are not taken from the desired tissue then despite a high quality of construction, 
the subsequent analysis will be affected as inappropriate tissue cores will have to 
be excluded. 
 
During scoring of the TMA’s in this study in addition to missing cores, a record of 
the number of cores that did not contain the correct tissue type and therefore were 
not included in analysis was kept. As discussed above, the number of missing 
cores in the TMA’s used was well within acceptable limits but no where in the 
literature is the mention of the expected loss of cores due to incorrect tissue. In 
this thesis a total of 2324 cores out of a total of 8880 were excluded from analysis 
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due to incorrect tissue type. In the case of tumour cores the reason for exclusion 
was the lack of tumour within the cored specimen (usually stroma, pancreatitis or 
normal pancreatic tissue). In the cores of normal ductal tissue there was a wide 
range of other tissues seen leading to exclusion (acinar tissue, pancreatitis, 
pancreatic tumour, pancreatic islet tissue, stroma).   
 
When the excluded cores are broken down it is clear that the majority occur in the 
normal ductal cores (750 cores of tumour excluded compared with 1574 of normal 
ductal cores). It would appear logical in this study that the majority of incorrect 
cores would occur in the normal tissue for a number of reasons. All the patients 
included on the TMA’s in this thesis had resections for cancer and therefore the 
amount of genuinely normal pancreatic tissue was minimal. In addition, the 
amount of normal ductal tissue within the small areas of normal pancreas was 
extremely small making coring of normal pancreatic ducts very difficult. The 
technique of TMA manufacture requires the use of H&E slides as a guide to 
enable coring of a specific area. It must be remembered that having identified a 
small area on the H&E slide with the aid of a microscope, to accurately core the 
exact area on the original tissue block is difficult, hence the large number of 
normal ductal cores that actually contained pancreatic acinar tissue in this study. 
The same problem is applicable to the tumour cores but as all the resections were 
for cancer there were larger areas of tumour which were more easily identified 
and therefore with the aid of H&E slides, cores are less likely to contain 
inappropriate tissue. As normal pancreatic tissue was not included in the analysis 
in this thesis then the loss of cores in this group is irrelevant. 
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On further analysis of the excluded cores there is a clear difference in numbers 
between the JAK-STAT and MAPK pathways, with a lot more cores excluded 
from analysis in the latter. There are a number of reasons why this may be the 
case. Firstly, as the MAPK scoring took place after the JAK-STAT, the author 
who performed the scoring may have gained in experience and therefore was able 
to exclude a number of cores that previously would have been scored. Secondly, 
immunohistochemical staining of antibodies from the MAPK pathway took place 
after staining of JAK-STAT antibodies, using TMA sections from deeper into the 
TMA. The H&E slides used as guidance on coring represent the surface of the 
original tissue block. The further into the original tissue block a core goes, the less 
representative the H&E slide becomes and hence as deeper sections of the TMA 
are cut the less likely the deeper sections are going to represent the tissue on the 
superficial sections. 
 
These are all established problems with the use of TMA’s as described earlier. 
The use of multiple cores (3 tumour and 2 normal for each patient in this study) 
not only allows for representation of heterogeneous tumours but also for the loss 
of cores. This means that despite significant losses of cores virtually every patient 
will have appropriate tissue scored for analysis. 
 
One criticism that could be levelled at this thesis is that the creation of the TMA’s 
was done entirely by the author. Before the selection and marking of slides took 
place, the author underwent an intensive period of histology training under the 
guidance of a consultant pathologist (KO). After the marking of slides took place, 
a selection was reviewed by the same consultant pathologist who agreed with the 
 205 
author who went on to manufacture the TMA’s. Therefore the TMA’s created for 
this thesis were done under the continual guidance of a consultant pathologist. 
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4.4.6 Immunohistochemistry 
Antibody specificity was confirmed in 11 of the 12 antibodies used, by scientific 
staff within the department using Western Blotting, described in section 2.3.2.2. 
The Phospho.JAK 1 antibody had not been used for IHC before and despite 
multiple attempts the author was unable to demonstrate specificity but analysed 
and included the results for completeness. 
 
The IHC protocols used were initially based on protocols used successfully in 
prostate and breast tissue. The author (SD) used these protocols as a starting point 
before optimising them on a practice pancreatic TMA over a period of months 
under the guidance of a scientist within the department (JE) with years of 
experience of IHC. Once satisfactory staining had been achieved using the 
practice pancreatic TMA, staining of the original TMA’s took place. 
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4.4.7 Scoring 
All patients in the cohort included in this thesis had tissue samples prepared in the 
same department following the same protocols. The use of tissue micro-arrays 
(TMA) means the area to be assessed is identical for all patients. Each patient has 
three 0.6mm diameter cores of tumour and two 0.6mm cores of normal pancreatic 
tissue included on the TMA’s, meaning all areas of the five cores could be scored 
for each patient. The heterogeneous nature of pancreatic cancer was taken into 
account when selecting the areas to be cored from the original paraffin blocks. For 
each patient areas of different differentiation were marked meaning the three cores 
taken were a representation of the whole tumour. 
 
The weighted histoscore is an immunohistochemical scoring system that enables 
qualitative as well as quantitative data to be collected and has been used 
extensively, mainly in the scoring of breast tissue, but also in prostate and colonic 
tissues284-290.  
 
The author (SD) underwent a period of training in scoring tissue and then scored a 
sample TMA slide. A scientist in the department with years of experience using 
the weighted histoscore (JE), double-scored the same TMA slide and an ICCC of 
>0.7 (rated as excellent) confirmed consistency of the authors scoring was 
achieved. Only after this training period did the author go on to score the actual 
TMA’s. All 12 of the antibodies were double scored by the same scientist (JE) 
and scoring consistency was again confirmed using the ICCC. All 12 antibodies 
had an ICCC of >0.5 or higher indicating a minimum of satisfactory scoring 
consistency.  
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4.4.8 Statistics 
All statistics were calculated using the SPSS statistical software package as 
described in section 2.6. Statistical analysis was performed under the guidance of 
(WA) a statistician in The University of Glasgow Department of Surgery. All 
survival analysis was performed using Kaplan Meier curves and the log-rank test. 
Multivariate analysis was performed using Cox’s regression analysis on variables 
identified as significant on univariate analysis.  
 
Following scoring of antibody staining, frequency graphs were plotted 
(appendices 1 and 2) demonstrating the distribution of scoring for each antibody. 
These graphs demonstrate skewing to the right. To dichotomise data and allow 
Kaplan Meier survival analysis, cut-off points between what is considered low 
and high levels need to be chosen. If it is required to test whether two groups (low 
and high scoring groups) differ in some other variable y (survival in this case) 
then for a given sample size, the greatest power to detect differences between 2 
groups is usually achieved if they are of equal size. That is why the median is so 
often used as a cut-off. However, if the distribution is asymmetrical (skewed) then 
a cut-off that separates the long tail of the distribution from the remainder 
clustered about the modal value may be best. Hence, in a distribution skewed to 
the right (the majority of antibodies in the JAK STAT and MAPK pathways in 
this thesis), an upper quartile is a more appropriate cut-off than the median. 
 
A second statistical analysis was performed on the data from JAK-STAT staining 
by (JP), a statistician at the Beatson Oncology Unit, Glasgow to see if analysing 
the data in a continuous fashion gave different results. The fractional polynomial 
approach was used in the analysis to establish the best shape of relationship 
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between the protein measurements and survival. This statistical technique allows 
data to be analysed continuously without the need for creating arbitrary cut off 
points. The results of this second analysis confirm the survival analysis done 
using Kaplan Meier curves and the log-rank test. 
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4.4.9 Justification of Methods: Conclusions 
The author believes that the scientific methods and techniques used in this thesis 
are justifiable and scientifically sound. The use of TMA’s is now commonplace 
and backed by a significant body of evidence. The creation of the TMA’s, done 
entirely by the author was supervised throughout by appropriately qualified 
people with experience in TMA manufacturing. The quality of the TMA’s 
matches that described within the literature and the immunohistochemical 
techniques employed by the author were standard and supervised by a scientist 
with multiple publications using similar techniques. Use of the weighted 
histoscore has been published widely in multiple tumours and scoring consistency 
(as measured by the ICCC) was in the main graded as excellent, never falling 
below satisfactory following double scoring. The statistics used in this thesis have 
been employed in numerous publications and were supervised by statisticians with 
extensive experience in medical statistics. The author maintains that the 
techniques used in this thesis and therefore the results are reproducible and 
confirm that the initial hypothesis stated in section 1.5.1 has been disproved. 
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4.5 Recently Published Data 
During the writing of this thesis there have been a number of relevant publications 
which are summarised below. 
 
Raised CRP levels have been associated with poor prognosis in metastatic 
prostate cancer291. Raised pre-operative CRP predicts poor outcome in operable 
gastric and oesophageal (squamous cell carcinoma and adenocarcinoma) 
cancers292,293. Hashimoto et al showed that pre-operative serum CRP is an 
independent and significant predictor of poor outcome and early recurrence in 
patients with hepato-cellular carcinoma294.  
 
The importance of CRP in cancer and more specifically its ability to predict 
outcome in most of the common solid tumours has led to the development of a 
prognostic scoring system involving CRP. The Glasgow Prognostic Score (GPS) 
is based on the inflammatory response, with serum CRP (>10mg/l signifying a 
raised level) and albumin (<35g/l signifying hypoalbuminaemia) being measured. 
The presence of both a raised CRP and hypoalbuminaemia gives a GPS of 2, the 
presence of either, a score of 1 and neither a score of 0. This scoring system has 
been used in advanced colo-rectal cancer295, inoperable gastro-oesophageal 
cancer296, inoperable non-small cell lung carcinoma297, metastatic renal cancer298 
and inoperable pancreatic cancer299. In all cases the GPS was shown to be a 
significant and independent predictor of survival. This scoring system has yet to 
be applied to operable cancers but based on these studies it may only be a matter 
of time before CRP becomes part of pre-operative staging in cancer. 
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In terms of pancreatic cancer and CRP very little new data has appeared in the 
literature since Jamieson et al in 2005 showed that pre-operative CRP was a 
significant predictor of outcome in operable ductal adenocarcinoma of the 
pancreas14. 
 
The evidence surrounding an inflammatory response in cancer and more 
specifically a pre-operative inflammatory response in pancreatic cancer has been 
discussed in detail in the introduction and support the authors findings in this 
thesis. The role of pre-operative CRP in cancer and more specifically pancreatic 
cancer now appears to be beyond doubt. 
 
Also discussed in the introduction is the role of IL-6 as the major inducer of 
plasma CRP levels183-186. CRP is synthesised predominantly in hepatocytes under 
the influence of cytokines, with Interleukin-6 (IL-6) the major inducer of 
hepatocyte CRP production184. Other sites of CRP production include smooth 
muscle cells, macrophages, kidney tubular cells, neurons, and lymphocytes, 
however, these sites contribute only a small proportion of the CRP value and 
plasma CRP measurements reflect hepatocyte production. There have been a 
number of key papers involving IL-6 and cancer published during this thesis and 
they will be discussed in detail later in this discussion. 
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4.6 What are the Factors Behind Inflammation and Poor 
Prognosis in Pancreatic Cancer? 
The role of the inflammatory response in cancer and specifically pancreatic cancer 
is now well established and the results of this thesis support this. The results 
reported here do not show any evidence for involvement of two major signalling 
pathways, both shown to be involved in inflammation and carcinogenesis in 
numerous other publications. So what are the explanations for this poor 
prognosis? 
 
There appear to be a number of possibilities that may explain the role of 
inflammation and poor prognosis and fit with the results reported here. One is that 
other signalling pathways, maybe multiple signalling pathways or signalling 
proteins are responsible for this poor prognosis. The other possibility is that the 
inflammatory response rather than just being the result of another process is itself 
responsible for poor outcome. Whether it is the tumour or the reaction of the host 
to the tumour that induces this response also needs to be addressed. These 
possibilities will be explored in the next section. 
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4.6.1 The SOCS Gene 
When STAT3 is activated in response to cytokine stimulus, this activation is rapid 
and transient. Even if the cytokine stimulus persists, STAT3 activation only lasts a 
few hours231. This suggests a feedback mechanism that in normal physiological 
conditions leads to the deactivation of STAT3 even under persistent cytokine 
stimulation. One such mechanism that terminates STAT3 activity is by the 
activation of a group of proteins known as the suppressors of cytokine signalling, 
or SOCS family.  
 
SOCS proteins, of which there are currently eight identified, were first discovered 
in 1997 when they were identified as JAK regulatory proteins300. Of the 8 SOCS 
proteins, SOCS-1 appears to be involved with the inhibition of IL-6 signalling. 
These proteins bind to JAK's, halting their activation and the subsequent 
activation of STAT3, essentially switching off cytokine signalling via the JAK 
STAT pathway. A number of cytokines, including IL-6 are responsible for the 
activation of SOCS proteins and there is some evidence that SOCS genes are 
actually among the target genes of STAT proteins creating a negative feedback 
loop231,301. Following the identification of the JAK STAT pathway as having a 
role in carcinogenesis and the progression of tumours, attention more recently has 
turned to the SOCS family of proteins in their role as negative regulators of JAK 
STAT signalling. As constitutive activation of STAT proteins, in particular 
STAT3 has been reported in a number of cancers, could it be loss of this negative 
feedback that is responsible, meaning a potential role in cancer for SOCS 
proteins?  
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Yoshikawa et al published their work on SOCS-1 in hepatocellular carcinoma 
(HCC) in 2001301. They were able to identify aberrant methylation of the SOCS-1 
gene in HCC cell lines and subsequent transcription silencing. Following the 
restoration of SOCS-1 there was suppression of growth seen in the cell lines. They 
identified that this growth suppression was caused by apoptosis and this apoptosis 
was recreated by using the JAK inhibitor AG490. The authors also demonstrated 
that in 26 HCC tissue samples removed at surgery, this same methylation of the 
SOCS-1 gene was seen in 65%. In non-tumour samples from the same patients, no 
methylation was seen. The authors conclude that constitutive activation of the 
JAK STAT pathway as a result of methylation of the SOCS-1 gene and the 
subsequent lack of growth suppression is a key step in the development of HCC. 
 
Multiple Myeloma (MM) is a malignancy where cytokines and particularly IL-6 
are known to have a crucial role in pathogenesis. Following the study of SOCS 
proteins in HCC, Galm et al looked at SOCS-1 methylation in MM cell lines and 
primary MM samples302. Aberrant methylation was identified in both IL-6 
dependent MM cell lines but not in acute myeloid leukaemia (AML), chronic 
myeloid leukaemia (CML), and lymphoma cell lines, nor in normal peripheral 
blood mono-nuclear cells. This methylation was seen to coincide with SOCS-1 
gene transcription silencing. Reversal of this methylation led to up-regulation of 
SOCS-1 transcription. The authors then went on to demonstrate similar 
methylation of the SOCS-1 gene in 63% of MM patient samples. Comparative 
assays on samples of various lymphomas identified SOCS-1 methylation in only 
3% of patients and no methylation in normal peripheral blood leucocytes or bone 
marrow. In their conclusion the authors state that methylation of the SOCS-1 gene 
in MM may contribute to cell survival by removing the negative feedback from 
 216 
the JAK STAT pathway and increasing cellular sensitivity to cytokines and 
particularly IL-6. 
 
As inflammation has been shown to influence survival in pancreatic cancer in this 
thesis in addition to other publications, may the SOCS protein have a role to play 
in the poor prognosis of patients with an inflammatory response? Komazaki et al 
examined a number of pancreatic tumours, looking for methylation of the SOCS-1 
gene303. They demonstrated methylation of the SOCS-1 gene in 50% of the 
cancers included in the study and resulting suppression of SOCS-1 mRNA. 
 
Fukushima et al also looked at the SOCS-1 gene in pancreatic cancer and went on 
to examine if there was any resulting affect on the JAK STAT pathway304. Similar 
to the previous studies outlined above the incidence of SOCS-1 gene methylation 
was initially established in both cell lines and tissue specimens. Aberrant 
methylation was seen in 31% of pancreatic cancer cell lines, which was associated 
with loss of gene transcription in 83% of cases. When 60 pancreatic cancer 
specimens were similarly examined, methylation was seen in 13 (22%) and in 6% 
of the intra-ductal papillary mucinous neoplasms (IPMN). However methylation 
was not seen in normal ductal epithelium, in pancreatic intra-epithelial neoplasia 
(PanIN) or in IPMN’s without invasive cancer. This study then went onto show 
that methylation of SOCS-1 gene in pancreatic cancer cell lines was associated 
with an IL-6 dependent, statistically significant increase in cellular growth. 
 
Although these studies are relatively few in number, some authors are actually 
describing the SOCS-1 gene as a possible tumour suppressor gene, as methylation 
is a common mechanism by which other established tumour suppression genes are 
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affected in cancer. Does this evidence for the methylation of SOCS genes fit with 
the results from this thesis? Could it be that a loss of negative regulation rather 
than increased activation leads to increased signalling via the JAK STAT 
pathway? This is certainly one possibility that would fit with the results reported 
in section 3. Those patients with a raised pre-operative CRP and therefore raised 
IL-6 may have increased transcription of STAT3 target genes via relatively weak 
signalling due to the removal of the negative feedback of SOCS proteins and may 
explain why there was no obvious evidence of upregulation of the JAK STAT 
pathway in this patient cohort. One other possibility is that inflammation and IL-6 
negatively effects survival via JAK STAT independent mechanisms and this will 
be explored later in this discussion. 
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4.6.2 NF-κB and Cancer 
NF-κB is an important protein in both the inflammatory response and 
tumourogenesis. It is a ubiquitously expressed transcription factor and regulates 
the expression of various inflammatory, apoptotic and oncogenic genes159. The 
active form of NF-κB is a heterodimer with two sub-units p65 (also called RelA) 
and p50 which are both members of the Rel family of transcription factors. 
Activation of NF-κB occurs by a number of stimuli including IL-1, protein kinase 
C, reactive oxygen species, viruses, TNF and radiation160,161. Once activated at 
sites of inflammation NF-κB causes increased transcription of 27 different genes 
encoding for cytokines, chemokines  and receptors crucial for neutrophil adhesion 
and migration including IL-2, IL-2R, IL-6, IL-8, IL-12 and TNF162. These 
cytokines can in turn activate the NF-κB pathway establishing a positive 
autoregulatory loop that sustains and amplifies the inflammatory response.  
 
Cancer is a hyper proliferative disorder resulting from the inability of cells to 
undergo normal programmed cell death or, apoptosis. One of the most potent well 
studied inducers of apoptosis in mammalian cells is tumour necrosis factor 
(TNF)305. Many members of the TNF superfamily induce apoptosis, but in 
addition, various chemotherapeutic agents and ionising radiation work by 
inducing apoptosis. Most agents that induce apoptosis are also known to activate 
NF-κB. A number of publications have shown that activation of NF-κB induces 
resistance to apoptosis induced by TNF, chemotherapeutic agents and 
radiotherapy305-309. NF-κB induces inhibition of apoptosis by upregulating anti-
apoptotic genes including Bcl-2, cIAP-1, cIAP-2, TRAF-1, TRAF-2 amongst 
others305. The ability of NF-κB to inhibit apoptosis has been demonstrated in 
many different cell types including myeloid cells, hepatocytes, melanoma cells, 
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prostate cancer cells, head and neck squamous cell carcinoma, and pancreatic 
cancer cells163,310-314. 
 
In the treatment of cancer, chemotherapeutic agents and radiotherapy are 
employed to induce apoptosis in abnormal cancerous cells, but paradoxically they 
both induce activation of NF-κB which acts as an inhibitor of apoptosis. This 
process is thought to be one of the ways that tumours become resistant to chemo 
and radiotherapy.  
 
Kim et al examined the effect of inhibiting NF-κB in human prostate cells, 
demonstrating increased sensitivity to radiation when it was blocked309. The 
authors also were able to show that this increased sensitivity was in cells that had 
mutated K-Ras, a relationship explored further below. 
 
In terms of chemoresistance, Wang et al were able to demonstrate increased 
chemosensitivity in chemoresistant tumours by inhibiting NF-κB315. They 
demonstrated tumour regression in cells with NF-κB inhibition and this was due 
to increased TNF mediated apoptosis.  
 
Pancreatic cancer is resistant to almost all cytotoxic drugs but Gemcitabine 
appears to have activity in some patients without having a significant effect on 
their survival. Arlt et al looked at the effects of Gemcitabine on a number of 
pancreatic cancer cell lines, some with and some without high basal NF-κB 
activity316. They were able to demonstrate that treatment with Gemcitabine led to 
a dose dependent increase in NF-κB and that treatment led to a significant 
induction of apoptosis in those cell lines without high basal NF-κB, but not in 
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those with high basal activity. They also showed that inhibition of NF-κB strongly 
diminished the resistance of those cell lines to Gemcitabine treatment. They 
conclude that constitutive activation of NF-κB in pancreatic cancer cell lines leads 
to resistance against Gemcitabine by the inhibition of apoptosis and that 
modulation of this activity leads to chemo-sensitivity. This then begs the question 
is there any evidence for upregulation of NF-κB in pancreatic cancer cells? 
 
Wang et al were able to demonstrate constitutive activation of NF-κB in 67% of 
human pancreatic cancer tissue and in 81% of pancreatic cancer cell lines (there 
was no activity in normal pancreatic cells or non-cancerous pancreatic cell 
lines)317. Interestingly, constitutive activation of NF-κB was found in 65% of 
pancreatic cancer tissue that had a K-Ras mutation and in 89% of pancreatic 
cancer cell lines that contained the K-Ras mutation. This study along with the 
study described above by Kim et al suggests a possible link between mutated K-
Ras (present in 90% of pancreatic cancers) and NF-κB activation. Kim et al also 
published another study looking specifically at the role mutated K-Ras 
(constitutively active) had in the activation of NF-κB in prostate tissue318. They 
were able to show that mutated K-Ras lead to the activation of NF-κB and 
inhibition of K-Ras lead to a corresponding reduction in phosphorylation of NF-
κB.  
 
To summarise, NF-κB has been shown to be constitutively active in pancreatic 
cancer cells and in turn this leads to increased transcription in multiple genes 
involved in inflammation including IL-6. These inflammatory growth factors in 
turn lead to further activation of NF-κB causing a pro-inflammatory 
autoregulatory loop. Activated NF-κB is also known to lead to increased 
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transcription in a number of genes involved in the inhibition of apoptosis which in 
addition to the pro-inflammatory conditions creates an environment ideal for 
tumour growth. NF-κB, as discussed above appears to aid tumour resistance to 
chemo and radiotherapy by this inhibition of apoptosis. With K-Ras being 
mutated (constitutively active) in around 90% of pancreatic cancers and known to 
activate NF-κB, could this pathway be responsible for the poor prognosis 
associated with an inflammatory response in patients with pancreatic cancer?  
 
K-Ras, as discussed earlier is known to activate the MAPK pathway. In this thesis 
it has been demonstrated that there is no relationship between poor survival and 
upregulation of the MAPK pathway and therefore if the above theory is true and 
the results in this thesis are to be believed then K-Ras must activate NF-κB via an 
MAPK-independent manner. A number of publications show that K-Ras can 
activate a number of downstream effector pathways, but of interest is its 
activation of the PI3K/Akt pathway. 
 
Chen et al published their findings after looking at the effects of lidamycin (an 
antibiotic) on apoptosis in human pancreatic cancer cell lines319. They describe 
mutant K-Ras leading to activation of the Akt pathway which in turn leads to 
activation of NF-κB. They were able to show that lidamycin treatment led to a 
dose dependent inhibition of Phospho.Akt and NF-κB along with down-regulation 
of K-Ras mRNA and protein expression in both of the two examined pancreatic 
cancer cell lines. Following this a remarkable improvement in chemo-sensitivity 
to mitomycin, adriamycin, taxol and gemcitabine was seen in both cell lines. In 
those cells treated with lidamycin there was also evidence of growth inhibition, 
apoptosis induction and cell cycle arrest. This study shows that NF-κB is not only 
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a potential therapeutic target in pancreatic cancer but its activation appears to be 
as a result of mutated K-Ras acting via the Akt pathway. K-Ras activating the Akt 
pathway is an established process that has been demonstrated in a number of other 
studies320,321. 
 
The above process would lead to a raised CRP and would support the findings in 
this thesis, explaining why activation of the JAK STAT and MAPK pathways was 
not seen. Clearly more research is needed, but this hypothesis needs to be 
explored. 
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4.6.3 The Systemic Inflammatory Response and Cancer 
When a literature review of the systemic inflammatory response syndrome (SIRS) 
or acute phase response (APR) and cancer is carried out, there is a huge amount of 
research detailing the relationship between inflammation and weight loss. Cancer-
related weight loss is more commonly referred to as cancer-related cachexia. In 
patients with pancreatic cancer the development of cachexia is a major therapeutic 
challenge and along with gastric tumours, pancreatic cancer has the highest rate of 
cachexia of all cancers at well over fifty percent322. 
 
Cancer-related cachexia is a syndrome and is difficult to define being more 
complex than just simple weight loss. It is characterised by a combination of 
some, if not all of the following signs and symptoms: anorexia; early satiety; 
weight loss; weakness; anaemia; oedema. Fearon et al looked at 170 patients with 
advanced pancreatic cancer who were losing weight to try and establish if weight 
loss alone or a three factor cachexia profile (weight loss, decreased intake, 
inflammatory status) best predicted functional and prognostic outcome.323. 
Patients were included if they had lost >5% of their pre-illness weight in the 
preceding six months and excluded if they had undergone surgery, stenting, 
radiotherapy or chemotherapy in the last four weeks. Through statistical analysis 
the authors were able to demonstrate that in that particular patient cohort, weight 
loss alone did not separate patients with poor function and prognosis sufficiently. 
However if the patients had all three of the cachexia factors present then there was 
a significant negative impact on survival and function emphasising that the 
negative impact of cancer-related cachexia may be due to more than just weight 
loss. This paper also highlights the involvement of inflammation and cancer-
related cachexia. 
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A much referenced paper by Dewys et al published in 1980 looked specifically at 
the prognostic role of weight loss in 3047 patients awaiting chemotherapy for 
cancer324. They described the rates of weight loss from as low as 31% in non-
Hodgkins lymphoma up to 87% in gastric cancer patients. This study 
demonstrates that patients with weight loss had a shorter median survival, poorer 
chemotherapy response rates and poorer overall performance status. This study 
did not analyse inflammation but clearly demonstrates in a large group of patients 
that weight loss alone can impact on survival.  
 
O’Gorman et al examined the relationship between weight loss, appetite, 
performance status and the inflammatory response in 50 patients with advanced 
GI malignancies who were losing weight325. Patients were observed for a six week 
period and then grouped into those who had lost weight (>3%), had stable weight 
(<3% change) and those who had gained weight (>3%). At baseline those patients 
who subsequently lost weight had higher CRP and lower albumin levels (P<0.05). 
During follow up the weight loss group had increased CRP levels, reduction in 
skin-fold thickness and reduction in performance status (P<0.05). Conversely, 
performance status improved in the group that gained weight. This study suggests 
that the presence of an inflammatory response causes increased weight loss and is 
associated with deterioration in performance status in patients with GI 
malignancy. This paper also outlines a relationship between weight loss, 
inflammation and albumin levels. 
 
The role that serum albumin plays in patients with cancer and the relationship it 
has with an inflammatory response has been explored by a number of authors. In a 
review article on serum albumin, Margarson stated that hypoalbuminaemia is 
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almost inevitable in disease states and is associated with poorer prognosis 326. 
They also stated that the systemic inflammatory response was in part responsible 
for the low serum albumin. The cause of hypoalbuminaemia associated with 
cancer was investigated by Fearon et al comparing six patients with pancreatic 
cancer and six healthy controls327. They were able to demonstrate that cancer 
patients had a higher serum CRP and a lower serum albumin (P<0.01 for both), 
but showed that the rate of albumin synthesis was similar between both groups. A 
review article by the same authors looking at pancreatic cancer, the inflammatory 
response and cancer cachexia, discusses the possibility that the APR leads to a 
reprioritisation of body protein metabolism which may be significant in the loss of 
lean tissue in these patients328. 
 
McMillan et al examined the relationship between albumin, weight loss, body cell 
mass ( as measured by total body potassium) and the presence of an inflammatory 
response in 40 male patients with either advanced GI or pulmonary malignancy329. 
They demonstrated that lower albumin levels significantly correlated with weight 
loss (P<0.01), with total body potassium (P<0.001) and inversely with CRP levels 
(P<0.001). They concluded that the inflammatory response is not only associated 
with lower serum albumin levels but also with the loss of body cell mass. They 
hypothesise that the inflammatory response creates an increased demand for 
specific amino acids and promotes the degradation of body proteins including 
albumin. Due to the relatively small pool of albumin when compared to body cell 
mass, hypoalbuminaemia is noted before weight loss which is likely due to loss of 
skeletal muscle mass. The inverse relationship between an APR (as measured by 
CRP) and albumin levels has been used to create a prognostic scoring system in 
patients with inoperable pancreatic cancer, discussed earlier in section 4.5.1299. 
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If the inflammatory response is responsible for hypoalbuminaemia, loss of body 
mass and possibly cancer-related cachexia, can attempting to abolish this response 
potentially reverse weight loss and improve outcome? A number of studies have 
attempted to manipulate the inflammatory response and assess whether weight 
loss or deteriorating function can be reversed. 
 
Lundholm et al retrospectively analysed 702 patients with cancer who were losing 
weight and had undergone no treatment330. They compared these patients with 132 
undernourished non-cancer patients and were able to demonstrate that at baseline 
the cancer patients had a significantly increased resting energy expenditure (REE) 
(P<0.001). This difference became significantly reduced by the administration of 
indomethacin (anti-inflammatory drug) (P<0.003). They also showed that total 
body fat was more preserved in those treated with indomethacin (P<0.005) 
although lean body mass was not affected. These changes were observed in 
addition to a significant reduction in the inflammatory response as measured by 
CRP in those patients treated with indomethacin (P<0.0004). Systemic 
inflammation and resting energy metabolism predicted weight loss in cancer 
patients (P<0.0001). 
 
Another study by Wigmore et al examined the effect of ibuprofen (anti-
inflammatory drug) on REE in patients with irresectable pancreatic cancer who 
were losing weight331. Ten patients with pancreatic cancer were given 1200mg of 
ibuprofen daily and their REE and CRP compared with six similar patients who 
were given a placebo over a 7 day period. Prior to treatment the pancreatic cancer 
patients had a significantly higher REE when compared with 17 healthy controls 
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(P<0.02). Following treatment the mean REE of the ibuprofen group fell 
significantly compared with pre-treatment values (P<0.02), but no difference was 
seen in the placebo group. Serum CRP also fell significantly in the ibuprofen 
group (P<0.05).  
 
These two studies by Lundholm and Wigmore demonstrate that in addition to 
causing hypoalbuminaemia and altering protein metabolism, an inflammatory 
response also leads to an increase in resting energy expenditure and that 
manipulating this response with simple anti-inflammatory medication can reduce 
a catabolic process which will undoubtedly contribute to weight loss and the 
cancer-cachexia syndrome. 
 
Both of the aforementioned studies show that anti-inflammatory drugs can reduce 
the abnormally high REE associated with cancer patients by decreasing the 
inflammatory response, but they don’t reveal if there is a resultant increase in 
weight or improved outcome for these patients. McMillan et al performed a 
prospective randomised trial examining the effects of giving patients with GI 
cancer and weight loss a combination of megestrol acetate (a progesterone 
derivative and known appetite enhancer) and ibuprofen or placebo332. The authors 
assessed CRP, appetite, performance status, quality of life, weight and albumin at 
baseline, 6 weeks and 12 weeks comparing both the ibuprofen and placebo groups 
(38 and 35 patients respectively). Analysis of the results revealed no significant 
difference between the two groups at baseline. After 6 weeks there was a weight 
gain seen in the ibuprofen group and a weight loss in the placebo group (P<0.01). 
At twelve weeks this difference was highly significant (P<0.001) with a median 
weight gain of 2.3kg in the ibuprofen group and median weight loss of 2.8kg in 
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the placebo group. There was also a significant improvement in the quality of life 
score in the ibuprofen group (P<0.05). This study shows that reducing an 
inflammatory response using anti-inflammatory drugs can actually reverse the 
weight loss suffered by patients with advanced cancer and improve their quality of 
life. 
 
These studies demonstrate the link between an inflammatory response and 
mechanisms which are likely to contribute to cancer-related cachexia including 
increased resting energy expenditure, altered protein metabolism and 
hypoalbuminaemia. A number of questions are still unanswered. Why do some 
patients with cancer get this inflammatory response which is responsible for the 
development of a cachexia syndrome? Is it the tumour itself or the reaction of the 
host to the tumour that leads to cancer cachexia? Do the results reported in this 
thesis fit with the theory that an inflammatory response causes cachexia in 
pancreatic cancer patients leading to a poorer prognosis? 
 
Falconer et al looked at the APR, REE and cytokines in cachectic patients with 
pancreatic cancer333. They looked at 21 patients with pancreatic cancer and 
compared them with 16 age-related healthy controls assessing REE, body 
composition, CRP, IL-6 and TNF. In addition they also designed an in vitro 
experiment on peripheral blood mononuclear cells (PBMC’s) examining their 
production of cytokines. Patients with pancreatic cancer had a significantly 
elevated REE compared to healthy controls (P<0.003) and that within the cancer 
group those with an inflammatory response (CRP>10mg/l) represented a subset of 
cancer patients who were significantly hypermetabolic (P<0.04). Serum levels of 
IL-6 were detected but there wasn’t a significant difference between cancer 
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patients with and those without an inflammatory response. TNF was not detected 
in the serum of any of the cancer patients. However, spontaneous production of 
TNF and IL-6 by PBMC was significantly greater in cancer patients with an APR 
than in those without (P<0.003). The authors conclude that the presence of an 
inflammatory response separates a subgroup of cancer patients who are markedly 
hypermetabolic. They also suggest that as serum IL-6 is not significantly different 
in the inflammatory subset but PBMC production of IL-6 is significantly raised, 
that local rather than systemic cytokine production may be important in regulating 
the APR. 
 
The findings from Falconers paper appear to be supported by O’Riordain et al 
who also looked at PBMC, APR and IL-6 in weight-losing cancer patients184. 
They were able to demonstrate that PBMC from cancer patients induced a 
significantly higher CRP than healthy controls (P<0.005). CRP production in vitro 
correlated with IL-6 production from PBMC in patients with pancreatic cancer 
(P<0.0001). When IL-6 neutralising antibodies were applied the CRP production 
was reduced by 84% (P<0.001). There was a statistically significant negative 
correlation between PBMC-induced CRP production and survival (P<0.01). This 
paper suggests that PBMC production of IL-6 leads to the hepatic acute phase 
response seen in cancer patients and that this APR is significantly associated with 
poor survival. 
 
A study looking specifically at patients with operable pancreatic cancer and the 
development of cachexia was published in 2005322. The aims were: to establish 
which factors were associated with the development of cachexia; to analyse 
whether the tumour or the reaction of the host to the tumour is the source of or the 
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reason for induction of cachexia; to establish whether the tumour or the host is the 
production site of the cachexia-mediating factors. This study is in multiple parts 
and each will be discussed in turn. 
 
In order to establish which factors were crucial to the development of cachexia, 
tissue from 8 patients with pancreatic cancer (4 with and 4 without cachexia 
[defined as >10% weight loss in preceding 6 months]), from 8 patients with 
alcohol induced chronic pancreatitis (CP) and 8 normal pancreatic specimens 
were obtained. DNA microanalysis was then carried out on all specimens and 
after analysing over 5600 human genes four showed significant differences in 
expression between the above three groups and between those patients with and 
those without cachexia. One of these four was the IL-6 gene. 
 
The authors then further analysed these four significant genes by quantitative 
reverse transcription-PCR analysis. RT-PCR was done in tumour samples of non-
cachectic (14) and cachectic (19) patients in addition to patients with CP (34) and 
normal controls (21). This analysis in a larger sample size revealed that only IL-6 
mRNA expression was significantly increased in tumour samples of cachectic 
patients compared with non-cachectic cancer patients, CP patients and healthy 
controls (P<0.01). 
 
Having established IL-6 as the key factor in those patients with cachexia, 
immunohistochemistry (IHC) was performed using paraffin embedded tissue from 
cancer patients without (9) and those with cachexia (11). Non-cancerous tissue 
from the surrounding area showed no IL-6 immunoreactivity, but in contrast it 
was strongly present in the cytoplasm of pancreatic cancer cells. When 
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comparison was made between those patients with and those without cachexia, 
much stronger IL-6 staining was seen in the cachectic patient samples. Next 
serum taken from 27 pancreatic cancer patients with and 14 without cachexia 
underwent analysis for IL-6 levels. A significant difference was seen between the 
groups, with levels being higher in cachectic patients (P<0.04). 
 
The final part of this study involved the coculture of PBMC from pancreatic 
cancer patients and healthy controls with pancreatic cancer cell lines. Two cell 
lines were used, T3M4 (known to produce IL-6) and Panc-1 (known not to 
produce IL-6). Following coculture IL-6 mRNA was measured. PBMC and Panc-
1 cell line coculture resulted in a modest but not significant increase in IL-6 
mRNA. PBMC and T3M4 in patients with cachexia led to a 14x upregulation of 
IL-6 mRNA expression in PBMC’s (P<0.002). This upregulation was reduced by 
60% when IL-6 neutralising antibody was added. In those cancer patients without 
cachexia and in healthy controls, PBMC and T3M4 coculture did not result in a 
change of IL-6 mRNA in the respective PBMC’s. When the PBMC’s from 
cachectic patients was cultured alone (without tumour cell lines) then IL-6 mRNA 
was low.  
  
This study confirms that IL-6 is the key cytokine involved in the development of 
cachexia in patients with pancreatic cancer. It demonstrates that pancreatic cancer 
cells in those patients with cachexia actually produce IL-6. In addition IL-6 serum 
levels were significantly higher in the cachectic patients. Using an in vitro model, 
coculture experiments showed that PBMC of patients with pancreatic cancer with 
IL-6 positive cells were sensitised to produce IL-6. The PBMC’s of those 
pancreatic cancer patients with cachexia who had IL-6 positive cells were 
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upregulated 14 times more strongly than non-cachectic patients. The authors 
hypothesise that cachectic patients PBMC’s may be sensitised by the tumour in 
vivo and trigger further IL-6 overexpression without having any direct contact 
with the tumour cells. They also observed that IL-6 mRNA is low after 24 hours 
of culture without tumour cells shows that there appears to be a need for constant 
tumour-derived stimulus to the PBMC’s to maintain IL-6 levels. 
 
Martignoni’s paper along with the other studies discussed above demonstrates the 
crucial role of IL-6 in pancreatic cancer and fits with the results reported in this 
thesis. A proportion of pancreatic tumours appear to produce high levels of IL-6 
and these same tumours sensitise PBMC to produce significantly higher levels of 
IL-6. With increased levels of serum IL-6 a hepatocyte-driven APR (as measured 
by CRP) occurs and the development of cachexia with increased REE, 
hypoalbuminaemia and altered protein metabolism with subsequent poor survival.  
 
Why some tumours produce high levels of IL-6 requires further investigation. Is 
the poor prognosis associated with an inflammatory response just due to the 
development of cachexia? This seems unlikely and it would seem probable that 
cachexia is only part of the story. Some of the possibilities discussed above such 
as the constitutive activation of NF-κB in pancreatic tumours and the subsequent 
development of an autoregulatory inflammatory loop leading to high levels of IL-
6 fit with the results from this thesis and may explain why some tumours produce 
high levels of IL-6. Constitutive activation of NF-κB would also lead to the 
upregulation of genes associated with growth and the inhibition of apoptosis. This 
would mean the poor prognosis may be multifactorial, a combination of a ‘pro-
growth’ tumour biology and a subsequent APR leading to cachexia, effectively 
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meaning a ‘double-hit’ for some patients. With around 90% of pancreatic cancers 
exhibiting mutation of the K-Ras gene and subsequent constitutive activation, 
further research is required to establish whether this has a role in NF-κB 
activation as discussed above in section 4.6.1. Further study is also required to 
establish whether the SOCS-1 gene also has a role to play in the above pathway as 
removal of negative feedback from the JAK STAT pathway rather than increased 
signalling may explain why no evidence of upregulation was seen in this thesis. 
Manipulation of the inflammatory response was examined in a number of studies 
discussed above. There was evidence for increasing weight, lowering of the REE 
and some functional status improvement in response to NSAID treatment in 
cancer patients but none of the studies provided evidence of an improvement in 
survival. A randomised trial of anti-inflammatory medication against placebo in 
patients with inoperable pancreatic cancer which is sufficiently powered with a 
primary endpoint of survival would be easy to set up and due to the dreadful 
prognosis associated with the disease results would be seen quickly. Even a 
modest improvement in survival would be important in patients with such a 
limited life expectancy and virtually no treatment options. A similar study in 
operable pancreatic cancer would be more difficult as such small numbers of 
patients have operable disease. 
  
A number of potential questions would need to be considered in a study including 
patients with operable disease who’s median survival is a little over a year. Would 
only those patients with a pre-operative inflammatory response benefit from pre-
operative anti-inflammatory medication? Would decreasing a pre-operative 
inflammatory response improve not only long-term survival but also short-term 
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outcome (operative morbidity and mortality) by effectively helping to optimise a 
patient nutritionally who may be losing weight?  
 
Other treatment approaches may include manipulation of cellular biology. Could 
the use of IL-6 neutralising antibody used in vitro by Martignoni et al have any 
application in vivo? Can further research identify a single common signalling 
pathway or signalling molecule that triggers the cellular changes leading to 
increased cellular IL-6 and subsequent inflammatory response and development 
of cachexia. Is NF-κB this key signalling molecule and can medical manipulation 
improve the outcome for patients with pancreatic cancer? These are all important 
questions the answers to which may produce novel treatments for patients with 
not only pancreatic cancer but all forms of the disease. 
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APPENDIX 1 
The following frequency histograms (figures 1-14) demonstrate the distribution of 
scoring for each antibody in each of the cellular compartments for the JAK-STAT 
pathway. As described in section 3.4.4 these graphs were used to select cut-off 
points prior to survival analysis. 
 
 
 
Figure 1: Frequency of histoscores for IL-6R in the cytoplasm. 
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Figure 2: Frequency of histoscores for IL-6R at the membrane. 
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Figure 3: Frequency of histoscores for IL-6R in the 
nucleus.
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Figure 4: Frequency of histoscores for JAK1 in the cytoplasm. 
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Figure 5: Frequency of histoscores for JAK1 at the membrane. 
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Figure 6: Frequency of histoscores for Phospho.JAK1 in the cytoplasm. 
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Figure 7: Frequency of histoscores for Phospho.JAK1 at the membrane. 
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Figure 8: Frequency of histoscores for Phospho.JAK1 in the nucleus. 
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Figure 9: Frequency of histoscores for STAT3 in the cytoplasm. 
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Figure 10: Frequency of histoscores for STAT3 at the membrane. 
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Figure 11: Frequency of histoscores for Phospho.STAT3 Ser727 in the 
cytoplasm. 
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Figure 12: Frequency of histoscores for Phospho.STAT3 Ser727 in the nucleus. 
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Figure 13: Frequency of histoscores for Phospho.STAT3 Tyr705 in the 
cytoplasm.
Phospho.stat3 Tyr705 Tumour/Cyto
90.080.070.060.050.040.030.020.010.00.0
Phospho.stat3 Tyr705 Tumour/Cyto
Fr
e
qu
e
n
cy
50
40
30
20
10
0
Std. Dev = 19.37  
Mean = 19.5
N = 148.00
 
 242 
 
Figure 14: Frequency of histoscores for Phospho.STAT3 Tyr705 in the nucleus. 
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APPENDIX 2 
The following frequency histograms (figures 1-14) demonstrate the distribution of 
scoring for each antibody in each of the cellular compartments for the MAPK 
pathway. As described in section 3.4.4 these graphs were used to select cut-off 
points prior to survival analysis 
 
 
 
Figure 1: Frequency of histoscores for K-Ras in the cytoplasm. 
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Figure 2: Frequency of histoscores for K-Ras at the membrane. 
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Figure 3: Frequency of histoscores for K-Ras in the nucleus. 
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Figure 4: Frequency of histoscores for Raf-1 in the cytoplasm. 
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Figure 5: Frequency of histoscores for Raf-1 at the membrane. 
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Figure 6: Frequency of histoscores for Phospho.Raf-1 259 in the cytoplasm. 
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Figure 7: Frequency of histoscores for Phospho.Raf-1 338 in the cytoplasm. 
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Figure 8: Frequency of histoscores for Phospho.Raf-1 338 at the membrane. 
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Figure 9: Frequency of histoscores for Phospho.Raf-1 338 in the nucleus. 
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Figure 10: Frequency of histoscores for MAPK in the cytoplasm. 
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Figure 11: Frequency of histoscores for MAPK at the membrane. 
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Figure 12: Frequency of histoscores for MAPK in the nucleus. 
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Figure 13: Frequency of histoscores for Phospho.MAPK in the cytoplasm. 
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Figure 14: Frequency of histoscores for Phospho.MAPK at the membrane. 
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Figure 15: Frequency of histoscores for Phospho.MAPK in the nucleus. 
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